Anti-MARCO antibodies and uses thereof

JP2023549555A5Inactive Publication Date: 2024-11-20PIONYR IMMUNOTHERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023529918
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-09-15
Filing Date
2021-11-18
Publication Date
2024-11-20
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is an unmet need for new cancer treatment approaches that enhance immune responses within the tumor microenvironment by selectively removing, reprogramming, or activating bone marrow cells such as T cells and NK cells, which are ineffective at stimulating immune cell responses.

Method used

Development of an isolated antibody or antigen-binding fragment that specifically binds to the scavenger receptor cysteine-rich (SRCR) domain of human macrophage receptor with collagen structure (MARCO), enhancing immune responses by repolarizing myeloid cells and increasing cytokine and chemokine expression.

Benefits of technology

The antibody enhances immune responses by repolarizing myeloid cells, increasing cytokine and chemokine expression, and inducing NK cell activation, thereby improving anti-tumor immune responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Provided herein are anti-MARCO antibodies, as well as methods for producing and using the anti-MARCO antibodies.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] Cross-reference of related applications This application claims priority to and benefits from U.S. Application No. 63 / 115,272, filed on November 18, 2020, and U.S. Application No. 63 / 244,662, filed on September 15, 2021. is incorporated herein by reference in its entirety.

[0002] Sequence list This application includes a sequence listing submitted via EFS-Web, which is incorporated herein by reference in its entirety. The ASCII copy, created in XX month, 20XX, is called XXXXXUS_sequencelisting.txt and has a size of X, XXX, XXX bytes. [Background technology]

[0003] background The bone marrow population of the tumor microenvironment prominently includes monocytes and neutrophils (sometimes loosely classified as myeloid-derived suppressor cells), macrophages, and dendritic cells. Although the intratumoral myeloid population as a whole has long been thought to be nonstimulatory or suppressive, it has been more recently recognized that not all tumor-infiltrating myeloid cells are created equal.

[0004] Macrophage Receptor with Collagen Structure (MARCO, also known as SCARA2. See HGNC:6895 and NCBI:NM_006770.3, available from the NCBI website on May 8, 2020. herein incorporated by reference for all purposes. (Incorporated in this book) belongs to the class A scavenger receptor family and is expressed in peritoneal macrophages and a subpopulation of macrophages in the spleen and lymph nodes (Hirano S, PLoS ONE 2015:10(11):e0142062 (Non-Patent Document) (see 1)). Recent studies have emphasized MARCO as a specific marker for TAM in human cancer (Lavin et al., Cell; 2017:169(4)750-765 (Non-Patent Document 2)). MARCO mediates macrophage internalization of non-opsonized particles and microorganisms such as bacteria (see Jing J, J Immunol 2013;190:(12)6360-6367). Recently, it has been shown that MARCO is involved in TLR-induced gene expression responses in dendritic cells and may play a role in inflammatory immune responses (Kissick HT,PLoS oNE 2014;9(8): 2104148 (Non-Patent Document 4)).

[0005] Involves enhancing immune responses within the tumor microenvironment by selectively removing, reprogramming, or activating bone marrow cells (e.g., T cells and NK cells) that are ineffective at stimulating immune cell responses. , there is an unmet need for new cancer treatment approaches. [Prior art documents] [Non-patent literature]

[0006] [Non-patent document 1] Hirano S,PLoS ONE 2015:10(11):e0142062 [Non-patent document 2] Lavin et al.,Cell;2017:169(4)750-765 [Non-patent document 3] Jing J,J Immunol 2013;190:(12)6360-6367 [Non-patent document 4] Kissick HT,PLoS oNE 2014;9(8):2104148 [Summary of the invention]

[0007] overview In some embodiments, provided herein is an isolated antibody or antigen-binding fragment thereof that binds human macrophage receptor with collagen structure (MARCO) (SEQ ID NO: 384).

[0008] In some embodiments, the antibody or antigen-binding fragment thereof binds to the scavenger receptor cysteine ​​rich (SRCR) domain of human MARCO (residues 424-519 of SEQ ID NO: 384).

[0009] In some embodiments, an isolated protein that binds to the scavenger receptor cysteine ​​rich (SRCR) domain (residues 424-519 of SEQ ID NO: 384) of the human macrophage receptor with collagen structure (MARCO) (SEQ ID NO: 384) Antibodies or antigen-binding fragments thereof are provided herein.

[0010] In some embodiments, the antibody has a heavy chain variable (VH) sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and three light chain CDR sequences, CDR-L1. , CDR-L2, and CDR-L3, CDR-H1 comprises the sequence GFSLTSYHVS (SEQ ID NO: 2), and CDR-H2 comprises the sequence AIWTGGSIA (SEQ ID NO: 3). CDR-H3 contains the sequence DLSDYYSSYTSFDY (SEQ ID NO: 4), and CDR-L1 contains the sequence ASEGISNDLA (SEQ ID NO: 431) or XASEGISNDLA (SEQ ID NO: 383), where X is arginine (R) or leucine (L). ), CDR-L2 contains the sequence AASRLQD (SEQ ID NO: 8), and CDR-L3 contains the sequence QQSYKYPLT (SEQ ID NO: 9).

[0011] In some embodiments, the antibody or antigen-binding fragment thereof has one of the following residues of MARCO (SEQ ID NO: 384): Q452, Y472, K473, E450, Q487, T499, H505, D507, S509, or E511. Combine at least one.

[0012] In some embodiments, the antibody or antigen-binding fragment comprises a chimeric, human, humanized, or rat antibody or antigen-binding fragment.

[0013] In some embodiments, CDR-L1 comprises the sequence ASEGISNDLA (SEQ ID NO: 431).

[0014] In some embodiments, CDR-L1 comprises the sequence RASEGISNDLA (SEQ ID NO: 27).

[0015] In some embodiments, CDR-L1 comprises the sequence LASEGISNDLA (SEQ ID NO: 7).

[0016] In some embodiments, the VH sequence comprises the VH sequence set forth in SEQ ID NO:61.

[0017] In some embodiments, the VH sequence comprises the VH sequence set forth in SEQ ID NO: 111.

[0018] In some embodiments, the VH sequences are those set forth in SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 434, 444, and 474. Contains an array selected from arrays.

[0019] In some embodiments, the VL sequence comprises the VL sequence set forth in SEQ ID NO: 66.

[0020] In some embodiments, the VL sequence comprises the VL sequence set forth in SEQ ID NO: 116.

[0021] In some embodiments, the VL sequences are those set forth in SEQ ID NOs: 6, 16, 26, 36, 46, 57, 66, 76, 86, 96, 106, 116, 126, 136, 439, 449, and 479. Contains an array selected from arrays.

[0022] In some embodiments, the VH sequence comprises the VH sequence set forth in SEQ ID NO: 61 and the VL sequence comprises the VL sequence set forth in SEQ ID NO: 66.

[0023] In some embodiments, the VH sequence comprises the VH sequence set forth in SEQ ID NO: 111 and the VL sequence comprises the VL sequence set forth in SEQ ID NO: 116.

[0024] In some embodiments, the VH sequences are those set forth in SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 434, 444, and 474. VL sequences include sequences selected from SEQ ID NOs: 6, 16, 26, 36, 46, 57, 66, 76, 86, 96, 106, 116, 126, 136, 439, 449, and 479. including sequences selected from those listed.

[0025] In some embodiments, the VH sequences are those set forth in SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 434, 444, and 474. and / or the VL sequence has at least 90%, 92%, 95%, 97%, 98%, or 99% identity to a sequence selected from the sequences SEQ ID NO: 6, 16 , 26, 36, 46, 57, 66, 76, 86, 96, 106, 116, 126, 136, 439, 449, and 479. , 95%, 97%, 98%, or 99% identity.

[0026] In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO: 65.

[0027] In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO: 115.

[0028] In some embodiments, the antibodies have the sequences set forth in SEQ ID NOs: 5, 15, 125, 35, 45, 55, 65, 75, 85, 95, 105, 115, 125, 145, 438, 448, and 478. A heavy chain sequence selected from

[0029] In some embodiments, the antibody comprises a light chain sequence set forth in SEQ ID NO:70.

[0030] In some embodiments, the antibody comprises a light chain sequence set forth in SEQ ID NO: 120.

[0031] In some embodiments, the antibodies have the sequences set forth in SEQ ID NOs: 10, 20, 30, 40, 50, 6, 70, 80, 90, 100, 110, 120, 130, 140, 443, 453, and 483. A light chain sequence selected from

[0032] In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO:65 and a light chain sequence set forth in SEQ ID NO:70.

[0033] In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO: 115 and a light chain sequence set forth in SEQ ID NO: 120.

[0034] In some embodiments, the antibodies have the sequences set forth in SEQ ID NOs: 5, 15, 125, 35, 45, 55, 65, 75, 85, 95, 105, 115, 125, 145, 438, 448, and 478. and from the sequences set forth in SEQ ID NOs: 10, 20, 30, 40, 50, 6, 70, 80, 90, 100, 110, 120, 130, 140, 443, 453, and 483. comprising a selected light chain sequence.

[0035] In some embodiments, the antibodies have the sequences set forth in SEQ ID NOs: 5, 15, 125, 35, 45, 55, 65, 75, 85, 95, 105, 115, 125, 145, 438, 448, and 478. a heavy chain sequence having at least 90%, 92%, 95%, 97%, 98%, or 99% identity to a sequence selected from and / or SEQ ID NO: 10, 20, 30, 40, 50 , 6, 70, 80, 90, 100, 110, 120, 130, 140, 443, 453, and 483; Contains light chain sequences with 98% or 99% identity.

[0036] In some embodiments, a heavy chain variable (VH) sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and three light chain CDR sequences, CDR-L1, CDR-L2. Provided herein is an isolated antibody or antigen-binding fragment thereof that binds to human MARCO (SEQ ID NO: 384), comprising a variable light chain (VL) sequence comprising CDR-L3, and a light chain variable (VL) sequence comprising CDR-H1. contains the sequence GYTFTDYAVN (SEQ ID NO: 232), CDR-H2 contains the sequence WINTQTGKPT (SEQ ID NO: 233), CDR-H3 contains the sequence DSYYYSSSLDY (SEQ ID NO: 234), and CDR-L1 contains the sequence ASAGISNDLA (SEQ ID NO: 234). No. 432) or XASAGISNDLA (SEQ ID No. 381), where X is arginine (R) or leucine (L), CDR-L2 comprises the sequence AASRLQD (SEQ ID No. 238), and CDR-L3 comprises the sequence Contains QQSYKYPWT (SEQ ID NO: 239).

[0037] In some embodiments, CDR-L1 comprises the sequence ASAGISNDLA (SEQ ID NO: 432).

[0038] In some embodiments, CDR-L1 comprises the sequence RASAGISNDLA (SEQ ID NO: 317).

[0039] In some embodiments, CDR-L1 comprises the sequence LASAGISNDLA (SEQ ID NO: 237).

[0040] In some embodiments, the VH sequence comprises the VH sequence set forth in SEQ ID NO: 454.

[0041] In some embodiments, the VH sequence comprises a sequence selected from the sequences set forth in SEQ ID NOs: 241, 311, 321, 331, 341, 351, 454, and 464.

[0042] In some embodiments, the VL sequence comprises the VL sequence set forth in SEQ ID NO: 459.

[0043] In some embodiments, the VL sequence comprises a sequence selected from the sequences set forth in SEQ ID NOs: 246, 316, 326, 336, 346, 356, 459, and 469.

[0044] In some embodiments, the VH sequence comprises the VH sequence set forth in SEQ ID NO: 454 and the VL sequence comprises the VL sequence set forth in SEQ ID NO: 459.

[0045] In some embodiments, the VH sequence comprises a sequence selected from the sequences set forth in SEQ ID NO: 241, 311, 321, 331, 341, 351, 454, and 464, and the VL sequence comprises a sequence set forth in SEQ ID NO: 246, 316. , 326, 336, 346, 356, 459, and 469.

[0046] In some embodiments, the VH sequence has at least 90%, 92%, 95 %, 97%, 98%, or 99% identity; Includes sequences that have at least 90%, 92%, 95%, 97%, 98%, or 99% identity to the selected sequence.

[0047] In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO: 458.

[0048] In some embodiments, the antibody comprises a heavy chain sequence selected from the sequences set forth in SEQ ID NOs: 245, 315, 325, 335, 345 355, 458, and 468.

[0049] In some embodiments, the antibody comprises a light chain sequence set forth in SEQ ID NO: 463.

[0050] In some embodiments, the antibody comprises a light chain sequence selected from the sequences set forth in SEQ ID NO: 250, 320, 330, 340, 350, 360, 463, and 473.

[0051] In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO: 458 and a light chain sequence set forth in SEQ ID NO: 463.

[0052] In some embodiments, the antibody has a heavy chain sequence selected from the sequences set forth in SEQ ID NO: 245, 315, 325, 335, 345 355, 458, and 468, and SEQ ID NO: 250, 320, 330, 340, 350, 360, 463, and 473.

[0053] In some embodiments, the antibody is at least 90%, 92%, 95%, 97 %, 98%, or 99% identity and / or to a sequence selected from the sequences set forth in SEQ ID NOs: 250, 320, 330, 340, 350, 360, 463, and 473. Contains light chain sequences that have at least 90%, 92%, 95%, 97%, 98%, or 99% identity.

[0054] In some embodiments, a heavy chain variable (VH) sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and three light chain CDR sequences, CDR-L1, CDR-L2. Provided herein is an isolated antibody or antigen-binding fragment thereof that binds to human MARCO (SEQ ID NO: 384), comprising a variable light chain (VL) sequence comprising CDR-L3, and a light chain variable (VL) sequence comprising CDR-H1. contains the sequence KFTFSNYGMN (SEQ ID NO: 142), CDR-H2 contains the sequence LIYYNSNNKY (SEQ ID NO: 143), CDR-H3 contains the sequence SLTGGSDYFDS (SEQ ID NO: 144), and CDR-L1 contains the sequence ASKSIGTFLA (SEQ ID NO: 144). No. 433) or XASKSIGTFLA (SEQ ID No. 382), where X is arginine (R) or leucine (L), CDR-L2 comprises the sequence SGSTLQS (SEQ ID No. 148), and CDR-L3 comprises the sequence Contains QQHDEYPFT (SEQ ID NO: 149).

[0055] In some embodiments, CDR-L1 comprises the sequence ASKSIGTFLA (SEQ ID NO: 433).

[0056] In some embodiments, CDR-L1 comprises the sequence KASKSIGTFLA (SEQ ID NO: 147).

[0057] In some embodiments, CDR-L1 comprises the sequence RASKSIGTFLA (SEQ ID NO: 157).

[0058] In some embodiments, the VH sequence comprises a sequence selected from the sequences set forth in SEQ ID NOs: 141, 151, 161, 171, 181, 191, 201, 211, and 221.

[0059] In some embodiments, the VL sequence comprises a sequence selected from the sequences set forth in SEQ ID NOs: 146, 156, 166, 176, 186, 196, 206, 216, and 226.

[0060] In some embodiments, the VH sequence comprises a sequence selected from the sequences set forth in SEQ ID NO: 141, 151, 161, 171, 181, 191, 201, 211, and 221, and the VL sequence comprises a sequence set forth in SEQ ID NO: 146. , 156, 166, 176, 186, 196, 206, 216, and 226.

[0061] In some embodiments, the VH sequence is at least 90%, 92% more , 95%, 97%, 98%, or 99% identical to SEQ ID NO: 146, 156, 166, 176, 186, 196, 206, 216, and 226. Includes sequences that have at least 90%, 92%, 95%, 97%, 98%, or 99% identity to a sequence selected from the listed sequences.

[0062] In some embodiments, the antibody comprises a heavy chain sequence selected from the sequences set forth in SEQ ID NO: 145, 155, 165, 175, 185, 195, 205, 215, and 225.

[0063] In some embodiments, the antibody comprises a light chain sequence selected from the sequences set forth in SEQ ID NO: 150, 160, 170, 180, 190, 200, 210, 220, and 230.

[0064] In some embodiments, the antibody has a heavy chain sequence selected from the sequences set forth in SEQ ID NO: 145, 155, 165, 175, 185, 195, 205, 215, and 225; , 180, 190, 200, 210, 220, and 230.

[0065] In some embodiments, the antibody is at least 90%, 92%, Heavy chain sequences comprising sequences with 95%, 97%, 98%, or 99% identity and / or as set forth in SEQ ID NO: 150, 160, 170, 180, 190, 200, 210, 220, and 230 A light chain sequence that includes a sequence that has at least 90%, 92%, 95%, 97%, 98%, or 99% identity to a sequence selected from the sequences.

[0066] In another aspect, a heavy chain variable (VH) sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and three light chain CDR sequences, CDR-L1, CDR-L2, Provided herein is an isolated antibody or antigen-binding fragment thereof that binds to human MARCO (SEQ ID NO: 384), comprising a variable light chain (VL) sequence comprising CDR-L3 and CDR-L3, wherein CDR-H1 is , contains the sequence GYTFTDYYLH (SEQ ID NO: 252), CDR-H2 contains the sequence YINPNNAYTS (SEQ ID NO: 253), CDR-H3 contains the sequence DTTDYYNLHFAY (SEQ ID NO: 254), and CDR-L1 contains the sequence LTSEGISNDLA (SEQ ID NO: 254). 257), CDR-L2 contains the sequence DASRLED (SEQ ID NO: 258), and CDR-L3 contains the sequence QQSYKYPLT (SEQ ID NO: 259).

[0067] In some embodiments, the VH sequence comprises a VH sequence set forth in SEQ ID NO: 251 or 261.

[0068] In some embodiments, the VL sequence comprises a VL sequence set forth in SEQ ID NO: 256 or 266.

[0069] In some embodiments, the VH sequence comprises the sequence set forth in SEQ ID NO: 251 or 261 and the VL sequence comprises the sequence set forth in SEQ ID NO: 256 or 266.

[0070] In some embodiments, the VH sequence comprises a sequence having at least 90%, 92%, 95%, 97%, 98, or 99% identity to the sequence set forth in SEQ ID NO: 251 or 261, and / or VL sequences include sequences that have at least 90%, 92%, 95%, 97%, 98, or 99% identity to the sequence set forth in SEQ ID NO: 256 or 266.

[0071] In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO: 255 or 265.

[0072] In some embodiments, the antibody comprises a light chain sequence set forth in SEQ ID NO: 260 or 270.

[0073] In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO: 255 or 265 and a light chain sequence set forth in SEQ ID NO: 260 or 270.

[0074] In some embodiments, the antibody has a heavy chain sequence that has at least 90%, 92%, 95%, 97%, 98%, or 99% identity to the sequence set forth in SEQ ID NO: 255 or 265. , and a light chain sequence comprising a sequence having at least 90%, 92%, 95%, 97%, 98%, or 99% identity to the sequence set forth in SEQ ID NO: 260 or 270.

[0075] In another aspect, a heavy chain variable (VH) sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and three light chain CDR sequences, CDR-L1, CDR-L2, Provided herein is an isolated antibody or antigen-binding fragment thereof that binds to human MARCO (SEQ ID NO: 384), comprising a variable light chain (VL) sequence comprising CDR-L3 and CDR-L3, wherein CDR-H1 is , contains the sequence GFSLTSYTLS (SEQ ID NO: 362), CDR-H2 contains the sequence AIWGGDNTD (SEQ ID NO: 363), CDR-H3 contains the sequence ELGGSFDY (SEQ ID NO: 364), and CDR-L1 contains the sequence KTSQNINKKLD (SEQ ID NO: 364). 367), CDR-L2 contains the sequence YTNNLQT (SEQ ID NO: 368) and CDR-L3 contains the sequence YQYDSGFT (SEQ ID NO: 369).

[0076] In some embodiments, the VH sequence comprises a VH sequence set forth in SEQ ID NO: 361 or 371.

[0077] In some embodiments, the VL sequence comprises a VL sequence set forth in SEQ ID NO: 366 or 376.

[0078] In some embodiments, the VH sequence comprises the sequence set forth in SEQ ID NO: 361 or 371 and the VL sequence comprises the sequence set forth in SEQ ID NO: 366 or 376.

[0079] In some embodiments, the VH sequence comprises a sequence having at least 90%, 92%, 95%, 97%, 98, or 99% identity to the sequence set forth in SEQ ID NO: 361 or 371, and / or VL sequences include sequences that have at least 90%, 92%, 95%, 97%, 98, or 99% identity to the sequence set forth in SEQ ID NO: 366 or 376.

[0080] In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO: 365 or 375 and a light chain sequence set forth in SEQ ID NO: 370 or 380.

[0081] In some embodiments, the antibody has a heavy chain sequence that has at least 90%, 92%, 95%, 97%, 98%, or 99% identity to the sequence set forth in SEQ ID NO: 365 or 375. , and a light chain sequence comprising a sequence having at least 90%, 92%, 95%, 97%, 98%, or 99% identity to the sequence set forth in SEQ ID NO: 370 or 380.

[0082] In some embodiments, the antibodies are monoclonal antibodies, neutralizing antibodies, antagonist antibodies, agonist antibodies, polyclonal antibodies, afucosylated antibodies, human antibodies, humanized antibodies, chimeric antibodies, full-length antibodies, and scFv.

[0083] In some embodiments, the antibody is an scFv.

[0084] In some embodiments, the antibody is a monoclonal antibody.

[0085] In some embodiments, the antibody is a humanized antibody.

[0086] In some embodiments, the antibody is a human antibody.

[0087] In some embodiments, the antibody includes an Fc region.

[0088] In some embodiments, the antibody comprises a human Fc region.

[0089] In some embodiments, the antibody comprises an active human Fc region.

[0090] In some embodiments, the antibody comprises a heavy chain human constant region of a class selected from IgG, IgA, IgD, IgE, and IgM.

[0091] In some embodiments, the antibody comprises a human heavy chain constant region of class IgG and subclasses selected from IgG1, IgG2, IgG3, and IgG4.

[0092] In some embodiments, the human Fc region comprises a wild type human IgG1 Fc region.

[0093] In some embodiments, the human Fc region comprises a wild type human IgG4 Fc region.

[0094] In some embodiments, the Fc region comprises one or more amino acid substitutions, and the one or more substitutions increase the antibody half-life compared to the Fc region without the one or more substitutions; resulting in an increase in ADCC activity, an increase in ADCP activity, an increase in CDC activity, a decrease in ADCC activity, a decrease in ADCP activity, or a decrease in CDC activity.

[0095] In some embodiments, the Fc region binds an Fcγ receptor selected from the group consisting of FcγRI, FcγRIIa, FcγRIIb, FcγRIIc, FcγRIIIa, and FcγRIIIb.

[0096] In some embodiments, the antibody is directed to human MARCO with a KD of about 0.5, 1, 2, 3, 4, 5, 6, or 7 x 10 M or less, as measured by surface plasmon resonance (SPR) assay. Join.

[0097] In some embodiments, binding of the antibody to human MARCO is divalent cation dependent.

[0098] In some embodiments, binding of the antibody to human MARCO is divalent cation independent.

[0099] In some embodiments, the divalent cation includes Ca2+ or Mg2+.

[0100] In some embodiments, the antibody binds to the extracellular domain of human MARCO.

[0101] In some embodiments, the antibody binds soluble MARCO.

[0102] In some embodiments, the antibody binds to human MARCO, cynomolgus MARCO, or the SRCR domain of human and cynomolgus MARCO.

[0103] In some embodiments, the antibody binds to the SRCR domain of human MARCO (residues 424-519 of SEQ ID NO: 384).

[0104] In some embodiments, the antibody or antigen-binding fragment thereof binds to at least one of Q452, Y472, K473, E450, Q487, T499, H505, D507, S509, or E511 of MARCO (SEQ ID NO: 384). do.

[0105] In some embodiments, the antibody has receptor ligand blocking activity.

[0106] In some embodiments, the antibody induces enhanced expression of at least one cytokine or chemokine upon contact with a cell, as compared to an isotype control antibody, optionally measured by a nucleic acid assay or a protein assay. do.

[0107] In some embodiments, the at least one cytokine or chemokine is IL-1α, IL-1β, IL-2, IL-4, IL-6, IL7R, IL-12, IL12-p70, IL-15, IL -18, IL-27, IP-10, IFN-γ, TNFα, MIP1-α, MIP1-β, MIP-2, CSF2, CSF3, G-CSF, M-CSF, CCL3, CCL4, CCL5, CCL20, CCL24 , CXCL1, CXCL3, CXCL8, CXCL9, CXCL10, CXCL12, gro-α, MCP-1, MCP-3, LIF, or eotaxin.

[0108] In some embodiments, upon cell contact, the antibody exhibits enhanced NK cell activation, B cell regulated T cell proliferation, as compared to an isotype control antibody, optionally measured by a nucleic acid assay or a protein assay. Induce T cell activation or T cell differentiation.

[0109] In some embodiments, upon cell contact, the antibody improves IL-2-STAT5 signaling, NF-kB signaling, TLR signaling, adhesion and motility signaling, cytoskeletal remodeling, as compared to an isotype control antibody. Induce constitutive signaling, NF-kB-mediated TNFα signaling, IL-6-JAK-STAT3 signaling, SYK signaling, MAPK signaling, TPL2 signaling, calcium signaling, IFNγ responses, or IFNα responses.

[0110] In some embodiments, upon cell contact, the antibody targets cell cycle pathways, cell survival, cell adhesion, Myc targeting pathway, E2F targeting pathway, hypoxia, mTOR signaling pathway, PI3K- Decrease AKT signaling pathway, Src signaling pathway, PKC signaling pathway, epithelial-mesenchymal transition signaling pathway, oxidative phosphorylation, or MAPK signaling pathway.

[0111] In some embodiments, upon cell contact, the antibody induces inflammasome activation as determined by IL-1β and / or IL-18 secretion and / or phagocytosis compared to an isotype control antibody.

[0112] In some embodiments, upon cell contact, the antibody repolarizes myeloid M2-like TAMS to M1-like tumor-associated macrophages (TAMs) and / or to proinflammatory monocytes compared to an isotype control antibody. induce repolarization of mMDSC.

[0113] In some embodiments, upon cell contact, the antibody increases CD8+ T cells, CD4+ T cells, NK cells, dendritic cells, MHCII+ macrophages, MHCIIhigh monocytes, or MHCIImid monocytes compared to an isotype control antibody. let

[0114] In some embodiments, upon cell contact, the antibody increases macrophages in the spleen, marginal zone macrophages, follicular B cells, and / or red pulp macrophages compared to an isotype control antibody.

[0115] In some embodiments, upon cell contact, the antibody increases TAMs, tumor-associated neutrophils, plasma B cells, marginal zone B cells, CD19+ B cells, MHCII-monocytes, and / or reduce MHCII-macrophages.

[0116] In some embodiments, upon administration to a subject, the antibody induces an enhanced anti-tumor memory response compared to an isotype control antibody.

[0117] In some embodiments, the cells are MARCO+ cells.

[0118] In some embodiments, the cells are human MARCO+ cells.

[0119] In some embodiments, the MARCO+ cells are monocytes, monocytic myeloid-derived suppressor cells (mMDSCs), or macrophages.

[0120] In some embodiments, the macrophage is a tumor-associated macrophage (TAM) or a monocyte-derived macrophage (MDM).

[0121] In some embodiments, the antibody binds to MARCO on the cell surface of MARCO+ cells.

[0122] In some embodiments, the antibody is a humanized PI-HX-3011, PI-HX-3031, PI-HX-3043, PI-HX-3061, PI-HX-3092 antibody for binding to human MARCO. Compete; binds to human MARCO; binds to cynomolgus monkey MARCO; binds to human and cynomolgus monkey MARCO; binds to the SRCR domain of human MARCO; binds to the SRCR domain of cynomolgus monkey MARCO; binds to the SRCR domain of human and cynomolgus monkey MARCO binds human or cynomolgus monkey MARCO in a divalent cation-dependent manner; binds human or cynomolgus monkey MARCO in a divalent cation-independent manner; stimulates MARCO signaling when bound to MARCO+ cells; MARCO+ cells upon binding to MARCO+ cells induces the secretion of cytokines or chemokines, and optionally the cytokines or chemokines induce IL-1α, IL-1β, IL -2, IL-4, IL-6, IL7R, IL-12, IL12-p70, IL-15, IL-18, IL-27, IP-10, IFN-γ, TNFα, MIP1-α, MIP1 -β, MIP-2, CSF2, CSF3, G-CSF, M-CSF, CCL3, CCL4, CCL5, CCL20, CCL24, CXCL1, CXCL3, CXCL8, CXCL9, CXCL10, CXCL12, gro-α, MCP-1, MCP -3, LIF, or eotaxin; upon binding to MARCO+ cells, induces NK cell activation, B cell regulation, T cell proliferation, T cell activation, or increased T cell differentiation; IL -2-STAT5 signaling, NF-kB signaling, TLR signaling, adhesion and motility signaling, cytoskeletal reorganization signaling, NF-kB-mediated TNFα signaling, IL-6-JAK-STAT3 signaling induces , SYK signaling, MAPK signaling, TPL2 signaling, calcium signaling, IFNγ response, or IFNα response; cell cycle pathway, cell survival, cell adhesion, Myc targeting pathway, E2F targeting pathway, hypoxia, mTOR signaling IL-1β and / or IL- induce inflammasome activation determined by secretion and / or phagocytosis of 18; repolarization of myeloid M2-like TAMs to M1-like TAMS and / or repolarization of mMDSCs to inflammatory monocytes. induces; upon binding to MARCO+ cells, modulates splenic B cells; in the spleen and / or tumor, CD8+ T cells, CD4+ T cells, NK cells, dendritic cells, MHCII+ macrophages, MHCIIhigh monocytes, and / or MHCIImid Increases monocytes; increases macrophages, marginal zone macrophages, follicular B cells, and / or red pulp macrophages in the spleen and / or tumors; TAMs, tumor-associated neutrophils, in the spleen and / or tumors; Decreases plasma B cells, marginal zone B cells, CD19+ B cells, MHCII-monocytes, and / or MHCII-macrophages; binding to MARCO+ cells induces changes in cell adhesion, cytoskeleton, chemotaxis, and cell migration. induces; upon binding to MARCO+ cells, induces cell signaling pathways including adhesion, migration, chemotactic cell cycle, T cell receptor, phagocytosis, autophagy, and wnt pathways; disables MARCO+ myeloid cells ; or any combination of the above is possible.

[0123] In some embodiments, the antibody is for use as a pharmaceutical.

[0124] In some embodiments, the antibody is for use in treating cancer or infectious disease.

[0125] In some embodiments, the antibody is for use in treating cancer, and the cancer is selected from solid tumors and liquid tumors.

[0126] In another aspect, provided herein is an isolated polynucleotide or set of polynucleotides encoding an antibody described herein, a VH thereof, a VL thereof, a light chain thereof, a heavy chain thereof, or an antigen binding portion thereof. and optionally the isolated polynucleotide or set of polynucleotides is a cDNA.

[0127] In another aspect, provided herein is a vector or set of vectors comprising a polynucleotide or set of polynucleotides.

[0128] In another aspect, provided herein is a host cell comprising a polynucleotide or set of polynucleotides, or a vector or set of vectors.

[0129] In another aspect, provided herein is a method of producing an antibody that includes expressing the antibody or antigen-binding fragment thereof in a host cell and isolating the expressed antibody.

[0130] In another aspect, provided herein is a pharmaceutical composition comprising an isolated antibody or antigen-binding fragment thereof and a pharmaceutically acceptable excipient.

[0131] In another aspect, provided herein is a kit comprising an isolated antibody or antigen-binding fragment thereof, or a pharmaceutical composition and instructions for use.

[0132] In another aspect, provided herein is a method of enhancing an immune response in a subject comprising administering to the subject a composition comprising an anti-human MARCO antibody or antigen-binding fragment thereof.

[0133] In some embodiments, the composition comprises an antibody that binds to the SRCR domain of human MARCO (residues 424-519 of SEQ ID NO: 384).

[0134] In some embodiments, the composition comprises an isolated antibody or a pharmaceutical composition.

[0135] In some embodiments, the antibody has receptor ligand blocking activity.

[0136] In some embodiments, the enhanced immune response is an adaptive immune response.

[0137] In some embodiments, the enhanced immune response is an innate immune response.

[0138] In some embodiments, the enhanced immune response comprises enhanced expression of at least one cytokine or chemokine by the cells as compared to an isotype control antibody, optionally measured by a nucleic acid assay or a protein assay. .

[0139] In some embodiments, the at least one cytokine or chemokine is IL-1α, IL-1β, IL-2, IL-4, IL-6, IL7R, IL-12, IL12-p70, IL-15, IL -18, IL-27, IP-10, IFN-γ, TNFα, MIP1-α, MIP1-β, MIP-2, CSF2, CSF3, G-CSF, M-CSF, CCL3, CCL4, CCL5, CCL20, CCL24 , CXCL1, CXCL3, CXCL8, CXCL9, CXCL10, CXCL12, gro-α, MCP-1, MCP-3, LIF, or eotaxin.

[0140] In some embodiments, the enhanced immune response includes enhanced NK cell activation, B cell-regulated T cell proliferation, as compared to isotype control antibodies, optionally measured by nucleic acid or protein assays. Including T cell activation, or T cell differentiation.

[0141] In some embodiments, upon cell contact, the antibody improves IL-2-STAT5 signaling, NF-kB signaling, TLR signaling, adhesion and motility signaling, cytoskeletal remodeling, as compared to an isotype control antibody. Induce constitutive signaling, NF-kB-mediated TNFα signaling, IL-6-JAK-STAT3 signaling, SYK signaling, MAPK signaling, TPL2 signaling, calcium signaling, IFNγ responses, or IFNα responses.

[0142] In some embodiments, upon cell contact, the antibody targets cell cycle pathways, cell survival, cell adhesion, Myc targeting pathway, E2F targeting pathway, hypoxia, mTOR signaling pathway, PI3K- Decrease AKT signaling pathway, Src signaling pathway, PKC signaling pathway, epithelial-mesenchymal transition signaling pathway, oxidative phosphorylation, or MAPK signaling pathway.

[0143] In some embodiments, upon cell contact, the antibody induces inflammasome activation as determined by IL-1β and / or IL-18 secretion and / or phagocytosis compared to an isotype control antibody.

[0144] In some embodiments, upon cell contact, the antibody repolarizes myeloid M2-like TAMs to M1-like TAMs and / or repolarizes mMDSCs to proinflammatory monocytes compared to an isotype control antibody. induce.

[0145] In some embodiments, upon cell contact, the antibody increases CD8+ T cells, CD4+ T cells, NK cells, dendritic cells, MHCII+ macrophages, MHCIIhigh monocytes, or MHCIImid monocytes compared to an isotype control antibody. let

[0146] In some embodiments, upon cell contact, the antibody increases macrophages in the spleen, marginal zone macrophages, follicular B cells, and / or red pulp macrophages compared to an isotype control antibody.

[0147] In some embodiments, upon cell contact, the antibody increases TAMs, tumor-associated neutrophils, plasma B cells, marginal zone B cells, CD19+ B cells, MHCII-monocytes, and / or reduce MHCII-macrophages.

[0148] In some embodiments, the antibody induces an enhanced memory immune response.

[0149] In some embodiments, the cells are MARCO+ cells.

[0150] In some embodiments, the cells are human MARCO+ cells.

[0151] In some embodiments, the MARCO+ cells are monocytes, monocytic myeloid-derived suppressor cells (mMDSCs), or macrophages.

[0152] In some embodiments, the macrophage is a tumor-associated macrophage (TAM) or a monocyte-derived macrophage (MDM).

[0153] In some embodiments, the antibody binds to MARCO on the cell surface of MARCO+ cells.

[0154] In some embodiments, the subject is a human.

[0155] In some embodiments, the subject has cancer.

[0156] In some embodiments, the cancer is a solid cancer.

[0157] In some embodiments, the cancer is a humoral cancer.

[0158] In some embodiments, the cancer is lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, small cell lung cancer, kidney cancer, liver cancer, renal cell carcinoma, cervical cancer, ovarian cancer, colorectal cancer, colon cancer. , neuroblastoma, breast cancer, type 3 negative breast cancer, basal cell carcinoma, gastric cancer, gastric cancer, bladder cancer, prostate cancer, skin cancer, lymphoma, diffuse large B-cell lymphoma (DLBCL) ), small lymphocytic lymphoma, non-Hodgkin's lymphoma, mesothelioma, pancreatic cancer, thyroid cancer, endometrial cancer, head and neck cancer, or head and neck squamous cell carcinoma (HNSC).

[0159] In some embodiments, the cancer is colon cancer, breast cancer, basal cell-like breast cancer, ovarian cancer, or gastric cancer.

[0160] In some embodiments, MARCO is expressed at higher levels on tumor immune cells compared to non-tumor immune cells.

[0161] In some embodiments, IL-10 is expressed at higher levels on tumor immune cells compared to non-tumor immune cells.

[0162] In another aspect, provided herein is a method of treating cancer in a subject comprising administering to the subject a composition comprising an anti-human MARCO antibody or antigen-binding fragment thereof.

[0163] In some embodiments, the composition comprises an antibody that binds to the SRCR domain of human MARCO (residues 424-519 of SEQ ID NO: 384).

[0164] In some embodiments, the composition comprises an antibody disclosed herein or a pharmaceutical composition thereof.

[0165] In another aspect, provided herein is a method of treating cancer in a subject comprising administering to the subject a composition comprising an anti-human MARCO antibody or antigen-binding fragment thereof or a pharmaceutical composition thereof.

[0166] In some embodiments, the subject has previously received, concurrently received, or will subsequently receive immunotherapy.

[0167] In some embodiments, the immunotherapy is at least one of a checkpoint inhibitor, a T cell checkpoint inhibitor, and an anti-PD1 antibody.

[0168] In some embodiments, the immunotherapy includes an anti-PD1 antibody.

[0169] In another aspect, provided herein is a method of treating cancer in a subject comprising administering to the subject a composition comprising an anti-human MARCO antibody or antigen-binding fragment thereof and an immunotherapy.

[0170] In some embodiments, the composition comprises an antibody that binds to the SRCR domain of human MARCO (residues 424-519 of SEQ ID NO: 384).

[0171] In some embodiments, the composition comprises an antibody disclosed herein or a pharmaceutical composition thereof.

[0172] In some embodiments, the immunotherapy is at least one of a checkpoint inhibitor, a T cell checkpoint inhibitor, and an anti-PD1 antibody.

[0173] In some embodiments, the immunotherapy includes an anti-PD1 antibody.

[0174] In some embodiments, the subject is a human.

[0175] In some embodiments, the cancer is a solid cancer.

[0176] In some embodiments, the cancer is a humoral cancer.

[0177] In some embodiments, the cancer is lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, small cell lung cancer, kidney cancer, liver cancer, renal cell carcinoma, cervical cancer, ovarian cancer, colorectal cancer, colon cancer. , neuroblastoma, breast cancer, type 3 negative breast cancer, basal cell carcinoma, gastric cancer, gastric cancer, bladder cancer, prostate cancer, skin cancer, lymphoma, diffuse large B-cell lymphoma (DLBCL) ), small lymphocytic lymphoma, non-Hodgkin's lymphoma, mesothelioma, pancreatic cancer, thyroid cancer, endometrial cancer, head and neck cancer, or head and neck squamous cell carcinoma (HNSC).

[0178] In some embodiments, the cancer is colon cancer, breast cancer, basal cell-like breast cancer, ovarian cancer, or gastric cancer.

[0179] In some embodiments, MARCO is expressed at higher levels on tumor immune cells compared to non-tumor immune cells.

[0180] In some embodiments, IL-10 is expressed at higher levels on tumor immune cells compared to non-tumor immune cells.

[0181] In some embodiments, the antibody induces an enhanced anti-tumor memory response compared to an isotype control antibody.

[0182] In some embodiments, the administration enhances an immune response in the subject compared to an isotype control antibody.

[0183] In some embodiments, the enhanced immune response is an adaptive immune response.

[0184] In some embodiments, the enhanced immune response is an innate immune response.

[0185] In some embodiments, the enhanced immune response comprises expression of at least one cytokine or chemokine by the cells as compared to an isotype control antibody, optionally measured by a nucleic acid or protein assay.

[0186] In some embodiments, the at least one cytokine or chemokine is IL-1α, IL-1β, IL-2, IL-4, IL-6, IL7R, IL-12, IL12-p70, IL-15, IL -18, IL-27, IP-10, IFN-γ, TNFα, MIP1-α, MIP1-β, MIP-2, CSF2, CSF3, G-CSF, M-CSF, CCL3, CCL4, CCL5, CCL20, CCL24 , CXCL1, CXCL3, CXCL8, CXCL9, CXCL10, CXCL12, gro-α, MCP-1, MCP-3, LIF, or eotaxin.

[0187] In some embodiments, the enhanced immune response includes enhanced NK cell activation, B cell-regulated T cell proliferation, as compared to isotype control antibodies, optionally measured by nucleic acid or protein assays. Including T cell activation, or T cell differentiation.

[0188] In some embodiments, upon cell contact, the antibody improves IL-2-STAT5 signaling, NF-kB signaling, TLR signaling, adhesion and motility signaling, cytoskeletal remodeling, as compared to an isotype control antibody. Induce constitutive signaling, NF-kB-mediated TNFα signaling, IL-6-JAK-STAT3 signaling, SYK signaling, MAPK signaling, TPL2 signaling, calcium signaling, IFNγ responses, or IFNα responses.

[0189] In some embodiments, upon cell contact, the antibody targets cell cycle pathways, cell survival, cell adhesion, Myc targeting pathway, E2F targeting pathway, hypoxia, mTOR signaling pathway, PI3K- Decrease AKT signaling pathway, Src signaling pathway, PKC signaling pathway, epithelial-mesenchymal transition signaling pathway, oxidative phosphorylation, or MAPK signaling pathway.

[0190] In some embodiments, upon cell contact, the antibody induces inflammasome activation as determined by IL-1β and / or IL-18 secretion and / or phagocytosis compared to an isotype control antibody.

[0191] In some embodiments, upon cell contact, the antibody repolarizes myeloid M2-like TAMs to M1-like TAMs and / or repolarizes mMDSCs to proinflammatory monocytes compared to an isotype control antibody. induce.

[0192] In some embodiments, upon cell contact, the antibody increases CD8+ T cells, CD4+ T cells, NK cells, dendritic cells, MHCII+ macrophages, MHCIIhigh monocytes, or MHCIImid monocytes compared to an isotype control antibody. let

[0193] In some embodiments, upon cell contact, the antibody increases macrophages in the spleen, marginal zone macrophages, follicular B cells, and / or red pulp macrophages compared to an isotype control antibody.

[0194] In some embodiments, upon cell contact, the antibody increases TAMs, tumor-associated neutrophils (TANs), plasma B cells, marginal zone B cells, CD19+ B cells, MHCII-monomers, as compared to an isotype control antibody. and / or MHCII-macrophages.

[0195] In some embodiments, the cells are MARCO+ cells.

[0196] In some embodiments, the cells are human MARCO+ cells.

[0197] In some embodiments, the MARCO+ cells are monocytes, monocytic myeloid-derived suppressor cells (mMDSCs), or macrophages.

[0198] In some embodiments, the macrophage is a tumor-associated macrophage (TAM) or a monocyte-derived macrophage (MDM).

[0199] In some embodiments, the antibody binds to MARCO on the cell surface of MARCO+ cells.

[0200] In another aspect, provided herein is a method of disabling bone marrow cells that express MARCO on the cell surface, comprising contacting the bone marrow cells with an anti-human MARCO antibody or antigen-binding fragment thereof.

[0201] In another aspect, provided herein is a method of disabling bone marrow cells expressing MARCO on the cell surface, the method comprising contacting the bone marrow cell with an antibody described herein or a pharmaceutical composition thereof. .

[0202] In some embodiments, the antibody disables bone marrow cells by at least one of ADCC activity, CDC activity, or ADCP activity, optionally, the antibody disables bone marrow cells by ADCC activity, and optionally, The antibody disables bone marrow cells through CDC activity, and optionally, the antibody disables bone marrow cells through ADCP activity.

[0203] In some embodiments, the bone marrow cells are MARCO+ cells.

[0204] In some embodiments, the bone marrow cells are human MARCO+ cells.

[0205] In some embodiments, the bone marrow cells are monocytes, monocytic myeloid-derived suppressor cells (mMDSCs), or macrophages.

[0206] In some embodiments, the macrophage is a tumor-associated macrophage (TAM) or a monocyte-derived macrophage (MDM).

[0207] In some embodiments, the bone marrow cells are intratumoral or splenic bone marrow cells.

[0208] In some embodiments, the contacting is in vitro or in vivo.

[0209] In some embodiments, the contact occurs in vivo in the subject, optionally the subject suffering from cancer.

[0210] In some embodiments, the subject is a human.

[0211] In some embodiments, the cancer is a solid cancer.

[0212] In some embodiments, the cancer is a humoral cancer.

[0213] In some embodiments, the cancer is lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, small cell lung cancer, kidney cancer, liver cancer, renal cell carcinoma, cervical cancer, ovarian cancer, colorectal cancer, colon cancer. , neuroblastoma, breast cancer, type 3 negative breast cancer, basal cell carcinoma, gastric cancer, gastric cancer, bladder cancer, prostate cancer, skin cancer, lymphoma, diffuse large B-cell lymphoma (DLBCL) ), small lymphocytic lymphoma, non-Hodgkin's lymphoma, mesothelioma, pancreatic cancer, thyroid cancer, endometrial cancer, head and neck cancer, or head and neck squamous cell carcinoma (HNSC).

[0214] In some embodiments, the cancer is colon cancer, breast cancer, basal cell-like breast cancer, ovarian cancer, or gastric cancer.

[0215] In some embodiments, the contacting enhances an immune response in the subject compared to an isotype control antibody.

[0216] In some embodiments, the enhanced immune response is an adaptive immune response.

[0217] In some embodiments, the enhanced immune response is an innate immune response.

[0218] In some embodiments, the enhanced immune response comprises expression of at least one cytokine or chemokine by the cells as compared to an isotype control antibody, optionally measured by a nucleic acid or protein assay.

[0219] In some embodiments, the at least one cytokine or chemokine is IL-1α, IL-1β, IL-2, IL-4, IL-6, IL7R, IL-12, IL12-p70, IL-15, IL -18, IL-27, IP-10, IFN-γ, TNFα, MIP1-α, MIP1-β, MIP-2, CSF2, CSF3, G-CSF, M-CSF, CCL3, CCL4, CCL5, CCL20, CCL24 , CXCL1, CXCL3, CXCL8, CXCL9, CXCL10, CXCL12, gro-α, MCP-1, MCP-3, LIF, or eotaxin.

[0220] In some embodiments, the enhanced immune response includes enhanced NK cell activation, B cell-regulated T cell proliferation, as compared to isotype control antibodies, optionally measured by nucleic acid or protein assays. Including T cell activation, or T cell differentiation.

[0221] In some embodiments, upon cell contact, the antibody improves IL-2-STAT5 signaling, NF-kB signaling, TLR signaling, adhesion and motility signaling, cytoskeletal remodeling, as compared to an isotype control antibody. Constitutive signaling, NF-kB-mediated TNFα signaling, IL-6-JAK-STAT3 signaling, SYK signaling, MAPK signaling, TPL2 signaling, calcium signaling, IFNγ response, or IFNα response.

[0222] In some embodiments, upon cell contact, the antibody targets cell cycle pathways, cell survival, cell adhesion, Myc targeting pathway, E2F targeting pathway, hypoxia pathway, mTOR signaling pathway, PI3K compared to isotype control antibody. -Decrease AKT signaling pathway, Src signaling pathway, PKC signaling pathway, epithelial-mesenchymal transition signaling pathway, oxidative phosphorylation, or MAPK signaling pathway.

[0223] In some embodiments, upon cell contact, the antibody induces inflammasome activation determined by IL-1β and / or IL-18 secretion and / or phagocytosis.

[0224] In some embodiments, upon cell contact, the antibody induces repolarization of myeloid M2-like TAMs into M1-like TAMs and / or repolarization of mMDSCs into proinflammatory monocytes.

[0225] In some embodiments, upon cell contact, the antibody increases CD8+ T cells, CD4+ T cells, NK cells, dendritic cells, MHCII+ macrophages, MHCIIhigh monocytes, or MHCIImid monocytes compared to an isotype control antibody. let

[0226] In some embodiments, upon cell contact, the antibody increases macrophages in the spleen, marginal zone macrophages, follicular B cells, and / or red pulp macrophages compared to an isotype control antibody.

[0227] In some embodiments, upon cell contact, the antibody increases TAMs, tumor-associated neutrophils, plasma B cells, marginal zone B cells, CD19+ B cells, MHCII-monocytes, and / or reduce MHCII-macrophages.

[0228] In some embodiments, the subject has previously received, concurrently received, or will subsequently receive immunotherapy.

[0229] In some embodiments, the immunotherapy is at least one of a checkpoint inhibitor, a T cell checkpoint inhibitor, and an anti-PD1 antibody.

[0230] In some embodiments, the immunotherapy includes an anti-PD1 antibody.

[0231] In some embodiments, determining the expression level of a MARCO protein in a sample from a subject includes contacting the sample with an anti-MARCO antibody and performing an immunohistochemical assay or a soluble MARCO assay.

[0232] In some embodiments, the assay is an immunohistochemical assay and the antibody comprises RDM5, RDM9, PI-3010.15, PI-3010.25, or PI-3030.41.

[0233] These and other features, aspects, and advantages of the invention will be better understood with reference to the following description and accompanying drawings. [Brief explanation of drawings]

[0234]

Figure 1

[0235]

Figure 2

[0236] [Figure 3] Figure 3A shows the correlation between MARCO and IL-10 expression in different tumor types. Figure 3B shows a correlation heatmap between TREM2 expression, CD45 expression, IL-10 expression, and MARCO expression.

[0237] [Figure 4] Figure 4A shows that MARCO expression is inversely correlated with patient survival probability in CRC. Figure 4B shows that MARCO expression is inversely correlated with patient survival probability in RCC. Figure 4C shows that MARCO expression is inversely correlated with patient survival probability in neuroblastoma. Figure 4D shows that MARCO expression increased as a function of neuroblastoma disease severity according to INSS stage.

[0238] [Figure 5] We show that MARCO is upregulated in basaloid breast cancer compared to other breast cancer subtypes.

[0239] [Figure 6A] Binding of 33 anti-human MARCO antibodies to GFP-239T control cells (left bar), cells expressing human MARCO (middle bar), or cells expressing mouse MARCO (right bar) is shown. [Figure 6B] Flow cytometry histograms of one MARCO antibody, PI-M014, binding to cells expressing huMARCO, muMARCO, and CynoMARCO compared to control cells (GFP control). [Figure 6C] Titration of PI-M014 and isotype control antibodies binding to cells expressing huMARCO is shown. [Figure 6D] Flow cytometry histogram of PI-M014 binding to human monocyte-derived macrophages is shown.

[0240] [Figure 7] A summary of the binding competition assay is shown showing that PI-M015 and PI-M017 competed with each other for binding to the MARCO antigen and that they bound to the same MARCO epitope.

[0241] [Figure 8A] We show that MARCO is expressed in human MDM. [Figure 8B] We show that MARCO is expressed in tumor-associated macrophages (TAMs) from primary human tumor samples (gastric and ovarian cancer).

[0242] [Figure 9] We show that RDM-9514 also blocked LDL binding to MARCO in a dose-dependent manner.

[0243] [Figure 10] Figure 10A shows that RDM-9514 bound to surface expressed MARCO on MHCIIhigh and MHCIIlow TAMs isolated from CT26 and Py8119 tumors. Figure 10B shows that MARCO is expressed on TAMs and monocytes in the CT26 syngeneic tumor model.

[0244] [Figure 11] Figure 11A shows anti-mouse MARCO antibodies PI-HX-3017 (left bar, renamed PI-3009), PI-HX-3016 (center left bar, renamed PI-3008), PI-HX-3021 (center right bar). , renamed PI-3007) and PI-HX-3012 (right bar) respectively bound to mouse BMDM. Figure 11B shows that the same antibody also bound MARCO on TAMs (right bar) and monocytes (left bar) isolated from tumors in the CT26 syngeneic tumor model (n=2).

[0245] [Figure 12] Mice treated with isotype antibodies, PD-1 antibodies alone, or PI-3008 and PD-1 antibodies, PI-3007 and PD-1 antibodies, PI-3009 and PD-1 antibodies, and PI-3007 and PD-1 antibodies Tumor volumes in groups are shown.

[0246] [Figure 13A] Tumor volumes in individual mice treated with isotype control antibody are shown. [Figure 13B] Tumor volumes in individual mice treated with anti-PD-1 antibody are shown. [Figure 13C] Tumor volumes in individual mice treated with PI-3008 and anti-PD-1 antibody are shown. [Figure 13D] Tumor volumes in individual mice treated with PI-3009 and anti-PD-1 antibody are shown. [Figure 13E] Tumor volumes in individual mice treated with isotype control antibody are shown. [Figure 13F] Tumor volumes in individual mice treated with fucosylated PI-3008 are shown. [Figure 13G] Tumor volumes of individual mice treated with afucosylated PI-3008 are shown. [Figure 13H] Tumor volumes in mice treated with the indicated antibodies are shown. [Figure 13I] Tumor volumes in mice treated with the indicated antibodies are shown. [Figure 13J] Percentage of tumor growth inhibition (TGI%) in mice treated with isotype control antibody (wt Fc) compared to wt Fc PI-3008 and PD-1 antibodies. [Figure 13K] Percentage of tumor growth inhibition (TGI%) in mice treated with isotype control antibody (effector dead Fc) compared to dead Fc PI-3021 and PD-1 antibodies.

[0247] [Figure 14] Tumor volumes of re-implanted CT26 tumor cells and EMT6 cells in mice previously treated with anti-MARCO and anti-PD-1 antibodies are shown.

[0248] [Figure 15]Figure 15A shows the timeline of the PD study. Figure 15B shows CT26 tumor volume in mice treated with isotype antibody or PI-3008. Figure 15C shows quantification of PI-3008 antibodies in mice after the first and second administration.

[0249] [Figure 16A] Figure 2 shows the expression of pro-inflammatory molecules within the TME of CT26 mice treated with PI-3008. [Figure 16B] Comparison of genes upregulated in BMDM and CT26 tumors after in vitro or in vivo treatment with PI-3008 is shown.

[0250] [Figure 17] Figure 17A shows a sequence comparison of PI-HX-3061 VH with human VH framework sequences and three humanized VH sequences based on PI-HX-3061. Figure 17B shows a sequence comparison of PI-HX-3061 VL with human VL framework sequences and one humanized VL sequence based on PI-HX-3061.

[0251] [Figure 18] Figure 2 shows a sequence comparison of PI-HX-3031 VL with human VL framework sequences and six humanized VL sequences based on PI-HX-3031.

[0252] [Figure 19] Geometric mean fluorescence intensity (gMFI) of cells incubated with anti-MARCO antibody and AF488 fluorescent bacteria in competition assays is shown. Preincubation of cells with anti-MARCO antibody reduced bacterial binding and fluorescence signal in a dose-dependent manner.

[0253] [Figure 20] Figure 20A shows the binding of a chimeric antibody that binds to 293T cells overexpressing MARCO, but not to immune cells present in PBL (peripheral blood leukocytes). Eosinophil binding was nonspecific with all antibodies tested, including the hIgG1 isotype control. PI-3010 is shown on the left, PI-3030 on the left center, PI-3031 on the right center, and isotype control hIgG1 on the right. Figure 20B shows binding of PI-HX-3031 to TAMs and monocytes from endometrial cancer (primary human tumor). Antibody binding is the right peak, isotype control binding is the left peak.

[0254] [Figure 21] Sequence comparison of wild-type SRCR domains in human and mouse MARCO and mutations made in the indicated mouse and human recombinant variant proteins are shown.

[0255] [Figure 22] The amino acid residues of the wild-type SRCR domain in human and mouse MARCO are shown, as well as the mutations made in the indicated recombinant mutant proteins.

[0256] [Figure 23] Figure 3 shows binding of the indicated antibodies to recombinant human SRCR MARCO hVar3 protein.

[0257] [Figure 24] Overlapping SRCR epitope residues (circled) in mouse SRCR (left, Q452) and human SRCR (right, D452) are shown.

[0258] [Figure 25] A shows the PK standard calibration curve of PI-3025. B shows the PK standard calibration curve of PI-3048.

[0259] [Figure 26] Figure 26A shows concentration-time profiles of PI-3025 and PI-3048 in a ligand binding PK assay. Figure 26B shows the concentration-time profile of PI-3025 and PI-3048 in the total PK assay.

[0260] [Figure 27] Cytokine and other related gene expression (MIP-1α, IL-27, LIF, IL-1β, IL-2, IL-4, IP-10, IL-6, IL-10, CD40, IL-12p70, G-CSF, IFNγ, GM-CSF, TNFα, MIP-1β, MCP-1, MIG, gro-α, IL-1α, IL-15, MCP- 3, M-CSF, and VEGF-A).

[0261] [Figure 28] Provides qPCR mRNA expression data for the indicated genes after treatment with PI-3010.15, PI-3010.25, PI-3030.41, or hIgG1 control.

[0262] [Figure 29-1] We show that human and mouse MARCO mAbs drive similar pathway regulation. [Figure 29-2] See description of Figure 29-1.

[0263] [Figure 30] The top immune activation genes and pathways increased by anti-MARCO antibodies in hDTC include IL-2-STAT5 signaling, NF-kB-mediated TNFα signaling, IL-6-JAK-STAT3 signaling, inflammatory response, Indicates that IFNγ response and IFNα response are included.

[0264] [Figure 31-1] We show that PI-3010.15 induced pro-inflammatory signatures in human suppressive macrophages (M2c). [Figure 31-2] See description of Figure 31-1.

[0265] [Figure 32] Provides a comparison of the indicated cytokine expression fold changes induced by PI-3010.15 and PI-3030.41.

[0266] [Figure 33] Figure 33A shows that PI-3008 induced statistically significant IL-1β secretion by inflammasomes in non-polarized macrophages from C57BL / 6 mice. Figure 33B shows that PI-3008 induced statistically significant IL-1β secretion by inflammasomes in IL-10 polarized macrophages from C57BL / 6 mice. Figure 33C shows that PI-3008 induced statistically significant IL-1β secretion by inflammasomes in non-polarized macrophages from Balb / c mice. Figure 33D shows that PI-3008 induced statistically significant IL-1β secretion by inflammasomes in IL-10 polarized macrophages from Balb / c mice.

[0267] [Figure 34] Figure 34A shows that PI-3025 (IgG1 format) and PI-3048 (IgG4 format) were statistically significant in IL-10 polarized macrophages after incubation with 0.1 μg / ml LPS+ATP and 1 μg / ml LSP+ATP. This indicates that IL-1β secretion was induced. Figure 34B shows that PI-3048 induced IL-1β secretion after treatment with 1 μg / ml LPS+ATP. The PI-3025 bar is displayed second from the left in each group, and the PI-3048 bar is displayed to the right of each group.

[0268] [Figure 35] Figure 4 shows that PI-3010.15, PI-3010.25, and PI-3030.41 induced IL-1β production when treated with LPS and ATP compared to untreated conditions.

[0269] [Figure 36] We show that PI-3008 showed antitumor activity as a single agent in the EMT6 model. Tumor volumes of mice treated with isotype control antibody are shown in the right panel, and tumor volumes of mice treated with PI-3008 antibody are shown in the left panel. PI-3008 treated mice were classified into responders and non-responders.

[0270] [Figure 37] Shows that PI-3008 showed antitumor activity as a single agent in the E0771 model. Tumor volumes from mice treated with isotype control antibody are shown in the top right and bottom right panels, tumor volumes from mice treated with PD-1 antibody are shown in the top left panel, and tumor volumes from mice treated with PI-3008 antibody are shown in the top left panel. Shown in the bottom left panel.

[0271] [Figure 38A] Figure 3 shows that mice receiving PI-3008 showed a statistically significant reduction in tumor volume compared to isotype controls (p=0.0037). [Figure 38B] Percentage of tumor growth inhibition (TGI) is shown for isotype antibodies and PI-3008. [Figure 38C] We show that both PI-3008 and effector-dead PI-3021 have antitumor activity in the E0771 model.

[0272] [Figure 39A] E0771 Provides a schematic diagram of the PD / PK / Efficacy Study Timeline. [Figure 39B] Tumor volumes over the course of the study in isotype control treated mice and PI-3008 treated mice are shown. [Figure 39C] Individual tumor volumes in isotype control mice are provided. [Figure 39D] Provides individual tumor volumes for PI-3008 mice. [Figure 39E] Provides the final tumor volume on day 28. [Figure 39F] Provide serum levels of PI-3008.

[0273] [Figure 40] Figure 40A provides PI-3008 serum concentrations in single and combination experiments with PD-1 antibodies. Figure 40B provides PD-1 antibody serum concentrations in combination experiments.

[0274] [Figure 41A] Provides IHC images of CD8 T cells and NCR1 (NK cells) stained with DAB after administration of isotype control or PI-3008. [Figure 41B] Provides quantification of inflammatory monocyte infiltration (CD8+ T cells, NCR1+ NK cells) by flow cytometry. [Figure 41C] Provides quantification of MHCIIHigh Ly6C+ monocytes, DC infiltration, and NK1.1 NK cells by flow cytometry. [Figure 41D] Provides quantification of CD206+ cells, MARCO+ cells, NCR1+ cells, and CD8a+ cells in the indicated regions.

[0275] [Figure 42] Figure 42A provides expression levels of the indicated pro-inflammatory cytokines and chemokines induced by PI-3008 in E0771 model tumor supernatants. Figure 42B provides expression levels of the indicated cytokines associated with T cell activation and NK cell activation observed at day 2 post-dose in tumor supernatants.

[0276] [Figure 43] Provides the results of receptor occupancy assays.

[0277] [Figure 44] Figure 44A provides quantification of the indicated cell types in spleen after treatment with isotype control antibody or PI-3008. Figure 44B provides quantification of the indicated cell types in the spleen after treatment with isotype control antibody or PI-3008. Figure 44C provides quantification of the indicated cell types in spleen after treatment with isotype control antibody or PI-3008. Figure 44D provides quantification of the indicated cell types in the spleen after treatment with isotype control antibody or PI-3008. In each figure, isotype samples are displayed on the left side of the pair and PI-3008 samples are displayed on the right side of the pair.

[0278] [Figure 45] Quantification of the indicated immunoglobulin types in spleen and serum after treatment with isotype control antibodies or PI-3008 is provided.

[0279] [Figure 46] Quantification of MARCO positive cells in the spleen after the second dose and at the end of the study after treatment with isotype control antibody or PI-3008 is provided.

[0280] [Figure 47] Figure 47A provides quantification of the indicated cell types in spleen after treatment with isotype control antibody or PI-3008. Figure 47B provides quantification of the indicated cell types in spleen after treatment with isotype control antibody or PI-3008. Figure 47C provides quantification of the indicated cell types in spleen after treatment with isotype control antibody or PI-3008. Figure 47D provides quantification of the indicated cell types in spleen after treatment with isotype control antibody or PI-3008.

[0281] [Figure 48] Figure 48A provides quantification of the percentage of positive cells per tissue compartment in the spleen after treatment with isotype control antibody or PI-3008. Figure 48B provides quantification of the percentage of positive cells per tissue compartment in the spleen after treatment with isotype control antibody or PI-3008. Figure 48C provides quantification of the percentage of positive cells per tissue compartment in the spleen after treatment with isotype control antibody or PI-3008. Figure 48D provides quantification of the percentage of positive cells per tissue compartment in the spleen after treatment with isotype control antibody or PI-3008. In each figure, isotype samples are displayed on the left side of the pair and PI-3008 samples are displayed on the right side of the pair.

[0282] [Figure 49] We show that PI-3008 induced an increase in CD8+ T cells and the cytotoxic marker granzyme B, as measured by IHC, compared to isotype control treated tumors.

[0283] [Figure 50] Showing changes in MARCO levels in marginal zone macrophages of the spleen, with significant gaps in the marginal zone region when stained with a non-PI-3008 competitive anti-mouse MARCO IHC-compatible antibody.

[0284] [Figure 51A] Representative images of colorectal tumor tissue (left) and lung tumor tissue (right) stained with 2.5 μg / mL RDM5 using the high pH (ER2) epitope search criteria in the top panel are shown. The bottom panel provides representative images of normal tissue cores from lung, spleen, and liver stained with 2.5 μg / ml RDM5 using high pH (ER2) epitope search conditions. Dark gay color indicates positive staining of bone marrow cells expressing MARCO. [Figure 51B] Shows the percentage of positive MARCO cancer cases in the indicated cancer types after IHC staining with RDM5 antibody. [Figure 51C] IHC scores in the indicated cancer types are shown after IHC staining with RDM5 antibody.

[0285] [Figure 52] We show that the binding of some anti-MARCO antibodies to MARCO was calcium dependent.

[0286] [Figure 53] Figure 3 shows binding of the indicated MARCO antibodies to human and cynomolgus monkey MARCO expressing cell lines.

[0287] [Figure 54] Figure 3 shows the binding of antibodies produced by stable transfection methods to MARCO expressing cells compared to reference antibodies produced by transient transfection.

[0288] [Figure 55] Figure 55A shows the sMARCO calibration curve for RG-3000A. Figure 55B shows sMARCO levels in normal and cancer serum samples.

[0289] [Figure 56-1] Tumor volumes of B cell-deficient mice are shown after treatment with MARCO antibodies, PD-1 antibodies, combinations, or isotype antibodies. [Figure 56-2] See description of Figure 56-1.

[0290] [Figure 57] NF-kB reporter activity induced by PI-3010.15 or isotype antibodies in combination with the indicated agonists at 4 or 24 hours is shown.

[0291] [Figure 58] Figure 4 shows that PI-3008 treatment induced the cytokines and chemokines shown in tumors of the E0771 model at early time points.

[0292] [Figure 59] Figure 4 shows that PI-3008 treatment induced the indicated cytokines and chemokines in the spleen of the E0771 model at early time points.

[0293] [Figure 60] Quantification of the indicated tumor bone marrow cell types on days 2 and 5 after administration of isotype control antibody or PI-3008 is provided.

[0294] [Figure 61] Quantification of the indicated tumor bone marrow cell types on days 2 and 5 after administration of isotype control antibody or PI-3008 is provided.

[0295] [Figure 62] Quantification of the indicated tumor bone marrow cell types on days 2 and 5 after administration of isotype control antibody or PI-3008 is provided.

[0296] [Figure 63] Quantification of the indicated tumor lymphoid cell types on days 2 and 5 after administration of isotype control antibody or PI-3008 is provided.

[0297] [Figure 64] Provides quantification of the indicated splenic lymphoid cell types 5 days after administration of isotype control antibody or PI-3008.

[0298] [Figure 65] Provides quantification of the indicated splenic lymphoid or myeloid cell types 5 days after administration of isotype control antibody or PI-3008.

[0299] [Figure 66] Provides quantification of the indicated splenic bone marrow cell types 5 days after administration of isotype control antibody or PI-3008.

[0300] [Figure 67] Provides quantification of the indicated splenic bone marrow cell types 5 days after administration of isotype control antibody or PI-3008.

[0301] [Figure 68] Provides quantification of the indicated splenic bone marrow cell types 5 days after administration of isotype control antibody or PI-3008.

[0302] [Figure 69] Provides quantification of cell types in the indicated blood 5 days after administration of isotype control antibody or PI-3008.

[0303] [Figure 70] Figure 3 shows that receptor occupancy of therapeutic MARCO antibodies was achieved in MARCO expressing cells in the spleen and tumors.

[0304] [Figure 71] Figure 4 shows that PI-3010.15 induced the expression of the indicated pro-inflammatory cytokines. [Details for carrying out the invention]

[0305] detailed description definition Terms used in the claims and specification are defined as set forth below, unless otherwise stated.

[0306] The term "improvement" refers to any therapeutically beneficial result in the treatment of a disease state, such as a cancer disease state, including prevention, reduction in severity or progression, amelioration, or cure thereof.

[0307] The term "in situ" refers to a process that occurs during the growth of living cells, such as in tissue culture, that are grown separately from a living organism.

[0308] The term "in vivo" refers to processes that occur within a living organism.

[0309] The term "mammal" as used herein includes both humans and non-humans, including but not limited to humans, non-human primates, dogs, cats, rats, cows, horses, and pigs. .

[0310] The term "percent identity" refers to the term "identity" in the context of two or more nucleic acid or polypeptide sequences using one of the sequence comparison algorithms described below (e.g., BLASTP and BLASTN or other algorithms available to those skilled in the art). Refers to two or more sequences or subsequences that have a specified percentage of nucleotide or amino acid residues that are identical when compared and aligned for maximum correspondence, as determined by visual inspection or by visual inspection. Depending on the application, percent "identity" can exist over a region of the sequences being compared, such as over a functional domain, or over the entire length of the two sequences being compared.

[0311] For sequence comparisons, typically one sequence serves as a reference sequence to which a test sequence is compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity of the test sequence(s) to the reference sequence based on predetermined program parameters.

[0312] Optimal alignment of sequences for comparison is determined, for example, by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the local homology algorithm of Needleman & Wunsch, J. Mol. by homology alignment algorithms, by the similarity seeking method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA85:2444 (1988), by computerized implementations of these algorithms (Wisconsin Genetics Software Package, Genetics Computer Group, 575 GAP, BESTFIT, FASTA, and TFASTA in Science Dr., Madison, Wis.) or by visual inspection (see generally Ausubel et al., below).

[0313] One example of an algorithm suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, described in Altschul et al., J. Mol. Biol. 215:403-410 (1990). . Software to perform BLAST analysis is publicly available through the National Center for Biotechnology Information (ncbi.nlm.nih.gov / ).

[0314] The term "sufficient amount" means an amount sufficient to produce the desired effect, eg, an amount sufficient to modulate protein aggregation within a cell.

[0315] The term "therapeutically effective amount" is an amount effective to ameliorate symptoms of a disease. Because prevention can be considered treatment, a therapeutically effective amount can be a "prophylactically effective amount."

[0316] Abbreviations used in this application include:

[0317] Note that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Must.

[0318] antibody structure This application provides antibodies and compositions that include antibodies that bind to MARCO proteins. Such antibodies include antibodies that enhance, potentiate, or induce an immune response or kill, disable, or deplete bone marrow cells.

[0319] The term "antibody" is used herein in its broadest sense and includes a specific type of immunoglobulin molecule that contains one or more antigen-binding domains that specifically bind an antigen or epitope. Antibodies specifically include whole antibodies (eg, complete immunoglobulins), antibody fragments, and multispecific antibodies.

[0320] The recognized immunoglobulin genes include the kappa constant region genes, the lambda constant region genes, the alpha constant region genes, the gamma constant region genes, the delta constant region genes, the epsilon constant region genes, and the mu constant region genes, as well as a vast number of immunoglobulin genes. Contains globulin variable region genes. Light chains are classified as either κ or λ. The "class" of an antibody or immunoglobulin refers to the type of constant domain or region possessed by its heavy chain. There are five major antibody classes, IgA, IgD, IgE, IgG, and IgM, and several of these have subclasses (isotypes), e.g., IgG1, IgG 2 , IgG 3 , IgG 4 , IgA1, and IgA 2 can be further subdivided into The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0321] An exemplary immunoglobulin (antibody) structural unit is composed of two pairs of polypeptide chains, each pair carrying one "light" chain (approximately 25 kD) and one "heavy" chain (approximately 50-70 kD). For example, it is a paired homodimer of a light chain and a heavy chain. The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids that is primarily responsible for antigen recognition. The terms "variable light chain" (VL) and "variable heavy chain" (VH) refer to these light chain and heavy chain domains, respectively. The IgG1 heavy chain is composed of VH, CH1, CH2, and CH3 domains from the N-terminus to the C-terminus, respectively. The light chain is composed of VL and CL domains from the N-terminus to the C-terminus. The IgG1 heavy chain contains a hinge between the CH1 and CH2 domains. In certain embodiments, the immunoglobulin construct comprises at least one immunoglobulin domain derived from IgG, IgM, IgA, IgD, or IgE linked to a therapeutic polypeptide. In some embodiments, the immunoglobulin domains found in the antibodies provided herein are derived from or derived from immunoglobulin-based constructs, such as diabodies or nanobodies. In certain embodiments, the immunoglobulin constructs described herein include at least one immunoglobulin domain derived from a heavy chain antibody, such as a camel antibody. In certain embodiments, the immunoglobulin constructs provided herein include at least one immunoglobulin domain derived from a mammalian antibody, such as a bovine antibody, human antibody, camel antibody, mouse antibody, or any chimeric antibody.

[0322] In some embodiments, the antibodies provided herein include a heavy chain. In one embodiment, the heavy chain is IgA. In one embodiment, the heavy chain is IgD. In one embodiment, the heavy chain is IgE. In one embodiment, the heavy chain is IgG. In one embodiment, the heavy chain is IgM. In one embodiment, the heavy chain is IgG1. In one embodiment, the heavy chain is IgG2. In one embodiment, the heavy chain is IgG3. In one embodiment, the heavy chain is IgG4. In one embodiment, the heavy chain is IgA1. In one embodiment, the heavy chain is IgA2.

[0323] As used herein, the term "hypervariable region" or "HVR" refers to antibody variable regions that are hypervariable in sequence and / or form structurally defined loops ("hypervariable loops"). Refers to each area of ​​the domain. Generally, natural four-chain antibodies contain six HVRs, three in the VH (H1, H2, H3) and three in the VL (L1, L2, L3). HVRs generally contain amino acid residues from hypervariable loops and / or from "complementarity determining regions" (CDRs), the latter of which have the highest sequence variability and / or are involved in antigen recognition. With the exception of CDR1 in VH, CDRs generally contain amino acid residues that form hypervariable loops. Hypervariable regions (HVRs) are also referred to as "complementarity determining regions" (CDRs), and these terms are used interchangeably herein with respect to the portion of the variable region that forms the antigen binding region. This particular region has been described by Kabat et al., U.S. Dept. of Health and Human Services, Sequences of Proteins of Immunological Interest (1983) and Chothia et al., J Mol Biol 196:901-917 (1987). and the definition includes overlapping or subsets of amino acid residues when compared to each other. Nevertheless, the application of any definition to refer to CDRs of an antibody or variant thereof is intended to be within the scope of the terms as defined and used herein. The exact number of residues encompassing a particular CDR will vary depending on the sequence and size of the CDR. One skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequences of an antibody.

[0324] Amino acid sequence boundaries of CDRs are defined by Kabat et al., supra (“Kabat” numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 (“Chothia” numbering scheme). scheme);MacCallum et al.,1996,J.Mol.Biol.262:732-745(“Contact” numbering scheme);Lefranc et al.,Dev.Comp.Immunol.,2003,27:55-77( “IMGT” numbering scheme); and Honegge and Pluckthun, J. Mol. Biol., 2001, 309:657-70 (“AHo” numbering scheme) (each of which is incorporated by reference in its entirety). can be determined by one of ordinary skill in the art using any of a number of known numbering schemes, including those described below.

[0325] Table A provides the positions of CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3 identified by the Kabat and Chothia scheme. For CDR-H1, residue numbering is provided using both the Kabat and Chothia numbering schemes.

[0326] CDRs are defined by antibody numbering such as Abnum, as described, for example, by Abhinandan and Martin, Immunology, 2008, 45:3832-3839, available at bioinf.org.uk / abs / abnum / and incorporated by reference in its entirety. May be assigned using software.

[0327] [Table A]

[0328] The "EU numbering scheme" is commonly used when referring to residues within antibody heavy chain constant regions (eg, as reported in Kabat et al., supra). Unless otherwise noted, the EU numbering scheme is used to refer to residues of the antibody heavy chain constant regions described herein.

[0329] The term "single chain" as used herein refers to a molecule that includes amino acid monomers linearly linked by peptide bonds. In certain such embodiments, the C-terminus of the Fab light chain is linked to the N-terminus of the Fab heavy chain of a single chain Fab molecule. As described in more detail herein, an scFv has a light chain variable domain (VL) linked from its C-terminus to the N-terminus of a heavy chain variable domain (VH) by a polypeptide chain. Alternatively, an scFv is composed of a polypeptide chain that connects the C-terminus of the VH to the N-terminus of the VL.

[0330] “Fab fragments” (also called fragment antigen binding) contain the constant domain of the light chain (CL) and the first constant domain of the heavy chain (CH1) with the variable domains VL and VH on the light and heavy chains, respectively. do. Variable domains include complementarity determining loops (CDRs, also called hypervariable regions) that are involved in antigen binding. Fab' fragments differ from Fab fragments by the addition of several residues at the carboxy terminus of the heavy chain CH1 domain, including one or more cysteines from the antibody hinge region.

[0331] 「F(ab’) 2 ' fragment contains two Fab' fragments that are joined near the hinge region by disulfide bonds. F(ab’) 2 Fragments can be produced, for example, by recombinant methods or by pepsin digestion of intact antibodies. F(ab') fragments can be dissociated, for example, by treatment with β-mercaptoethanol.

[0332] An "Fv" fragment comprises a non-covalently linked dimer of one heavy chain variable domain and one light chain variable domain.

[0333] A "single chain Fv" or "scFv" comprises the VH and VL domains of an antibody, which domains are present in a single polypeptide chain. In one embodiment, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains that allows the scFv to form the desired structure for antigen binding. For a review of scFvs, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994). HER2 antibody scFv fragments are described in WO93 / 16185; US Patent No. 5,571,894; and US Patent No. 5,587,458.

[0334] A "scFv-Fc" fragment comprises an scFv linked to an Fc domain. For example, an Fc domain can be attached to the C-terminus of an scFv. The Fc domain is defined by the orientation of the variable domains within the scFv (i.e., V H -V L or V L -V H ), V H or V L can be followed by Any suitable Fc domain known in the art or described herein can be used. In some cases, the Fc domain comprises an IgG4 Fc domain. In some cases, the Fc domain comprises an IgG1 Fc domain.

[0335] The term "single domain antibody" or "sdAb" refers to a molecule in which one variable domain of the antibody specifically binds to an antigen without the presence of other variable domains. Single domain antibodies and fragments thereof are described in Arabi Ghahroudi et al., FEBS Letters, 1998, 414: 521-526 and Muyldermans et al., Trends in Biochem. Sci., 2001, 26: 230-245; each of which is incorporated by reference in its entirety. Single domain antibodies are also known as sdAbs or nanobodies. Sdab is fairly stable and easily expressed as a fusion partner with the Fc chain of antibodies (Harmsen MM, De Haard HJ (2007). “Properties, production, and applications of camelid single-domain antibody fragments”. Appl .Microbiol Biotechnol.77(1):13-22).

[0336] The terms "full-length antibody," "intact antibody," and "whole antibody" are used herein to refer to an antibody that has a heavy chain that has a structure substantially similar to that of a naturally occurring antibody and that includes an Fc region. used interchangeably. For example, when used to refer to an IgG molecule, a "full length antibody" is an antibody that includes two heavy chains and two light chains.

[0337] The term "epitope" refers to the part of an antigen that specifically binds to an antibody. Epitopes often consist of surface-accessible amino acid residues and / or sugar side chains and may have specific three-dimensional structural characteristics and specific charge characteristics. Conformational and nonconformational epitopes are distinguished in that binding to the former but not the latter can be lost in the presence of denaturing solvents. An epitope can include amino acid residues that are directly involved in binding, as well as other amino acid residues that are not directly involved in binding. The epitope to which the antibody binds can be determined using known techniques for epitope determination, such as, for example, testing antibody binding to MARCO variants with different point mutations or chimeric MARCO variants. In some embodiments, the MARCO epitope is in the SRCR domain. In some embodiments, the MARCO epitope is in a collagen-like domain. In some embodiments, the anti-MARCO antibody or antigen-binding fragment thereof binds to an SRCR domain. In some embodiments, the anti-MARCO antibody or antigen-binding fragment thereof binds a collagen-like domain.

[0338] A "multispecific antibody" is an antibody that contains two or more different antigen binding domains that collectively and specifically bind two or more different epitopes. Two or more different epitopes can be on the same antigen (e.g., a single MARCO molecule expressed by a cell) or different antigens (e.g., different MARCO molecules expressed by the same cell, or MARCO molecules and non-MARCO molecules). It may be an epitope. In some embodiments, a multispecific antibody binds two different epitopes (ie, a "bispecific antibody"). In some embodiments, a multispecific antibody binds three different epitopes (ie, a "trispecific antibody").

[0339] A "monospecific antibody" is an antibody that contains one or more binding sites that specifically bind a single epitope. An example of a monospecific antibody is a naturally occurring IgG molecule that is bivalent (ie, has two antigen binding domains) but recognizes the same epitope on each of the two antigen binding domains. Binding specificity may be present at any suitable valence.

[0340] The term "monoclonal antibody" refers to an antibody derived from a substantially homogeneous population of antibodies. A substantially homogeneous population of antibodies includes antibodies that are substantially similar and bind to the same epitope(s), excluding mutations that may normally occur during the production of monoclonal antibodies. Such variants generally exist only in small amounts. Monoclonal antibodies are usually obtained by a process that involves selecting a single antibody from multiple antibodies. For example, the selection process can be the selection of unique clones from multiple clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody may be further modified, for example, to improve its affinity for the target (“affinity maturation”), to humanize the antibody, to improve its production in cell culture, and / or to improve its immunogenicity in a subject. Modifications can be made to reduce this.

[0341] "Effector function" refers to the biological activity mediated by the Fc region of an antibody, which activity can vary depending on the antibody isotype. Examples of antibody effector functions include C1q binding that activates complement-dependent cytotoxicity (CDC), Fc receptor binding that activates antibody-dependent cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). , receptor ligand blockade, agonism, or antagonism. An active Fc region is a region capable of Fc-based effector functions such as ADCC, CDC, and / or ADCP.

[0342] Anti-MARCO antibodies may include those described herein, such as the clones shown in the table. In some embodiments, the antibody includes an alternative scaffold. In some embodiments, the antibody consists of an alternative scaffold. In some embodiments, the antibody consists essentially of an alternative scaffold. In some embodiments, antibodies include antibody fragments. In some embodiments, the antibody consists of antibody fragments. In some embodiments, the antibody consists essentially of antibody fragments. A "MARCO antibody," "anti-MARCO antibody," or "MARCO-specific antibody" is an antibody provided herein that specifically binds the antigen MARCO. In some embodiments, the antibody binds to the extracellular domain of MARCO. In certain embodiments, the MARCO antibodies provided herein bind to epitopes of MARCO that are conserved among MARCO proteins from different species.

[0343] The term "chimeric antibody" or "chimeric antibody" means that a portion of the heavy and / or light chain is derived from a particular source or species, but the remainder of the heavy and / or light chain is derived from a different source or species. Refers to antibodies derived from species.

[0344] A "humanized" form of a non-human antibody is a chimeric antibody that contains minimal sequence derived from a non-human antibody. A humanized antibody is generally a human antibody (recipient antibody) in which residues from one or more CDRs have been replaced by residues from one or more CDRs of a non-human antibody (donor antibody). . The donor antibody can be any suitable non-human antibody, such as a mouse, rat, rabbit, chicken, or non-human primate antibody, with the desired specificity, affinity, or biological effect. When administered to a human subject, humanized antibodies are less likely to induce an immune response and / or induce a less severe immune response compared to antibodies of non-human species. In some cases, selected framework region residues of the recipient antibody are replaced by corresponding framework region residues from the donor antibody. Humanized antibodies may contain residues that are found in neither the recipient antibody nor the donor antibody. These modifications can be made to further refine antibody performance. Examples of methods for making humanized antibodies can be found in US Patent Nos. 6,054,297, 5,886,152, and 5,877,293, each of which is incorporated by reference in its entirety. For further details see Jones et al., Nature, 1986, 321:522-525; Riechmann et al., Nature, 1988, 332: 323-329; and Presta, Curr. Op. Structure. Biol., 1992, 2 :593-596, each of which is incorporated by reference in its entirety.

[0345] In some embodiments, the antibody comprises a rat MARCO antibody. In some embodiments, the antibody comprises a chimeric MARCO antibody. In some embodiments, the antibody comprises a humanized MARCO antibody. In some embodiments, the antibody comprises a human MARCO antibody.

[0346] In some embodiments, the humanized MARCO antibody VH sequence has 16G, 19R, 23A, 37V, 42G, 48V, 49S, 82Q, 88A, 93V, 114T compared to the rat VH sequence set forth in SEQ ID NO: 141. , 115L, S16G, K19R, V23A, I37V, K42G, I48V, A49S, E82Q, S88A, M93V, V114T, or M115L. In some embodiments, the humanized MARCO antibody VH sequence is at least one of G16, R19, A23, V37, G42, V48, S49, Q82, A88, V93, T114, L115 numbered according to the EU index. Including one. In some embodiments, the humanized MARCO antibody VH sequence is one of I38, I48, A49, S54, Q54, A54, G56, S56, Q56, A56, S57, Q57, or A57 numbered according to the EU index. Contains at least one of the following.

[0347] In some embodiments, the humanized MARCO antibody VL sequence has 2I, 10S, 13S, 16V, 18D, 19R, 21T, 23T, 25R, 38Q, 41G as compared to the rat VL sequence set forth in SEQ ID NO: 146. , 43A, 44P, 50D, 51A, 53S, 55E, 58V, 76S, 77S, 79Q, 85T, 99Q, V2I, Y10S, A13S, P16V, E18D, S19R, S21T, S23T, K25R, E38Q, E41G, T43A, N44P , S50D, G51A, T53S, Q55E, T58V, R76S, N77S, E79Q, V85T, and S99Q. In some embodiments, the humanized MARCO antibody VL sequences are numbered according to the EU index: I2, S10, S13, V16, D18, R19, T21, T23, R25, Q38, G41, A43, P44, D50, Contains at least one of A51, S53, E55, V58, S76, S77, Q79, T85, or Q99. In some embodiments, the humanized MARCO antibody VL sequence comprises at least one of V2, R24, K24, Q38, E38, A43, T43, N44, or P44 numbered according to the EU index.

[0348] In some embodiments, the humanized MARCO antibody VH sequence is 2V, 9A, 11V, 16A, 20V, 38R, 43Q, 46E, 62Q, 63K, 65Q compared to the rat VH sequence set forth in SEQ ID NO: 231. , 66G, 68V, 69T, 70M, 71T, 72R, 73D, 76T, 78A, 79Y, 80M, 81E, 82L, 83S, 84S, 86R, 87S, 92V, 94Y, 96A, 114T, 115L, I2V, P9A, L11V , E16A, I20V, K38R, N43Q, K46E, D62Q, D63K, K65Q, Q66G, F68V, V69T, F70M, S71T, L72R, E73D, A76T, S78A, F79Y, L80M, Q81E, I82L, N83S, N84S, N86R, I87S , T92V, F94Y, T96A, V114T, M115L. In some embodiments, the humanized MARCO antibody VH sequences are numbered according to the EU index: V2, A9, V11, A16, V20, R38, Q43, E46, Q62, K63, Q65, G66G, V68, T69, Contains at least one of M70, T71, R72, D73, T76, A78, Y79, M80, E81, L82, S83, S84, R86, S87, V92, Y94, A96, T114, L115.

[0349] In some embodiments, the humanized MARCO antibody VL sequence has 9S, 15V, 17D, 18R, 20T, 22T, 24R, 40P, 43A, 45K, 70D compared to the rat VL sequence set forth in SEQ ID NO: 236. , 72T, 73T, 76S, 77L, 82F, 84T, 86Y, 100Q, 106I, A9S, L15V, E17D, T18R, S20T, E22T, L24R, S40P, S43A, Q45K, R70D, S72T, K73T, D76S, M77L, E82F , D84T, F86Y, G100Q, L106I. In some embodiments, the humanized MARCO antibody VL sequences are numbered according to the EU index: S9, V15, D17, R18, T20, T22, R24, P40, A43, K45, D70, T72, T73, S76, Contains at least one of L77, F82, T84, Y86, Q100, or I106.

[0350] In some embodiments, the humanized MARCO antibody VH sequence has 1E, 5Q, 13K, 16E, 48I, 61P, 62S, 67V, 68T, 76N, 79S as compared to the rat VH sequence set forth in SEQ ID NO: 1. , 82L, 83S, 85V, 86T, 87A, 88A, 92V, 116T, 117L, Q1E, K5Q, Q13K, Q16E, M48I, S61P, L62S, L67V, S68T, S76N, F79S, M82L, N83S, L85V, Q86T, T87A , E88A, T92V, V116T, or M117L. In some embodiments, the humanized MARCO antibody VH sequences are numbered according to the EU index: E1, Q5, K13, E16, I48, P61, S62, V67, T68, N76, S79, L82, S83, V85, Contains at least one of T86, A87, A88, V92, T116, or L117.

[0351] In some embodiments, the humanized MARCO antibody VL sequence has 9S, 13A, 15V, 17D, 18R, 20T, 22T, 24R, 40P, 43A, 45K as compared to the rat VL sequence set forth in SEQ ID NO: 6. , 56S, 70D, 71F, 72T, 74T, 77S, 78L, 92F, 94T, 96Y, 100Q, 9S, T13A, L15V, E17D, T18R, S20T, E22T, L24R, S40P, S43A, Q45K, D56S, R70D, Y71F , S72T, K74T, G77S, M78L, E92F, D94T, F96Y, or S100Q. In some embodiments, the humanized MARCO antibody VL sequences are numbered according to the EU index: S9, T13, A13, D17, R18, T20, T22, L24, R24, N31, S31, Q31, A31, D31, Of P40, A43, S43, I43, K45, D56, S56, D70, Y71, F71, T72, T74, S77, L78, M78, F83, E83, T85, Y87, F87, F92, T94, S100, or Q100 Contains at least one of the following.

[0352] In one embodiment, constant domain(s) from a human antibody are fused to variable domain(s) of a non-human species. In another embodiment, one or more amino acid residues in one or more CDR sequences of a non-human antibody increase the immunogenic potential of the non-human antibody when it is administered to a human subject. Either the amino acid residues that are changed to reduce are not important for immunospecific binding of the antibody to the antigen, or the changes to the amino acid sequence that are made are conservative changes that result in , the binding of humanized antibodies to antigens is not significantly lower than the binding of non-human antibodies to antigens.

[0353] "Human antibody" is a non-human antibody produced by a human or human cells, or which utilizes a human antibody repertoire or human antibody coding sequences (e.g., obtained from a human source or designed de novo). It has an amino acid sequence that corresponds to that of the antibody derived from the source. Human antibodies specifically exclude humanized antibodies. In one embodiment, all variable and constant domains are derived from human immunoglobulin sequences (fully human antibodies). These antibodies can be prepared in a variety of ways, including immunization with the antigen of interest of mice genetically modified to express antibodies derived from genes encoding human heavy and / or light chains. .

[0354] In some embodiments, antibodies provided herein include antibody fragments. In some embodiments, the antibodies provided herein consist of antibody fragments. In some embodiments, the antibodies provided herein consist essentially of antibody fragments. In some embodiments, the antibody fragment is an Fv fragment. In some embodiments, the antibody fragment is a Fab fragment. In some embodiments, the antibody fragment is F(ab') 2 It is a fragment. In some embodiments, the antibody fragment is a Fab' fragment. In some embodiments, the antibody fragment is an scFv (sFv) fragment. In some embodiments, the antibody fragment is a scFv-Fc fragment. In some embodiments, the antibody fragment is a fragment of a single domain antibody.

[0355] MARCO antibody sequence Table B provides names and SEQ ID numbers of exemplary anti-MARCO antibodies provided herein.

[0356] [Table B] TIFF2023549555000004.tif142165

[0357] CDR In some embodiments, the isolated antibody or antigen-binding fragment thereof that binds human MARCO (SEQ ID NO: 384) has a heavy chain comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3. and a light chain variable (VL) sequence comprising three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, with CDR-H1 having the sequence GFSLTSYHVS (SEQ ID NO: 2). ), CDR-H2 contains the sequence AIWTGGSIA (SEQ ID NO: 3), CDR-H3 contains the sequence DLSDYYSSYTSFDY (SEQ ID NO: 4), and CDR-L1 contains the sequence ASEGISNDLA (SEQ ID NO: 431) or XASEGISNDLA (SEQ ID NO: 4). 383) (wherein X is arginine (R) or leucine (L)), CDR-L2 contains the sequence AASRLQD (SEQ ID NO: 8), and CDR-L3 contains the sequence QQSYKYPLT (SEQ ID NO: 9) .

[0358] In some embodiments, CDR-L1 comprises the sequence LASEGISNDLA (SEQ ID NO: 7). In some embodiments, CDR-L1 comprises the sequence RASEGISNDLA (SEQ ID NO: 27). In some embodiments, CDR-L1 comprises the sequence ASEGISNDLA (SEQ ID NO: 431).

[0359] In some embodiments, the antibodies provided herein have CDR-H3 of SEQ ID NO: 4, CDR-H2 of SEQ ID NO: 3, CDR-H1 of SEQ ID NO: 2, CDR-L3 of SEQ ID NO: 9, Contains CDR-L2 of SEQ ID NO: 8 and CDR-L1 of SEQ ID NO: 7. In some embodiments, the antibodies provided herein have CDR-H3 of SEQ ID NO:4, CDR-H2 of SEQ ID NO:3, CDR-H1 of SEQ ID NO:2, CDR-L3 of SEQ ID NO:9, Contains CDR-L2 with number 8 and CDR-L1 with SEQ ID NO: 27. In some embodiments, the antibodies provided herein have CDR-H3 of SEQ ID NO:4, CDR-H2 of SEQ ID NO:3, CDR-H1 of SEQ ID NO:2, CDR-L3 of SEQ ID NO:9, Contains CDR-L2 with number 8 and CDR-L1 with SEQ ID NO: 431. In some embodiments, the CDR-H3 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity to CDR-H3 of SEQ ID NO: 4, and the CDR-H3 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with CDR-H2 of SEQ ID NO: 3; has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity, and the CDR-L3 is at least about 50%, 75%, 80% identical to CDR-L3 of SEQ ID NO:9. , 85%, 90%, or 95% identity, and the CDR-L2 is at least about 50%, 75%, 80%, 85%, 90%, or 95% identical to the CDR-L2 of SEQ ID NO: 8. and the CDR-L1 is at least about 50%, 75%, 80%, 85%, 90%, or 95% identical to the CDR-L1 of SEQ ID NO: 431, 383, 7, or 27. has. In some embodiments, the CDR-H3 is a CDR-H3 of SEQ ID NO: 4 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; CDR-H2 of SEQ ID NO: 3 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions and CDR-H1 with up to 1, 2, 3, 4, or 5 amino acid substitutions and CDR-L3 is CDR-L3 of SEQ ID NO: 9 with up to 1, 2, 3, 4, or 5 amino acid substitutions; is CDR-L2 of SEQ ID NO: 8 with up to 1, 2, 3, or 4 amino acid substitutions, and CDR-L1 is with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions. CDR-L1 having SEQ ID NO: 431, 383, 7, or 27.

[0360] In some embodiments, a heavy chain variable (VH) sequence comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and three light chain CDR sequences, CDR-L1, CDR- Provided herein is an isolated antibody or antigen-binding fragment thereof that binds to human MARCO (SEQ ID NO: 384), comprising a light chain variable (VL) sequence comprising CDR-L2, and CDR-L3. H1 contains the sequence GYTFTDYAVN (SEQ ID NO: 232), CDR-H2 contains the sequence WINTQTGKPT (SEQ ID NO: 233), CDR-H3 contains the sequence DSYYYSSSLDY (SEQ ID NO: 234), and CDR-L1 contains the sequence ASAGISNDLA ( SEQ ID NO: 432) or XASAGISNDLA (SEQ ID NO: 381), where X is leucine (L) or arginine (R), CDR-L2 includes the sequence AASRLQD (SEQ ID NO: 238), and CDR-L3 Contains the sequence QQSYKYPWT (SEQ ID NO: 239). In some embodiments, CDR-L1 comprises the sequence LASAGISNDLA (SEQ ID NO: 237). In some embodiments, CDR-L1 comprises the sequence RASAGISNDLA (SEQ ID NO: 317). In some embodiments, CDR-L1 comprises the sequence ASAGISNDLA (SEQ ID NO: 432).

[0361] In some embodiments, the antibodies provided herein have CDR-H3 of SEQ ID NO: 234, CDR-H2 of SEQ ID NO: 233, CDR-H1 of SEQ ID NO: 232, CDR-L3 of SEQ ID NO: 239, Contains CDR-L2 with number 238 and CDR-L1 with SEQ ID NO: 237. In some embodiments, the antibodies provided herein have CDR-H3 of SEQ ID NO: 234, CDR-H2 of SEQ ID NO: 233, CDR-H1 of SEQ ID NO: 232, CDR-L3 of SEQ ID NO: 319, Contains CDR-L2 with number 318 and CDR-L1 with SEQ ID NO: 317. In some embodiments, the antibodies provided herein have CDR-H3 of SEQ ID NO: 234, CDR-H2 of SEQ ID NO: 233, CDR-H1 of SEQ ID NO: 232, CDR-L3 of SEQ ID NO: 239, Contains CDR-L2 with number 238 and CDR-L1 with SEQ ID NO: 432. In some embodiments, the CDR-H3 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity to CDR-H3 of SEQ ID NO: 234; has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with CDR-H2 of SEQ ID NO: 233; has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity, and the CDR-L3 is at least about 50%, 75%, 80% identical to CDR-L3 of SEQ ID NO: 239 , 85%, 90%, or 95% identity, and the CDR-L2 is at least about 50%, 75%, 80%, 85%, 90%, or 95% identical to the CDR-L2 of SEQ ID NO: 238. and the CDR-L1 is at least about 50%, 75%, 80%, 85%, 90%, or 95% identical to a CDR-L1 of SEQ ID NO: 432, 237, 317, or 381. has. In some embodiments, the CDR-H3 is the CDR-H3 of SEQ ID NO: 234 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; CDR-H2 of SEQ ID NO: 233 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions and CDR-H1 with up to 1, 2, 3, 4, or 5 amino acid substitutions and CDR-L3 is CDR-L3 of SEQ ID NO: 239 with up to 1, 2, 3, 4, or 5 amino acid substitutions; is CDR-L2 of SEQ ID NO: 238 with up to 1, 2, 3, or 4 amino acid substitutions, and CDR-L1 is with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions. CDR-L1 having SEQ ID NO: 432, 237, 317, or 381.

[0362] In some embodiments, the isolated antibody or antigen-binding fragment thereof that binds human MARCO (SEQ ID NO: 363) has a heavy chain comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3. a variable (VH) sequence and a light chain variable (VL) sequence comprising three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, where CDR-H1 is the sequence GYTFTDYYLH ( CDR-H2 contains the sequence YINPNNAYTS (SEQ ID NO: 253), CDR-H3 contains the sequence DTTDYYNLHFAY (SEQ ID NO: 254), and CDR-L1 contains the sequence LTSEGISNDLA (SEQ ID NO: 257). , CDR-L2 contains the sequence DASRLED (SEQ ID NO: 258), and CDR-L3 contains the sequence QQSYKYPLT (SEQ ID NO: 259).

[0363] In some embodiments, the antibodies provided herein include CDR-H3 of SEQ ID NO: 254, CDR-H2 of SEQ ID NO: 253, CDR-H1 of SEQ ID NO: 252, CDR-L3 of SEQ ID NO: 259, Contains CDR-L2 with number 258 and CDR-L1 with SEQ ID NO: 257. In some embodiments, the CDR-H3 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity to CDR-H3 of SEQ ID NO: 254, and the CDR-H3 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with CDR-H2 of SEQ ID NO: 253; at least about 50%, 75%, 80%, 85%, 90%, or 95% identical to CDR-L3 of SEQ ID NO: 259; , 85%, 90%, or 95% identity, and the CDR-L2 is at least about 50%, 75%, 80%, 85%, 90%, or 95% identical to the CDR-L2 of SEQ ID NO: 258. CDR-L1 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with CDR-L1 of SEQ ID NO: 257. In some embodiments, the CDR-H3 is the CDR-H3 of SEQ ID NO: 254 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; CDR-H2 of SEQ ID NO: 253 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, and CDR-H1 with up to 1, 2, 3, 4, or 5 amino acid substitutions and CDR-L3 is CDR-L3 of SEQ ID NO: 259 with up to 1, 2, 3, 4, or 5 amino acid substitutions; is CDR-L2 of SEQ ID NO: 258 with up to 1, 2, 3, or 4 amino acid substitutions, and CDR-L1 is with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions. It is CDR-L1 with SEQ ID NO: 257.

[0364] In some embodiments, the isolated antibody or antigen-binding fragment thereof that binds human MARCO (SEQ ID NO: 363) has a heavy chain comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3. comprises a variable (VH) sequence and a light chain variable (VL) sequence comprising three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, where CDR-H1 has the sequence KFTFSNYGMN ( CDR-H2 contains the sequence LIYYNSNNKY (SEQ ID NO: 143), CDR-H3 contains the sequence SLTGGSDYFDS (SEQ ID NO: 144), and CDR-L1 contains the sequence ASKSIGTFLA (SEQ ID NO: 433) or XASKSIGTFLA (SEQ ID NO: 382), where X is lysine (K) or arginine (R), CDR-L2 includes the sequence SGSTLQS (SEQ ID NO: 148), and CDR-L3 includes the sequence QQHDEYPFT (SEQ ID NO: 149). )including.

[0365] In some embodiments, CDR-L1 comprises the sequence KASKSIGTFLA (SEQ ID NO: 147). In some embodiments, CDR-L1 comprises the sequence RASKSIGTFLA (SEQ ID NO: 157). In some embodiments, CDR-L1 comprises the sequence ASKSIGTFLA (SEQ ID NO: 433).

[0366] In some embodiments, the antibodies provided herein include CDR-H3 of SEQ ID NO: 144, CDR-H2 of SEQ ID NO: 143, CDR-H1 of SEQ ID NO: 142, CDR-L3 of SEQ ID NO: 149, Contains CDR-L2 with number 148 and CDR-L1 with SEQ ID NO: 147. In some embodiments, the antibodies provided herein include CDR-H3 of SEQ ID NO: 144, CDR-H2 of SEQ ID NO: 143, CDR-H1 of SEQ ID NO: 142, CDR-L3 of SEQ ID NO: 149, Contains CDR-L2 with number 148 and CDR-L1 with SEQ ID NO: 157. In some embodiments, the antibodies provided herein include CDR-H3 of SEQ ID NO: 144, CDR-H2 of SEQ ID NO: 143, CDR-H1 of SEQ ID NO: 142, CDR-L3 of SEQ ID NO: 149, Contains CDR-L2 with number 148 and CDR-L1 with SEQ ID NO: 433. In some embodiments, the CDR-H3 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity to CDR-H3 of SEQ ID NO: 144, and the CDR-H3 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with CDR-H2 of SEQ ID NO: 143; at least about 50%, 75%, 80%, 85%, 90%, or 95% identical to CDR-L3 of SEQ ID NO: 149; , 85%, 90%, or 95% identity, and the CDR-L2 is at least about 50%, 75%, 80%, 85%, 90%, or 95% identical to the CDR-L2 of SEQ ID NO: 148. and the CDR-L1 is at least about 50%, 75%, 80%, 85%, 90%, or 95% identical to a CDR-L1 of SEQ ID NO: 433, 382, ​​147, or 157. has. In some embodiments, the CDR-H3 is the CDR-H3 of SEQ ID NO: 144 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; CDR-H2 of SEQ ID NO: 143 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions and CDR-H1 with up to 1, 2, 3, 4, or 5 amino acid substitutions and CDR-L3 is CDR-L3 of SEQ ID NO: 149 with up to 1, 2, 3, 4, or 5 amino acid substitutions; is CDR-L2 of SEQ ID NO: 148 with up to 1, 2, 3, or 4 amino acid substitutions, and CDR-L1 is with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions. CDR-L1 having SEQ ID NO: 433, 382, ​​147, or 157.

[0367] In some embodiments, the isolated antibody or antigen-binding fragment thereof that binds human MARCO (SEQ ID NO: 384) has a heavy chain comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3. comprises a variable (VH) sequence and a light chain variable (VL) sequence comprising three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3, where CDR-H1 has the sequence GFSLTSYTLS ( CDR-H2 contains the sequence AIWGGDNTD (SEQ ID NO: 363), CDR-H3 contains the sequence ELGGSFDY (SEQ ID NO: 364), CDR-L1 contains the sequence KTSQNINKKLD (SEQ ID NO: 367), CDR -L2 contains the sequence YTNNLQT (SEQ ID NO: 368) and CDR-L3 contains the sequence YQYDSGFT (SEQ ID NO: 369).

[0368] In some embodiments, the CDR-H3 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity to CDR-H3 of SEQ ID NO: 364; has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with CDR-H2 of SEQ ID NO: 363; has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity, and the CDR-L3 is at least about 50%, 75%, 80% identical to CDR-L3 of SEQ ID NO: 369 , 85%, 90%, or 95% identity, and the CDR-L2 is at least about 50%, 75%, 80%, 85%, 90%, or 95% identical to the CDR-L2 of SEQ ID NO: 368. CDR-L1 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with CDR-L1 of SEQ ID NO: 367. In some embodiments, the CDR-H3 is a CDR-H3 of SEQ ID NO: 364 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions; CDR-H2 of SEQ ID NO: 363 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, and CDR-H1 with up to 1, 2, 3, 4, or 5 amino acid substitutions and CDR-L3 is CDR-L3 of SEQ ID NO: 369 with up to 1, 2, 3, 4, or 5 amino acid substitutions; is CDR-L2 of SEQ ID NO: 368 with up to 1, 2, 3, or 4 amino acid substitutions, and CDR-L1 is with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions. It is CDR-L1 with SEQ ID NO: 367.

[0369] In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described herein are referred to herein as "variants." In some embodiments, such variants are produced by, for example, affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. , derived from the sequences provided herein. In some embodiments, such variants are not derived from the sequences provided herein and can be isolated de novo, e.g., according to the methods provided herein for obtaining antibodies. .

[0370] In some embodiments, the antibodies provided herein are SEQ ID NO: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94, 104, 114, 124, 134, 144, 154 , 164, 174, 184, 194, 204, 214, 224, 234, 244, 254, 264, 274, 284, 294, 304, 314, 324, 334, 344, 354, 364, 374, 437, 447, 457 , 467, or 477. In some embodiments, the CDR-H3 is SEQ ID NO. , 194, 204, 214, 224, 234, 244, 254, 264, 274, 284, 294, 304, 314, 324, 334, 344, 354, 364, 374, 437, 447, 457, 467, or 477 At least about 50%, 75%, 80%, 85%, 90%, or 95% identity with CDR-H3. In some embodiments, the CDR-H3 is SEQ ID NO. 184, 194, 204, 214, 224, 234, 244, 254, 264, 274, 284, 294, 304, 314, 324, 334, 344, 354, 364, 374, 437, 447, 457, 467, or 477 CDR-H3 selected from CDR-H3 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.

[0371] In some embodiments, the antibodies provided herein are SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, 133, 143, 513 , 163, 173, 183, 193, 203, 213, 223, 233, 243, 253, 263, 273, 283, 293, 303, 313, 323, 333, 343, 353, 363, 373, 376, 436, 446 , 456, 466, or 476 CDR-H2. In some embodiments, the CDR-H2 is SEQ ID NO. or has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with CDR-H2 of 476. In some embodiments, the CDR-H2 is SEQ ID NO. 183, 193, 203, 213, 223, 233, 243, 253, 263, 273, 283, 293, 303, 313, 323, 333, 343, 353, 363, 373, 376, 436, 446, 456, 466, or 476 CDR-H2 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.

[0372] In some embodiments, the antibodies provided herein are SEQ ID NO: 2, 12, 22, 32, 42, 52, 62, 72, 82, 92, 102, 112, 122, 132, 142, 152 , 162, 172, 182, 192, 202, 212, 222, 232, 242, 252, 262, 272, 282, 292, 302, 312, 322, 332, 342, 352, 362, 372, 435, 445, 455 , 465, or 475 CDR-H1. In some embodiments, CDR-H1 is SEQ ID NO. , 192, 202, 212, 222, 232, 242, 252, 262, 272, 282, 292, 302, 312, 322, 332, 342, 352, 362, 372, 435, 445, 455, 465, or 475 At least about 50%, 75%, 80%, 85%, 90%, or 95% identity with CDR-H1. In some embodiments, the CDR-H1 is SEQ ID NO. 182, 192, 202, 212, 222, 232, 242, 252, 262, 272, 282, 292, 302, 312, 322, 332, 342, 352, 362, 372 435, 445, 455, 465, or 475 CDR-H1 with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.

[0373] In some embodiments, the antibodies provided herein are SEQ ID NO: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94, 104, 114, 124, 134, 144, 154 , 164, 174, 184, 194, 204, 214, 224, 234, 244, 254, 264, 274, 284, 294, 304, 314, 324, 334, 344, 354, 364, 374, 437, 447, 457 , 467, or 477 CDR-H3, SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, 133, 143, 513, 163, 173, 183, 193, 203, 213, 223, 233, 243, 253, 263, 273, 283, 293, 303, 313, 323, 333, 343, 353, 363, 373, 376, 436, 446, 456, 466, or 476 CDR-H2, and SEQ ID NO: 2, 12, 22, 32, 42, 52, 62, 72, 82, 92, 102, 112, 122, 132, 142, 152, 162, 172, 182, 192, 202, 212, 222, 232, 242, 252, 262, 272, 282, 292, 302, 312, 322, 332, 342, 352, 362, 372 435, 445, 455, 465, or 475 CDR-H1. In some embodiments, the CDR-H3 is SEQ ID NO. 184, 194, 204, 214, 224, 234, 244, 254, 264, 274, 284, 294, 304, 314, 324, 334, 344, 354, 364, 374, 437, 447, 457, 467, or 477 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with CDR-H3 of SEQ ID NO: 3, 13, 23, 33, 43, 53 , 63, 73, 83, 93, 103, 113, 123, 133, 143, 513, 163, 173, 183, 193, 203, 213, 223, 233, 243, 253, 263, 273, 283, 293, 303 , 313, 323, 333, 343, 353, 363, 373, 376, 436, 446, 456, 466, or 476 CDR-H2 and at least about 50%, 75%, 80%, 85%, 90%, or 95% identity, and CDR-H1 is SEQ ID NO: 2, 12, 22, 32, 42, 52, 62, 72, 82, 92, 102, 112, 122, 132, 142, 152, 162 , 172, 182, 192, 202, 212, 222, 232, 242, 252, 262, 272, 282, 292, 302, 312, 322, 332, 342, 352, 362, 372 435, 445, 455, 465, or at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with CDR-H1 of 475. In some embodiments, the CDR-H3 has up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, SEQ ID NO: 4, 14, 24, 34, 44, 54, 64, 74, 84, 94, 104, 114, 124, 134, 144, 154, 164, 174, 184, 194, 204, 214, 224, 234, 244, 254, 264, 274, 284, 294, 304, 314, 324, 334, 344, 354, 364, 374, 437, 447, 457, 467, or 477 CDR-H3 and CDR-H2 up to 1, 2, 3, 4, 5, 6, 7 , or having 8 amino acid substitutions, SEQ ID NO: 3, 13, 23, 33, 43, 53, 63, 73, 83, 93, 103, 113, 123, 133, 143, 513, 163, 173, 183, 193, 203, 213, 223, 233, 243, 253, 263, 273, 283, 293, 303, 313, 323, 333, 343, 353, 363, 373, 376, 436, 446, 456, 466, or 476 and CDR-H1 has up to 1, 2, 3, 4 or 5 amino acid substitutions, SEQ ID NO: 2, 12, 22, 32, 42, 52, 62, 72, 82, 92, 102, 112, 122, 132, 142, 152, 162, 172, 182, 192, 202, 212, 222, 232, 242, 252, 262, 272, 282, 292, 302, 312, 322, 332, 342, 352, 362, 372 435, 445, 455, 465, or 475 CDR-H1. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.

[0374] In some embodiments, the antibodies provided herein are SEQ ID NOs: 9, 19, 29, 39, 49, 59, 69, 79, 89, 99, 109, 119, 129, 139, 149, 159 , 169, 179, 189, 199, 209, 219, 229, 239, 249, 259, 269, 279, 289, 299, 309, 319, 329, 339, 349, 359, 369, 379, 442, 452, 462 , 472, or 482 CDR-L3. In some embodiments, the CDR-L3 is SEQ ID NO. , 199, 209, 219, 229, 239, 249, 259, 269, 279, 289, 299, 309, 319, 329, 339, 349, 359, 369, 379, 442, 452, 462, 472, or 482 At least about 50%, 75%, 80%, 85%, 90%, or 95% identity with CDR-L3. In some embodiments, the CDR-L3 has up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, SEQ ID NO: 9, 19, 29, 39, 49, 59, 69 , 79, 89, 99, 109, 119, 129, 139, 149, 159, 169, 179, 189, 199, 209, 219, 229, 239, 249, 259, 269, 279, 289, 299, 309, 319 , 329, 339, 349, 359, 369, 379, 442, 452, 462, 472, or 482 CDR-L3. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.

[0375] In some embodiments, the antibodies provided herein are SEQ ID NOs: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98, 108, 218, 228, 238, 248, 258 , 268, 278, 288, 298, 308, 318, 328, 338, 348, 358, 368, 378, 441, 451, 461, 471, or 481 CDR-L2. In some embodiments, the CDR-L2 is SEQ ID NO. , 298, 308, 318, 328, 338, 348, 358, 368, 378, 441, 451, 461, 471, or 481 CDR-L2 and at least about 50%, 75%, 80%, 85%, 90 %, or 95% identical. In some embodiments, the CDR-L2 has up to 1, 2, 3, 4, 5, 6, 7 or 8 amino acid substitutions, SEQ ID NO: 8, 18, 28, 38, 48, 58, 68 , 78, 88, 98, 108, 218, 228, 238, 248, 258, 268, 278, 288, 298, 308, 318, 328, 338, 348, 358, 368, 378, 441, 451, 461, 471 , or 481 CDR-L2. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.

[0376] In some embodiments, the antibodies provided herein are SEQ ID NOs: 7, 17, 27, 37, 47, 57, 67, 77, 87, 97, 107, 117, 127, 137, 147, 157 , 167, 177, 187, 197, 207, 217, 227, 237, 247, 257, 267, 277, 287, 297, 307, 317, 327, 337, 347, 357, 367, 377, 381, 382, ​​383 , 440, 450, 460, 470, or 480 CDR-L1. In some embodiments, CDR-L1 is SEQ ID NO. , 197, 207, 217, 227, 237, 247, 257, 267, 277, 287, 297, 307, 317, 327, 337, 347, 357, 367, 377, 381, 382, ​​or 383, 440, 450, has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with 460, 470, or 480 CDR-L1. In some embodiments, the CDR-L1 has up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, SEQ ID NO: 7, 17, 27, 37, 47, 57, 67, 77, 87, 97, 107, 117, 127, 137, 147, 157, 167, 177, 187, 197, 207, 217, 227, 237, 247, 257, 267, 277, 287, 297, 307, CDR-L1 of 317, 327, 337, 347, 357, 367, 377, 381, 382, ​​383, 440, 450, 460, 470, or 480.

[0377] In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies provided herein are SEQ ID NOs: 9, 19, 29, 39, 49, 59, 69, 79, 89, 99, 109, 119, 129, 139, 149, 159 , 169, 179, 189, 199, 209, 219, 229, 239, 249, 259, 269, 279, 289, 299, 309, 319, 329, 339, 349, 359, 369, 379, 442, 452, 462 , 472, or 482 CDR-L3, and SEQ ID NO: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98, 108, 218, 228, 238, 248, 258, 268, 278, 288 , 298, 308, 318, 328, 338, 348, 358, 368, 378, 441, 451, 461, 471, or 481 CDR-L2. In some embodiments, the antibodies provided herein are SEQ ID NOs: 9, 19, 29, 39, 49, 59, 69, 79, 89, 99, 109, 119, 129, 139, 149, 159 , 169, 179, 189, 199, 209, 219, 229, 239, 249, 259, 269, 279, 289, 299, 309, 319, 329, 339, 349, 359, 369, 379, 442, 452, 462 , 472, or 482 CDR-L3, SEQ ID NO: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98, 108, 218, 228, 238, 248, 258, 268, 278, 288, CDR-L2 of 298, 308, 318, 328, 338, 348, 358, 368, 378, 441, 451, 461, 471, or 481, and SEQ ID NO: 77, 17, 27, 37, 47, 57, 67, 77, 87, 97, 107, 117, 127, 137, 147, 157, 167, 177, 187, 197, 207, 217, 227, 237, 247, 257, 267, 277, 287, 297, 307, 317, 327, 337, 347, 357, 367, 377, 381, 382, ​​or 383, 440, 450, 460, 470, or 480 CDR-L1. In some embodiments, the CDR-L3 is SEQ ID NO. 189, 199, 209, 219, 229, 239, 249, 259, 269, 279, 289, 299, 309, 319, 329, 339, 349, 359, 369, 379, 442, 452, 462, 472, or 482 has at least about 50%, 75%, 80%, 85%, 90%, or 95% identity with a CDR-L3 of SEQ ID NO: 8, 18, 28, 38, 48, 58 , 68, 78, 88, 98, 108, 218, 228, 238, 248, 258, 268, 278, 288, 298, 308, 318, 328, 338, 348, 358, 368, 378, 441, 451, 461 , 471, or 481; , 37, 47, 57, 67, 77, 87, 97, 107, 117, 127, 137, 147, 157, 167, 177, 187, 197, 207, 217, 227, 237, 247, 257, 267, 277 , 287, 297, 307, 317, 327, 337, 347, 357, 367, 377, 381, 382, ​​or 383, 440, 450, 460, 470, or 480 CDR-L1 and at least about 50%, 75% , 80%, 85%, 90%, or 95% identical. In some embodiments, the CDR-L3 is SEQ ID NO: 9, 19, 29, 39, 49, 59, 69, 79, 89, 99 with up to 1, 2, 3, 4, or 5 amino acid substitutions. , 109, 119, 129, 139, 149, 159, 169, 179, 189, 199, 209, 219, 229, 239, 249, 259, 269, 279, 289, 299, 309, 319, 329, 339, 349 , 359, 369, 379, 442, 452, 462, 472, or 482, the CDR-L2 having up to 1, 2, 3, or 4 amino acid substitutions, SEQ ID NO: 8, 18, 28, 38, 48, 58, 68, 78, 88, 98, 108, 218, 228, 238, 248, 258, 268, 278, 288, 298, 308, 318, 328, 338, 348, 358, 368, 378, 441, 451, 461, 471, or 481, and CDR-L1 is SEQ ID NO: 7, 17, 27 with up to 1, 2, 3, 4, 5, or 6 amino acid substitutions , 37, 47, 57, 67, 77, 87, 97, 107, 117, 127, 137, 147, 157, 167, 177, 187, 197, 207, 217, 227, 237, 247, 257, 267, 277 , 287, 297, 307, 317, 327, 337, 347, 357, 367, 377, 381, 382, ​​383, 440, 450, 460, 470, or 480 CDR-L1. In some embodiments, the amino acid substitutions are conservative amino acid substitutions.

[0378] In some embodiments, the antibodies provided herein have 1 to 3 of SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121 , 131, 141, 151, 161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361, 371 V selected from , 434, 444, 454, 464, or 474 H Contains the domain's CDR. In some embodiments, the antibodies provided herein have 2 to 3 of SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121 , 131, 141, 151, 161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361, 371 V selected from , 434, 444, 454, 464, or 474 H Contains the domain's CDR. In some embodiments, the antibodies provided herein have three SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131 , 141, 151, 161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361, 371, 434 , 444, 454, 464, or 474. In some embodiments, the CDR is a Kabat CDR. In some embodiments, the CDR is a Chothia CDR. In some embodiments, the CDR is an AbM CDR. In some embodiments, the CDR is a Contact CDR. In some embodiments, the CDR is an IMGT CDR.

[0379] In some embodiments, the CDR-H1 has up to 1, 2, 3, 4, or 5 amino acid substitutions, SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 141, 151, 161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361, 371, 434, 444, 454, 464, or 474. In some embodiments, the CDR-H2 is SEQ ID NO: 1, 11, 21, 31, 41, 51, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. 61, 71, 81, 91, 101, 111, 121, 131, 141, 151, 161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361, 371, 434, 444, 454, 464, or 474. In some embodiments, the CDR-H3 is SEQ ID NO: 1, 11, 21, 31, 41, 51, with up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions. 61, 71, 81, 91, 101, 111, 121, 131, 141, 151, 161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361, 371, 434, 444, 454, 464, or 474. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants." In some embodiments, such variants are produced by, for example, affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. , derived from the sequences provided herein. In some embodiments, such variants are not derived from the sequences provided herein and can be isolated de novo, e.g., according to the methods provided herein for obtaining antibodies. .

[0380] In some embodiments, the antibodies provided herein have 1 to 3 of SEQ ID NOs: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126. , 136, 146, 156, 166, 176, 186, 196, 206, 216, 226, 236, 246, 256, 266, 276, 286, 296, 306, 316, 326, 336, 346, 356, 366, 376 , 434, 444, 454, 464, or 474. In some embodiments, the antibodies provided herein have 2 to 3 of SEQ ID NOs: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126. , 136, 146, 156, 166, 176, 186, 196, 206, 216, 226, 236, 246, 256, 266, 276, 286, 296, 306, 316, 326, 336, 346, 356, 366, 376 , 434, 444, 454, 464, or 474. In some embodiments, the antibodies provided herein have three SEQ ID NOs: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136. , 146, 156, 166, 176, 186, 196, 206, 216, 226, 236, 246, 256, 266, 276, 286, 296, 306, 316, 326, 336, 346, 356, 366, 376, 434 , 444, 454, 464, or 474. In some embodiments, the CDR is a Kabat CDR. In some embodiments, the CDR is a Chothia CDR. In some embodiments, the CDR is an AbM CDR. In some embodiments, the CDR is a Contact CDR. In some embodiments, the CDR is an IMGT CDR.

[0381] In some embodiments, the CDR-L1 has up to 1, 2, 3, 4, or 5 amino acid substitutions, SEQ ID NO: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 156, 166, 176, 186, 196, 206, 216, 226, 236, 246, 256, 266, 276, 286, 296, 306, 316, 326, 336, CDR-L1 of a VL domain selected from 346, 356, 366, 376, 434, 444, 454, 464, or 474. In some embodiments, the CDR-L2 has up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, SEQ ID NO: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 156, 166, 176, 186, 196, 206, 216, 226, 236, 246, 256, 266, 276, 286, 296, 306, CDR-L2 of a VL domain selected from 316, 326, 336, 346, 356, 366, or 376. In some embodiments, the CDR-L3 has up to 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions, SEQ ID NO: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 156, 166, 176, 186, 196, 206, 216, 226, 236, 246, 256, 266, 276, 286, 296, 306, CDR-L3 of a VL domain selected from 316, 326, 336, 346, 356, 366, 376, 434, 444, 454, 464, or 474. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants." In some embodiments, such variants are produced by, for example, affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. , derived from the sequences provided herein. In some embodiments, such variants are not derived from the sequences provided herein and can be isolated de novo, e.g., according to the methods provided herein for obtaining antibodies. .

[0382] In some embodiments, the antibodies provided herein have 1 to 3 of SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121 , 131, 141, 151, 161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361, 371 , 434, 444, 454, 464, or 474, and 1 to 3 of SEQ ID NOs: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 156, 166, 176, 186, 196, 206, 216, 226, 236, 246, 256, 266, 276, 286, 296, 306, 316, 326, 336, 346, 356, 366, 376, 434, 444, 454, 464, or 474. In some embodiments, the antibodies provided herein have 2 to 3 of SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121 , 131, 141, 151, 161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361, 371 , 434, 444, 454, 464, or 474, and two to three SEQ ID NOs: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 156, 166, 176, 186, 196, 206, 216, 226, 236, 246, 256, 266, 276, 286, 296, 306, 316, 326, 336, 346, 356, 366, 376, 434, 444, 454, 464, or 474. In some embodiments, the antibodies provided herein have three SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131 , 141, 151, 161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361, 371, 434 , 444, 454, 464, or 474, and three SEQ ID NOs: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 156, 166, 176, 186, 196, 206, 216, 226, 236, 246, 256, 266, 276, 286, 296, 306, 316, 326, 336, 346, 356, 366, 376, 434, 444, 454, 464, or 474. In some embodiments, the CDR is a Kabat CDR. In some embodiments, the CDR is a Chothia CDR. In some embodiments, the CDR is an AbM CDR. In some embodiments, the CDR is a Contact CDR. In some embodiments, the CDR is an IMGT CDR.

[0383] V H domain In some embodiments, the antibodies or antigen-binding fragments thereof provided herein are SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 141, 151, 161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361, 371, V selected from 434, 444, 454, 464, or 474 H Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO:1. H Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO:21. H Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 121. H Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 181. H Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 191. H Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 221. H Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 241. H Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 261. H Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 351. H Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 371. H Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 434. H Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 444. H Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 454. H Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 464. H Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 474. H Contains arrays.

[0384] In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 1, and any variant from SEQ ID NO: 1 occurs within CDR-H1, CDR-H2, or CDR-H3. do not have. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 21, and any variant from SEQ ID NO: 21 occurs within CDR-H1, CDR-H2, or CDR-H3. do not have. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 121, and any variant from SEQ ID NO: 121 occurs within CDR-H1, CDR-H2, or CDR-H3. do not have. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 181, and any variant from SEQ ID NO: 181 occurs within CDR-H1, CDR-H2, or CDR-H3. do not have. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 191, and any variant from SEQ ID NO: 191 occurs within CDR-H1, CDR-H2, or CDR-H3. do not have. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 221, and any variant from SEQ ID NO: 221 occurs within CDR-H1, CDR-H2, or CDR-H3. do not have. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 241, and any variant from SEQ ID NO: 241 occurs within CDR-H1, CDR-H2, or CDR-H3. do not have. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 261, and any variant from SEQ ID NO: 261 occurs within CDR-H1, CDR-H2, or CDR-H3. do not have. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 351, and any variant from SEQ ID NO: 351 occurs within CDR-H1, CDR-H2, or CDR-H3. do not have. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 371, and any variant from SEQ ID NO: 371 occurs within CDR-H1, CDR-H2, or CDR-H3. do not have. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 434, and any variant from SEQ ID NO: 434 occurs within CDR-H1, CDR-H2, or CDR-H3. do not have. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 444, and any variant from SEQ ID NO: 444 occurs within CDR-H1, CDR-H2, or CDR-H3. do not have. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 454, and any variant from SEQ ID NO: 454 occurs within CDR-H1, CDR-H2, or CDR-H3. do not have. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 464, and any variant from SEQ ID NO: 464 occurs within CDR-H1, CDR-H2, or CDR-H3. do not have. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 474, and any variant from SEQ ID NO: 474 occurs within CDR-H1, CDR-H2, or CDR-H3. do not have.

[0385] In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO:1. have V H Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO:21. have V H Contains arrays. In some embodiments, antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 121. have V H Contains arrays. In some embodiments, antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 181. have V H Contains arrays. In some embodiments, antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 191. have V H Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 221. have V H Contains arrays. In some embodiments, antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 241. have V H Contains arrays. In some embodiments, antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 261. have V H Contains arrays. In some embodiments, antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 351. have V H Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 371. have V H Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 434. have V H Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 444. have V H Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 454. have V H Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 464. have V H Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 474. have V H Contains arrays.

[0386] In some embodiments, the antibodies provided herein are SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 141, 151 , 161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361, 371, 434, 444, 454 , 464, or 474. H V having at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to the sequence H Contains arrays. In some embodiments, the antibodies provided herein have up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111 with 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acid substitutions , 121, 131, 141, 151, 161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361 , 371, 434, 444, 454, 464, or 474 H Contains arrays. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants." In some embodiments, such variants are produced by, for example, affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. , derived from the sequences provided herein. In some embodiments, such variants are not derived from the sequences provided herein and can be isolated de novo, e.g., according to the methods provided herein for obtaining antibodies. .

[0387] In some embodiments, the antibodies or antigen-binding fragments described herein are SEQ ID NOs: 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, or 426.

[0388] V L domain In some embodiments, the antibodies or antigen-binding fragments thereof provided herein are SEQ ID NOs: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 156, 166, 176, 186, 196, 206, 216, 226, 236, 246, 256, 266, 276, 286, 296, 306, 316, 326, 336, 346, 356, 366, 376, V selected from 439, 449, 459, 469, or 479 L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 6. L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 26. L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 126. L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 186. L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 196. L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 226. L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 246. L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 266. L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 356. L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 376. L Contains arrays.

[0389] In some embodiments, V L The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 6, and any variant from SEQ ID NO: 6 occurs within CDR-L1, CDR-L2, or CDR-L3. do not have. In some embodiments, V L The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 26, and any variant from SEQ ID NO: 26 occurs within CDR-L1, CDR-L2, or CDR-L3. do not have. In some embodiments, V L The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 126, and any variant from SEQ ID NO: 126 occurs within CDR-L1, CDR-L2, or CDR-L3. do not have. In some embodiments, V L The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 186, and any variant from SEQ ID NO: 186 occurs within CDR-L1, CDR-L2, or CDR-L3. do not have. In some embodiments, V L the sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 196, and no mutations from SEQ ID NO: 196 occur within CDR-L1, CDR-L2, or CDR-L3 . In some embodiments, V L The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 226, and any variant from SEQ ID NO: 226 occurs within CDR-L1, CDR-L2, or CDR-L3. do not have. In some embodiments, V L The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 246, and any variant from SEQ ID NO: 246 occurs within CDR-L1, CDR-L2, or CDR-L3. do not have. In some embodiments, V L The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 266, and any variant from SEQ ID NO: 266 occurs within CDR-L1, CDR-L2, or CDR-L3. do not have. In some embodiments, V L The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 356, and any variant from SEQ ID NO: 356 occurs within CDR-L1, CDR-L2, or CDR-L3. do not have. In some embodiments, V L The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 376, and any variant from SEQ ID NO: 376 occurs within CDR-L1, CDR-L2, or CDR-L3. do not have. In some embodiments, V L The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 439, and any variant from SEQ ID NO: 439 occurs within CDR-L1, CDR-L2, or CDR-L3. do not have. In some embodiments, V L The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 449, and any variant from SEQ ID NO: 449 occurs within CDR-L1, CDR-L2, or CDR-L3. do not have. In some embodiments, V L The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 459, and any variant from SEQ ID NO: 459 occurs within CDR-L1, CDR-L2, or CDR-L3. do not have. In some embodiments, V L The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 469, and any variant from SEQ ID NO: 469 occurs within CDR-L1, CDR-L2, or CDR-L3. do not have. In some embodiments, V L The sequence has at least 70%, 80%, or 90% identity with SEQ ID NO: 479, and any variant from SEQ ID NO: 479 occurs within CDR-L1, CDR-L2, or CDR-L3. do not have.

[0390] In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 6. have V L Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 26. have V L Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 126. have V L Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 186. have V L Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 196. have V L Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 226. have V L Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 246. have V LContains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 266. have V L Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 356. have V L Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 376. have V L Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 439. have V L Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 449. have V L Contains arrays. In some embodiments, the antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 459. have V L Contains arrays. In some embodiments, antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 469. have V L Contains arrays. In some embodiments, antibodies provided herein have at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 479. have V L Contains arrays.

[0391] In some embodiments, the antibodies provided herein are SEQ ID NO: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 156 , 166, 176, 186, 196, 206, 216, 226, 236, 246, 256, 266, 276, 286, 296, 306, 316, 326, 336, 346, 356, 366, 376, 439, 449, 459 , 469, or 479, examples V L V having at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to the sequence L Contains arrays. In some embodiments, the antibodies provided herein are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 , 18, 19, 20, 21, 22, 23, 24, or 25 amino acid substitutions; 126, 136, 146, 156, 166, 176, 186, 196, 206, 216, 226, 236, 246, 256, 266, 276, 286, 296, 306, 316, 326, 336, 346, 356, 366, V provided in 376, 439, 449, 459, 469, or 479 L Contains arrays. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants." In some embodiments, such variants are produced by, for example, affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. , derived from the sequences provided herein. In some embodiments, such variants are not derived from the sequences provided herein and can be isolated de novo, e.g., according to the methods provided herein for obtaining antibodies. .

[0392] V H -V L combination In some embodiments, the antibodies or antigen-binding fragments thereof provided herein are SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 141, 151, 161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361, 371, V selected from 434, 444, 454, 464, or 474 H Sequence, and SEQ ID NO: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 156, 166, 176, 186, 196, 206, 216, 226 , 236, 246, 256, 266, 276, 286, 296, 306, 316, 326, 336, 346, 356, 366, 376, 439, 449, 459, 469, or 479 L Contains arrays.

[0393] In some embodiments, the antibodies provided herein are V of SEQ ID NO:1. H Sequence, and V of SEQ ID NO. 6 L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO:21. H Sequence and V of sequence number 26 L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 121. H Sequence, and V of sequence number 126 L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 181. H Sequence and V of SEQ ID NO: 186 L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 191. H Sequence, and V of SEQ ID NO: 196 L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 221. H Sequence, and V of SEQ ID NO: 226 L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 241. H Sequence, and V of sequence number 246 L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 261. H Sequence, and V of sequence number 266 L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 351. H Sequence, and V of sequence number 356 L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 371. H Sequence, and V of SEQ ID NO: 376 L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 434. H Sequence, and V of SEQ ID NO: 439 L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 444. H Sequence, and V of SEQ ID NO: 449 L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 454. H Sequence, and V of SEQ ID NO: 459 L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 464. H Sequence, and V of SEQ ID NO: 469 L Contains arrays. In some embodiments, the antibodies provided herein are V of SEQ ID NO: 474. H Sequence, and V of SEQ ID NO: 479 L Contains arrays.

[0394] In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 1, and the light chain variable region has at least 70%, 80%, or 90% identity to SEQ ID NO: 6. identical, variants derived from SEQ ID NO: 1 do not occur within CDR-H1, CDR-H2, or CDR-H3, and variants derived from SEQ ID NO: 6 do not occur within CDR-L1, CDR-L2, or CDR -Does not occur within L3. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 21, and the light chain variable region has at least 70%, 80%, or 90% identity to SEQ ID NO: 26. identical, variants derived from SEQ ID NO: 21 do not occur within CDR-H1, CDR-H2, or CDR-H3, and variants derived from SEQ ID NO: 26 do not occur within CDR-L1, CDR-L2, or CDR -Does not occur within L3. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 121, and the light chain variable region has at least 70%, 80%, or 90% identity to SEQ ID NO: 126. identical, variants derived from SEQ ID NO: 121 do not occur within CDR-H1, CDR-H2, or CDR-H3, and variants derived from SEQ ID NO: 126 do not occur within CDR-L1, CDR-L2, or CDR -Does not occur within L3. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 181, and the light chain variable region has at least 70%, 80%, or 90% identity to SEQ ID NO: 186. identical, variants derived from SEQ ID NO: 181 do not occur within CDR-H1, CDR-H2, or CDR-H3, and variants derived from SEQ ID NO: 186 do not occur within CDR-L1, CDR-L2, or CDR -Does not occur within L3. In some embodiments, V HThe sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 191, and the light chain variable region has at least 70%, 80%, or 90% identity to SEQ ID NO: 196. identical, variants derived from SEQ ID NO: 191 do not occur within CDR-H1, CDR-H2, or CDR-H3, and variants derived from SEQ ID NO: 196 do not occur within CDR-L1, CDR-L2, or CDR -Does not occur within L3. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 221, and the light chain variable region has at least 70%, 80%, or 90% identity to SEQ ID NO: 226. identical, variants derived from SEQ ID NO: 221 do not occur within CDR-H1, CDR-H2, or CDR-H3, and variants derived from SEQ ID NO: 226 do not occur within CDR-L1, CDR-L2, or CDR -Does not occur within L3. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 241, and the light chain variable region has at least 70%, 80%, or 90% identity to SEQ ID NO: 246. identical, variants derived from SEQ ID NO: 241 do not occur within CDR-H1, CDR-H2, or CDR-H3, and variants derived from SEQ ID NO: 246 do not occur within CDR-L1, CDR-L2, or CDR -Does not occur within L3. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 261, and the light chain variable region has at least 70%, 80%, or 90% identity to SEQ ID NO: 266. identical, variants derived from SEQ ID NO: 261 do not occur within CDR-H1, CDR-H2, or CDR-H3, and variants derived from SEQ ID NO: 266 do not occur within CDR-L1, CDR-L2, or CDR -Does not occur within L3. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 351, and the light chain variable region has at least 70%, 80%, or 90% identity to SEQ ID NO: 356. identical, variants derived from SEQ ID NO: 351 do not occur within CDR-H1, CDR-H2, or CDR-H3, and variants derived from SEQ ID NO: 356 do not occur within CDR-L1, CDR-L2, or CDR -Does not occur within L3. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 371, and the light chain variable region has at least 70%, 80%, or 90% identity to SEQ ID NO: 376. identical, variants derived from SEQ ID NO: 371 do not occur within CDR-H1, CDR-H2, or CDR-H3, and variants derived from SEQ ID NO: 376 do not occur within CDR-L1, CDR-L2, or CDR -Does not occur within L3. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 434, and the light chain variable region has at least 70%, 80%, or 90% identity to SEQ ID NO: 439. identical, variants derived from SEQ ID NO: 434 do not occur within CDR-H1, CDR-H2, or CDR-H3, and variants derived from SEQ ID NO: 439 do not occur within CDR-L1, CDR-L2, or CDR -Does not occur within L3. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 444, and the light chain variable region has at least 70%, 80%, or 90% identity to SEQ ID NO: 449. identical, variants derived from SEQ ID NO: 444 do not occur within CDR-H1, CDR-H2, or CDR-H3, and variants derived from SEQ ID NO: 449 do not occur within CDR-L1, CDR-L2, or CDR -Does not occur within L3. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 454, and the light chain variable region has at least 70%, 80%, or 90% identity to SEQ ID NO: 459. identical, variants derived from SEQ ID NO: 454 do not occur within CDR-H1, CDR-H2, or CDR-H3, and variants derived from SEQ ID NO: 459 do not occur within CDR-L1, CDR-L2, or CDR -Does not occur within L3. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 464, and the light chain variable region has at least 70%, 80%, or 90% identity to SEQ ID NO: 469. identical, variants derived from SEQ ID NO: 464 do not occur within CDR-H1, CDR-H2, or CDR-H3, and variants derived from SEQ ID NO: 469 do not occur within CDR-L1, CDR-L2, or CDR -Does not occur within L3. In some embodiments, V H The sequence has at least 70%, 80%, or 90% identity to SEQ ID NO: 474, and the light chain variable region has at least 70%, 80%, or 90% identity to SEQ ID NO: 479. identical, variants derived from SEQ ID NO: 474 do not occur within CDR-H1, CDR-H2, or CDR-H3, and variants derived from SEQ ID NO: 479 do not occur within CDR-L1, CDR-L2, or CDR -Does not occur within L3.

[0395] In certain embodiments, SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 141, 151, 161, 171, 181, 191, 201, 211 , 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361, 371, 434, 444, 454, 464, or 474 is a sequence number 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 156, 166, 176, 186, 196, 206, 216, 226, 236, 246, Can be combined with any of 256, 266, 276, 286, 296, 306, 316, 326, 336, 346, 356, 366, 376, 439, 449, 459, 469, or 479. For example, SEQ ID NO: 11 is SEQ ID NO: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 156, 166, 176, 186, 196, 206 , 216, 226, 236, 246, 256, 266, 276, 286, 296, 306, 316, 326, 336, 346, 356, 366, 376, 439, 449, 459, 469, or 479 I can do it. As another example, SEQ ID NO. 16 is SEQ ID NO. Any of 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361, 371, 434, 444, 454, 464, or 474 It can be combined with

[0396] In some embodiments, the antibodies provided herein are SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 141, 151 , 161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361, or 371; Example V H V having at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to the sequence H Sequence, and SEQ ID NO: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96, 106, 116, 126, 136, 146, 156, 166, 176, 186, 196, 206, 216, 226 , 236, 246, 256, 266, 276, 286, 296, 306, 316, 326, 336, 346, 356, 366, 376, 439, 449, 459, 469, or 479 to at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identical to V L Contains arrays. In some embodiments, the antibodies provided herein have up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111 with 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acid substitutions , 121, 131, 141, 151, 161, 171, 181, 191, 201, 211, 221, 231, 241, 251, 261, 271, 281, 291, 301, 311, 321, 331, 341, 351, 361 , 371, 434, 444, 454, 464, or 474, and up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, SEQ ID NO: 6, 16, 26, 36, 46, 56, 66, 76, 86, 96 with 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acid substitutions , 106, 116, 126, 136, 146, 156, 166, 176, 186, 196, 206, 216, 226, 236, 246, 256, 266, 276, 286, 296, 306, 316, 326, 336, 346 , 356, 366, 376, 439, 449, 459, 469, or 479. In some embodiments, the amino acid substitutions are conservative amino acid substitutions. In some embodiments, the antibodies described in this paragraph are referred to herein as "variants." In some embodiments, such variants are produced by, for example, affinity maturation, site-directed mutagenesis, random mutagenesis, or any other method known in the art or described herein. , derived from the sequences provided herein. In some embodiments, such variants are not derived from the sequences provided herein and can be isolated de novo, e.g., according to the methods provided herein for obtaining antibodies. .

[0397] In some embodiments, the heavy or light chain variable percent homology is calculated outside of the CDRs. For example, percent homology can be calculated in framework regions.

[0398] In some embodiments, the antibody or antigen-binding fragment thereof is SEQ ID NO. , 175, 185, 195, 205, 215, 225, 235, 245, 255, 265, 275, 285, 295, 305, 315, 325, 335, 345, 355, 365, 375, 438, 448, 458, 468 , or a heavy chain provided in 478.

[0399] In some embodiments, the antibody or antigen-binding fragment thereof is SEQ ID NO. , 180, 190, 210, 220, 230, 240, 250, 260, 270, 280, 290, 310, 320, 330, 340, 350, 360, 370, 380, 443, 453, 463, 473, or 483 Contains a provided light chain.

[0400] In certain embodiments, SEQ ID NO: 5, 15, 25, 35, 45, 55, 65, 75, 85, 95, 105, 115, 125, 135, 145, 155, 165, 175, 185, 195, 205, 215 , 225, 235, 245, 255, 265, 275, 285, 295, 305, 315, 325, 335, 345, 355, 365, 375, 438, 448, 458, 468 or 478 is a sequence number: 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 210, 220, 230, 240, 250, 260, Can be combined with any of 270, 280, 290, 310, 320, 330, 340, 350, 360, 370, 380, 443, 453, 463, 473, or 483.

[0401] In some embodiments, the antibodies provided herein are SEQ ID NO: 5, 15, 25, 35, 45, 55, 65, 75, 85, 95, 105, 115, 125, 135, 145, 155 , 165, 175, 185, 195, 205, 215, 225, 235, 245, 255, 265, 275, 285, 295, 305, 315, 325, 335, 345, 355, 365, 375, 438, 448, 458 , 468 or 478. H a heavy chain sequence having at least about 50%, 60%, 70%, 80%, 90%, 95%, or 99% identity to SEQ ID NO: 10, 20, 30, 40, 50, 60 , 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 210, 220, 230, 240, 250, 260, 270, 280, 290, 310, 320, 330 , 340, 350, 360, 370, 380, 443, 453, 463, 473, or 483 at least about 50%, 60%, 70%, 80%, 90%, 95% , or light chain sequences with 99% identity. In some embodiments, the antibodies provided herein have up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, SEQ ID NO: 5, 15, 25, 35, 45, 55, 65, 75, 85, 95, 105, 115 with 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acid substitutions , 125, 135, 145, 155, 165, 175, 185, 195, 205, 215, 225, 235, 245, 255, 265, 275, 285, 295, 305, 315, 325, 335, 345, 355, 365 , 375, 438, 448, 458, 468, or 478, and up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 , 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 amino acid substitutions, SEQ ID NO: 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 210, 220, 230, 240, 250, 260, 270, 280, 290, 310, 320, 330, 340, 350, 360, 370, 380, 443, 453, 463, 473 or 483.

[0402] In some embodiments, the polynucleotide sequence of the antibody or antigen-binding fragment includes a signal sequence set forth in SEQ ID NO: 427 or 430. In some embodiments, the polynucleotide sequence of the antibody or antigen-binding fragment includes a signal sequence set forth in SEQ ID NO: 428 or 429.

[0403] Fc area The term "Fc domain" or "Fc region" herein is used to define the C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and diversity Fc regions. Unless otherwise specified herein, numbering of amino acid residues in Fc or constant regions refers to Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, According to the EU numbering system, also called the EU index, as described in MD, 1991. As used herein, an "Fc polypeptide" of dimeric Fc refers to one of two polypeptides that form a dimeric Fc domain, i.e., an immunoglobulin heavy chain capable of stable self-association. refers to a polypeptide containing the C-terminal constant region of For example, the Fc polypeptide of dimeric IgGFc includes IgG CH2 and IgG CH3 constant domain sequences. Fc can be of the classes IgA, IgD, IgE, IgG, and IgM, some of which are further subclasses (isotypes), e.g. IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 , and IgA 2 It can be divided into

[0404] The terms "Fc receptor" and "FcR" are used to describe receptors that bind to the Fc region of antibodies. For example, the FcR can be a native sequence human FcR. In general, FcRs are those that bind IgG antibodies (gamma receptors) and include the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternatively spliced ​​forms of these receptors. FcγRII receptors include FcγRIIA (“activating receptor”) and FcγRIIB (“inhibiting receptor”), which have similar amino acid sequences that differ primarily in the cytoplasmic domain. Immunoglobulins of other isotypes can also bind to specific FcRs (e.g., Janeway et al., Immuno Biology: the immune system in health and disease, (Elsevier Science Ltd., NY) (4th ed., 1999 )checking). The activating receptor FcγRIIA contains an immunoreceptor tyrosine activation motif (ITAM) in its cytoplasmic domain. The inhibitory receptor FcγRIIB contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in the cytoplasmic domain (reviewed in Daeron, Annu. Rev. Immunol. 15:203-234 (1997)). FcR is defined by Ravetch and Kinet, Annu.Rev.Immunol 9:457-92(1991); Capel et al., Immunomethods 4:25-34(1994), and de Haas et al., J.Lab.Clin.Med. .126:330-41 (1995). Other FcRs, including those to be identified in the future, are encompassed herein by the term "FcR." The term also includes the neonatal receptor FcRn, which is involved in the transfer of maternal IgG to the fetus (Guyer et al., J. Immunol. 117:587 (1976); and Kim et al., J. Immunol. 24:249 (1994)).

[0405] In some embodiments, the antibody is an IgG1 antibody.

[0406] In some embodiments, the antibody is an IgG3 antibody.

[0407] In some embodiments, the antibody is an IgG2 antibody.

[0408] In some embodiments, the antibody is an IgG4 antibody.

[0409] Modifications of the CH2 domain can affect the binding of FcR to Fc. Numerous amino acid modifications in the Fc region are known in the art to selectively alter the affinity of Fc for different Fc gamma (Fcγ) receptors. In one embodiment, the Fc includes one or more modifications that promote selective binding of Fc gamma receptors.

[0410] In some embodiments, the antibodies described herein include modifications that improve their ability to mediate effector functions. Such modifications are known in the art and include afucosylation or manipulation of Fc affinity for activated receptors, primarily FCGR3a for ADCC and C1q for CDC.

[0411] In certain embodiments, antibodies provided herein include an Fc region with one or more amino acid substitutions that improve ADCC.

[0412] In some embodiments, antibodies provided herein include one or more modifications that improve or reduce C1q binding and / or CDC. See US Pat. No. 6,194,551, WO99 / 51642, and Idusogie et al., J. Immunol., 2000, 164:4178-4184, each of which is incorporated by reference in its entirety.

[0413] Thus, in one embodiment, the antibodies described herein can include a dimeric Fc that includes one or more amino acid modifications that confer improved effector function. In another embodiment, antibodies can be afucosylated to improve effector function.

[0414] Fc modifications that reduce FcγR and / or complement fixation and / or effector function are known in the art. Recent publications describe strategies that have been used to engineer antibodies with reduced or silenced effector activity (Strohl, WR (2009), Curr Opin Biotech 20:685-691 and Strohl, WR and (See Strohl LM, “Antibody Fc engineering for optimal antibody performance” In Therapeutic Antibody Engineering, Cambridge: Woodhead Publishing (2012), pp 225-249). These strategies include reducing effector function by modifying glycosylation, using IgG2 / IgG4 scaffolds, or introducing mutations in the hinge or CH2 region of the Fc. For example, US Patent Publication No. 2011 / 0212087 (Strohl), International Patent Publication No. WO 2006 / 105338 (Xencor), US Patent Publication No. 2012 / 0225058 (Xencor), US Patent Publication No. 2012 / 0251531 (Genentech), and Strop et al ((2012) J. Mol. Biol. 420:204-219) describe certain modifications that reduce FcγR or complement binding to Fc.

[0415] Methods of producing antibodies that contain little or no fucose on the Fc glycosylation site (Asn 297 EU numbering) without altering the amino acid sequence are well known in the art. GlymaxX® technology (ProBioGen AG) is based on the introduction of the gene for an enzyme that diverts the cellular pathway of fucose biosynthesis into cells used for antibody production. This prevents the addition of the sugar "fucose" to N-linked antibody carbohydrate moieties by antibody-producing cells (von Horsten et al. (2010) Glycobiology. 2010 Dec;20(12):1607-18). An example of a cell line capable of producing defucosylated antibodies includes the bacterial oxidoreductase GDP-6-deoxy-D-lyxo-4-hexylose reductase, which is deficient in protein fucosylation. CHO-DG44 (see Henning von Horsten et al., Glycobiol 2010,20:1607-1618) or Lec13 CHO cells (Ripka et al., Arch.Biochem.Biophys., 1986,249:533-545; US Patent Publication No. 2003 / 0157108; WO2004 / 056312 (each of which is incorporated by reference in its entirety), as well as the alpha-1,6-fucosyltransferase gene, knockout cell lines or FUT8 knockout CHO cells (Yamane-Ohnuki et al.,Biotech.Bioeng.,2004,87:614-622;Kanda et al.,Biotechnol.Bioeng.,2006,94:680-688; and WO 2003 / 085107 (each of which is incorporated by reference in its entirety). Another approach to obtaining antibodies with reduced levels of fucosylation can be found in U.S. Patent No. 8,409,572, which describes the ability of cell lines for antibody production to produce reduced levels of fucosylation in antibodies. Teach them to choose.

[0416] An example of a cell line capable of producing defucosylated antibodies includes the bacterial oxidoreductase GDP-6-deoxy-D-lyxo-4-hexylose reductase, which is deficient in protein fucosylation. CHO-DG44 (see Henning von Horsten et al., Glycobiol 2010,20:1607-1618) or Lec13 CHO cells (Ripka et al., Arch.Biochem.Biophys., 1986,249:533-545; US Patent Publication No. 2003 / 0157108; WO2004 / 056312 (each of which is incorporated by reference in its entirety), as well as the alpha-1,6-fucosyltransferase gene, knockout cell lines or FUT8 knockout CHO cells (Yamane-Ohnuki et al.,Biotech.Bioeng.,2004,87:614-622;Kanda et al.,Biotechnol.Bioeng.,2006,94:680-688; and WO 2003 / 085107 (each of which is incorporated by reference in its entirety).

[0417] Antibodies can be fully afucosylated, meaning they contain no detectable fucose, or they can be partially afucosylated, which means that the isolated antibody , less than 95%, less than 85%, less than 75%, less than 65%, less than 55%, less than 45%, less than 35%, 25 of the amount of fucose normally detected for similar antibodies produced by mammalian expression systems. %, 15%, or 5%.

[0418] In some embodiments, the antibodies provided herein include an IgG1 domain with reduced fucose content at position Asn297 compared to a naturally occurring IgG1 domain. Such Fc domains are known to have improved ADCC. See Shields et al., J. Biol. Chem., 2002, 277:26733-26740, which is incorporated by reference in its entirety. In some embodiments, such antibodies do not include any fucose at position Asn297. The amount of fucose may be determined using any suitable method, for example as described in WO2008 / 077546, which is incorporated by reference in its entirety.

[0419] In some embodiments, the antibodies provided herein include a bisected oligosaccharide, such as a biantennary oligosaccharide attached to the Fc region of the antibody bisected by GlcNAc. Such antibody variants may have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described, for example, in WO2003 / 011878, US Pat. No. 6,602,684, and US Pat. No. 2005 / 0123546, each of which is incorporated by reference in its entirety.

[0420] Other exemplary glycosylation variants that can be incorporated into the antibodies provided herein are, for example, U.S. Patent Publications Nos. 2003 / 0157108; 2004 / 0093621; 2003 / 0157108; International Patent Publication No. 2000 / 61739, No. 2001 / 29246, No. 2003 / 085119, No. 2003 / 084570, No. 2005 / 035586, No. 2005 / 035778, No. 2005 / 053742, No. No. 2002 / 031140, Okazaki et al., J. Mol. Biol., 2004, 336: 1239-1249, and Yamane-Ohnuki et al., Biotech. Bioeng., 2004, 87: 614-622, and these each of which is incorporated by reference in its entirety.

[0421] In some embodiments, antibodies provided herein include an Fc region that has at least one galactose residue in an oligosaccharide attached to the Fc region. Such antibody variants may have improved CDC function. Examples of such antibody variants are described, for example, in WO1997 / 30087; WO1998 / 58964; and WO1999 / 22764, each of which is incorporated by reference in its entirety.

[0422] An example of a cell line capable of producing defucosylated antibodies includes the bacterial oxidoreductase GDP-6-deoxy-D-lyxo-4-hexylose reductase, which is deficient in protein fucosylation. CHO-DG44 (see Henning von Horsten et al., Glycobiol 2010,20:1607-1618) or Lec13 CHO cells (Ripka et al., Arch.Biochem.Biophys., 1986,249:533-545; US Patent Publication No. 2003 / 0157108; WO2004 / 056312 (each of which is incorporated by reference in its entirety), as well as the alpha-1,6-fucosyltransferase gene, knockout cell lines or FUT8 knockout CHO cells (Yamane-Ohnuki et al.,Biotech.Bioeng.,2004,87:614-622;Kanda et al.,Biotechnol.Bioeng.,2006,94:680-688; and WO 2003 / 085107 (each of which is incorporated by reference in its entirety).

[0423] In some embodiments, the antibody has antibody-dependent cellular phagocytosis (ADCP) activity. ADCP can occur when antibodies bind to antigens on the surface of pathogenic or tumorigenic target cells. Phagocytes, including monocytes and macrophages, which possess Fc receptors on their cell surfaces, recognize and bind to the Fc region of antibodies bound to target cells. When Fc receptors bind to antibody-bound target cells, they can initiate phagocytosis of the target cells. ADCP can be considered a form of ADCC.

[0424] In some embodiments, antibodies are capable of forming immune complexes. For example, an immune complex can be a tumor cell coated with antibodies.

[0425] In some embodiments, the anti-MARCO antibody does not substantially bind to bone marrow cells present outside of cancer tissue. In some embodiments, the anti-MARCO antibody does not substantially bind to stimulatory myeloid cells present in cancer tissue.

[0426] In some embodiments, the antibody is a monoclonal antibody.

[0427] In some embodiments, the antibody is a polyclonal antibody.

[0428] In some embodiments, antibodies are produced by hybridomas. In other embodiments, antibodies are produced by recombinant cells engineered to express the desired variable and constant domains.

[0429] In some embodiments, the antibody may be a single chain antibody or other antibody derivative that retains antigen specificity and a lower hinge region or variant thereof.

[0430] In some embodiments, the antibody can be a multifunctional antibody, a recombinant antibody, a human antibody, a humanized antibody, a fragment, or a variant thereof. In certain embodiments, the antibody fragment or derivative thereof is selected from Fab fragments, Fab'2 fragments, CDRs and ScFvs.

[0431] In some embodiments, the antibody is specific for a surface antigen, such as a MARCO protein. In some embodiments, the therapeutic antibody is specific for a tumor antigen (eg, a molecule specifically expressed by tumor cells). In certain embodiments, therapeutic antibodies may have human or non-human primate IgG1 or IgG3 Fc portions.

[0432] join With respect to the binding of an antibody to a target molecule, "binds to", "specifically binds to", "specifically binds to" a particular antigen (e.g., a polypeptide target) or an epitope on a particular antigen; The terms "specific for," "selectively binds to," and "selective for" mean that non-specific or non-selective interactions (e.g. with non-target molecules) are Meaning different combinations possible. Specific binding can be determined, for example, by measuring binding to a target molecule and comparing it to binding to non-target molecules. Specific binding can also be determined by competition with a control molecule that mimics the epitope recognized on the target molecule. In that case, specific binding is indicated when the binding of the antibody to the target molecule is competitively inhibited by the control molecule. Cross-linking of antigen targets is a type of conjugation. In some embodiments, the anti-MARCO antibody cross-links MARCO to MARCO on MARCO+ cells.

[0433] "Affinity" refers to the strength of the aggregate non-covalent interactions between a single binding site of a molecule (eg, an antibody) and its binding partner (eg, an antigen or epitope). Unless otherwise specified, "affinity" as used herein refers to the inherent binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen or epitope). refers to The affinity of molecule X for its partner Y is determined by the dissociation equilibrium constant (K D ). The kinetic factors contributing to the dissociation equilibrium constant are discussed in more detail below. Affinity can be determined using methods in the art, including those described herein, such as surface plasmon resonance (SPR) techniques (e.g., BIACORE®) or biolayer interferometry (e.g., FORTEBIO®). It can be measured by a known general method.

[0434] As used herein, "k" d ”(sec. -1 ) refers to the dissociation rate constant for a particular antibody-antigen interaction. This value is k off Also called value.

[0435] As used herein, "k" a ”(M -1 ×sec -1 ) refers to the association rate constant for a particular antibody-antigen interaction. This value is k on Also called value.

[0436] As used herein, "k" D The term "(M)" refers to the dissociation equilibrium constant of a particular antibody-antigen interaction. K D =k d / k a . In some embodiments, the affinity of an antibody is determined by the K of interaction between such antibody and its antigen. D will be described. For clarity, as known in the art, K D A smaller value indicates a higher affinity interaction, and K D A larger value indicates a lower affinity interaction.

[0437] “K” as used herein A ”(M -1 ) refers to the association equilibrium constant of a particular antibody-antigen interaction. K A =k a / k d .

[0438] When used herein in the context of two or more antibodies, the term "competes with" or "cross-competes with" means that the two or more antibodies are bound to an antigen (e.g., MARCO). Indicates conflict. In one exemplary assay, MARCO is coated onto a surface and contacted with a first MARCO antibody, after which a second MARCO antibody is added. In another exemplary assay, a first MARCO antibody is coated onto a surface and contacted with MARCO, and then a second MARCO antibody is added. In either assay, antibodies compete with each other if the presence of a first MARCO antibody reduces binding of a second MARCO antibody. The term "competes with" also includes combinations of antibodies in which one antibody reduces the binding of another antibody, but when the antibodies are added in the reverse order, no competition is observed. However, in some embodiments, the first and second antibodies inhibit binding to each other regardless of the order in which they are added. In some embodiments, one antibody enhances the binding of another antibody to the antigen by at least 25%, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, Reduce by at least 95%, or at least 99%. One skilled in the art can select the concentration of antibody used in a competition assay based on the antibody's affinity for MARCO and the valency of the antibody. The assays described in this definition are exemplary and one of skill in the art can utilize any suitable assay to determine whether antibodies compete with each other. Suitable assays include, for example, Cox et al., “Immunoassay Methods,” in Assay Guidance Manual [Internet], Updated December 24, 2014 (ncbi.nlm.nih.gov / books / NBK92434 / ;accessed September 29, 2015) ; Silman et al., Cytometry, 2001, 44: 30-37; and Finco et al., J. Pharm. Biomed. Anal., 2011, 54: 351-358, each of which is Incorporated by reference.

[0439] In some embodiments, the antibodies provided herein bind human MARCO. In some embodiments, the antibodies provided herein bind mouse MARCO. In some embodiments, the antibodies provided herein bind macaque MARCO. In some embodiments, the antibodies provided herein bind to cynomolgus monkey MARCO. In some embodiments, the antibodies provided herein bind to human, rhesus, and / or cynomolgus MARCO.

[0440] In some embodiments, the antibodies provided herein are about 0.001, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 7, 8, 9, or 10×10 -9 K less than or equal to M D binds to human MARCO (as measured by Biacore assay). In some embodiments, the K of the antibodies provided herein is D is approximately 0.001~0.01, 0.01~0.1, 0.01~0.05, 0.05~0.1, 0.1~0.5, 0.5~1, 0.25~0.75, 0.25~0.5, 0.5~0.75, 0.75~1, 0.75~2, 1.1~1.2 , 1.2~1.3, 1.3~1.4, 1.4~1.5, 1.5~1.6, 1.6~1.7, 1.7~1.8, 1.8~1.9, 1.9~2, 1~2, 1~5, 2~7, 3~8, 3 ~5, 4~6, 5~7, 6~8, 7~9, 7~10, or 5~10×10 -9 M (measured by Biacore assay).

[0441] In some embodiments, the antibodies provided herein are about 2, 1.98, 1.95, 1.9, 1.85, 1.8, 1.75, 1.7, 1.65, 1.6, 1.55, 1.50, 1.45, or 1.4×10 -9 K less than or equal to M D binds to human MARCO (as measured by Biacore assay). In some embodiments, the antibodies provided herein are 1.9-1.8, 1.8-1.7, 1.7-1.6, 1.6-1.5, or 1.9-1.5×10 -9 K between M D binds to human MARCO (as measured by Biacore assay). In some embodiments, the antibodies provided herein are about 10, 9.56, 9.5, 9.0, 8.88, 8.84, 8.5, 8, 7.5, 7.32, 7, 6.5, 6, 5.5, 5, 4.5, 4, 3.5, 3, 2.5, 2, 1.5, or 1×10 -4 (1 / s) or less d binds to human MARCO (as measured by Biacore assay). In some embodiments, the antibodies provided herein are 7-10, 7-8, 8-9, 9-10, 7-7.5, 7.5-8, 8-8.5, 8.5-9, 9 ~9.5, or 9.5~10×10 -4 K of (1 / s) d binds to human MARCO (as measured by Biacore assay). In some embodiments, the antibodies provided herein are about 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 45, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 7, 8, 9 or 10x10 5 (1 / Ms) or more a binds to human MARCO (as measured by Biacore assay). In some embodiments, the antibodies provided herein are 4-7, 4-4.5, 4.5-5, 5-5.5, 5.5-6, 6-6.5, or 6.5-7, 7-8, 8~9 or 9~10×10 5 K of (1 / Ms) a binds human MARCO (as measured by Biacore assay).

[0442] In some embodiments, the antibodies provided herein are 2, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3 Binds to human MARCO with an EC50 (measured by flow cytometry) of , 0.2, or 0.1 nM or less. In some embodiments, the antibody binds human MARCO with an EC50 (measured by flow cytometry) of between 0.6 and 1.4 nM. In some embodiments, the antibody binds human MARCO with an EC50 (measured by flow cytometry) of about 0.5, 0.6, 0.9, 1.1, 1.2, 1.3, 1.4, or 1.5 nM.

[0443] In some embodiments, the antibodies provided herein are 2, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3 Binds to mouse MARCO with an EC50 (measured by flow cytometry) of , 0.2, or 0.1 nM or less. In some embodiments, the antibody binds mouse MARCO with an EC50 (measured by flow cytometry) of between 0.6 and 1.4 nM. In some embodiments, the antibody binds mouse MARCO with an EC50 (measured by flow cytometry) of about 0.5, 0.6, 0.9, 1.1, 1.2, 1.3, 1.4, or 1.5 nM.

[0444] In some embodiments, the antibodies provided herein do not bind human MARCO with an EC50 (measured by flow cytometry) of 20 nM or greater. In some embodiments, the antibodies provided herein do not bind mouse MARCO with an EC50 (measured by flow cytometry) of 3 nM or greater.

[0445] To screen for antibodies that bind to the epitope on the target antigen bound by the antibody of interest (e.g., MARCO), use the method described in Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and David Lane (1988). Certain cross-blocking assays can be performed. Alternatively or additionally, epitope mapping can be performed by methods known in the art.

[0446] Competition between antibodies can be determined by assays in which the antibody under test inhibits or blocks the specific binding of a reference antibody to a common antigen (e.g., Junghans et al., Cancer Res. 50:1495, 1990 ;Fendly et al. Cancer Research 50:1550-1558; US6,949,245). An excess of test antibody (e.g., at least 2x, 5x, 10x, 20x, or 100x) reduces the binding of the reference antibody by, e.g., at least 50%, 60%, 70%, 75%, 80%, 85 A test antibody competes with a reference antibody if it inhibits or blocks %, 90%, 95%, or 99% (as measured in a competitive binding assay). Antibodies identified by competition assays (competing antibodies) include those that bind to the same epitope as the reference antibody and those that bind to adjacent epitopes that are sufficiently close to the epitope to which the reference antibody is bound for steric hindrance to occur. include. For example, a second competing antibody that competes with a first antibody described herein for binding to MARCO can be identified. In certain cases, the second antibody blocks binding of the first antibody by, for example, at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%. or inhibit (as determined by competitive binding assay). In certain cases, the second antibody can replace the first antibody by more than 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%. .

[0447] In some embodiments, the antibody binds to the scavenger receptor cysteine ​​rich (SRCR) domain of MARCO.

[0448] In some embodiments, the antibody binds to an epitope on SRCR that includes at least one of residues Q452, Y472, or K473 of wild-type human MARCO (SEQ ID NO: 363). In some embodiments, the antibody binds to an epitope on SRCR that includes at least one of residues H505, D507, S509, or E511 of wild-type human MARCO (SEQ ID NO: 363). In some embodiments, the antibody binds to an epitope on SRCR that includes at least one of residues E450, Q452, Q487, or T499 of wild-type human MARCO (SEQ ID NO: 363). In some embodiments, the antibody targets an epitope on SRCR that includes at least one of residues E450, Q452, Q487, T499, H505, D507, S509, or E511 of wild-type human MARCO (SEQ ID NO: 363). join to.

[0449] In some embodiments, the antibody or antigen-binding fragment thereof has one of the following residues of MARCO set forth in SEQ ID NO: 363: Q452, Y472, K473, E450, Q487, T499, H505, D507, S509, or E511. combine with at least one of the In some embodiments, the antibody or antigen-binding fragment thereof has at least two, three of the following residues of SEQ ID NO: 363: Q452, Y472, K473, E450, Q487, T499, H505, D507, S509, or E511; Combine into 4, 5, 6, 7, 8, 9, or 10 pieces. In some embodiments, the antibody or antigen-binding fragment thereof has one of the following residues of MARCO (SEQ ID NO: 384): Q452, Y472, K473, E450, Q487, T499, H505, D507, S509, or E511. Combine at least two. In some embodiments, the antibody or antigen-binding fragment thereof has one of the following residues of MARCO (SEQ ID NO: 384): Q452, Y472, K473, E450, Q487, T499, H505, D507, S509, or E511. Combine at least three. In some embodiments, the antibody or antigen-binding fragment thereof has one of the following residues of MARCO (SEQ ID NO: 384): Q452, Y472, K473, E450, Q487, T499, H505, D507, S509, or E511. Combine at least four.

[0450] In some embodiments, the antibody or antigen-binding fragment thereof binds at least Q452. In some embodiments, the antibody or antigen-binding fragment thereof binds at least Y472. In some embodiments, the antibody or antigen-binding fragment thereof binds at least K473. In some embodiments, the antibody or antigen-binding fragment thereof binds at least an E450. In some embodiments, the antibody or antigen-binding fragment thereof binds at least Q487. In some embodiments, the antibody or antigen-binding fragment thereof binds at least T499. In some embodiments, the antibody or antigen-binding fragment thereof binds at least H505. In some embodiments, the antibody or antigen-binding fragment thereof binds at least D507. In some embodiments, the antibody or antigen-binding fragment thereof binds at least S509. In some embodiments, the antibody or antigen-binding fragment thereof binds at least S509. In some embodiments, the antibody or antigen-binding fragment thereof binds at least E511.

[0451] function In some embodiments, the antibody has antibody-dependent cellular cytotoxicity (ADCC) activity. ADCC can occur when antibodies bind to antigens on the surface of pathogenic or tumorigenic target cells. Effector cells with Fc gamma receptors (FcγR or FCGR) on their cell surface, including cytotoxic T cells, natural killer (NK) cells, macrophages, neutrophils, eosinophils, dendritic cells, or monocytes recognizes and binds to the Fc region of antibodies bound to target cells. Such binding can cause activation of intracellular signaling pathways leading to cell death. In certain embodiments, the immunoglobulin Fc region subtypes (isotypes) of the antibody include human IgG1 and IgG3. As used herein, ADCC refers to the binding of nonspecific cytotoxic cells (e.g., natural killer (NK) cells, neutrophils, and macrophages) that express Fc receptors (FcR) to target cells. refers to a cell-mediated response that recognizes a target antibody and subsequently causes lysis of the target cell. NK cells, the primary cells that mediate ADCC, express only FcγRIII, whereas monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991). In vitro ADCC assays, such as those described in US Pat. No. 5,500,362 or US Pat. No. 5,821,337, may be performed to assess the ADCC activity of a molecule of interest. Effector cells useful in such assays include peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells. Alternatively or additionally, the ADCC activity of a molecule of interest can be determined in an animal model such as that disclosed in Clynes et al., Proc. Natl. Acad. Sci. (USA) 95:652-656 (1998). , which can be evaluated in vivo.

[0452] In some embodiments, the antibody has complement dependent cytotoxicity (CDC) activity. Antibody-induced CDC is mediated by typical complement cascade proteins and is caused by the binding of complement protein C1q to antibodies. Antibody Fc regions that bind Clq can induce activation of the complement cascade. In certain embodiments, the immunoglobulin Fc region subtypes (isotypes) of the antibody include human IgG1 and IgG3. As used herein, CDC refers to the ability of a molecule to lyse a target in the presence of complement. The complement activation pathway is initiated by the binding of the first component of the complement system (C1q) to a molecule (eg, a polypeptide (eg, antibody)) complexed with a cognate antigen. To assess complement activation, a CDC assay can be performed, eg, as described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996).

[0453] In some embodiments, the antibody is an agonist antibody. An agonist antibody can induce (eg, increase) one or more activities or functions of a MARCO-expressing cell after the antibody binds to a MARCO protein expressed on the cell. Agonist antibodies may bind to and activate MARCO-expressing cells, causing changes in the cell's proliferation or modifying its ability to present antigen. Agonist antibodies can bind to and activate MARCO-expressing cells, triggering intracellular signaling pathways that lead to modification of cell growth or apoptosis.

[0454] In some embodiments, the antibody is an antagonist antibody. An antagonist antibody can block (eg, reduce) one or more activities or functions of a MARCO-expressing cell after the antibody binds to a MARCO protein expressed on the cell. For example, an antagonist antibody may bind to and block a ligand that binds to one or more MARCO proteins, preventing differentiation and proliferation of cells, or modifying their ability to present antigens. Antagonist antibodies can bind to and prevent activation of MARCO proteins by ligands, modifying intracellular signaling pathways that contribute to cell growth and survival.

[0455] In some embodiments, the antibody is a depleted antibody. A depleting antibody is one that kills MARCO expressing cells upon contact via the interaction of the antibody with other immune cells of the molecule. For example, when antibodies bind to cells with MARCO proteins, they can capture complement proteins and induce complement-dependent cell lysis. When antibodies bind to cells with MARCO proteins, they can also induce neighboring cells with Fc receptors to kill them by antibody-dependent cellular cytotoxicity (ADCC).

[0456] In some embodiments, the antibody is a neutralizing antibody, and the antibody neutralizes one or more biological activities of MARCO-expressing cells. In some embodiments, the MARCO protein is expressed on the surface of MARCO-expressing cells and the antibody recognizes the extracellular domain of the MARCO protein.

[0457] In some embodiments, the antibody is selective for MARCO-expressing cells (preferentially binds MARCO). In certain embodiments, antibodies that selectively bind to MARCO-expressing cells have a dissociation constant (Kd) in the range of 0.0001 nM to 1 μM. In certain embodiments, the antibody specifically binds to an epitope on the MARCO protein that is conserved among proteins from different species. In another embodiment, selective binding includes, but does not require exclusive binding.

[0458] In one embodiment, an anti-MARCO antibody that binds to a target causes in vivo depletion of MARCO-expressing cells to which it binds. In some embodiments, effector proteins induced by clustered antibodies can elicit a variety of responses, including release of inflammatory cytokines, modulation of antigen production, endocytosis, or cell killing. In one embodiment, the antibody recruits and activates complement in vivo, or mediates antibody-dependent cellular cytotoxicity (ADCC), or induces phagocytosis by binding to Fc receptors in vivo. can be mediated. Antibodies can also deplete MARCO-expressing cells by inducing apoptosis or necrosis of MARCO-expressing cells upon binding.

[0459] In some embodiments, the disabling of MARCO-expressing cells is in vitro by a) killing non-stimulated bone marrow cells, b) magnetic bead depletion of non-stimulated bone marrow cells; or c) non-stimulated bone marrow cells. This is accomplished by fluorescence-activated cell sorting (FACS) sorting of cells.

[0460] In some embodiments, the antibody is bound or conjugated to an effector molecule. In certain embodiments, the antibody is a radionuclide, a cytotoxin, a chemotherapeutic agent, a drug, a prodrug, a toxin, an enzyme, an immunomodulatory agent, an anti-angiogenic agent, a pro-apoptotic agent, a cytokine, a hormone, an oligonucleotide, an antisense agent. molecule, siRNA, a second antibody, and a second antibody fragment.

[0461] In certain embodiments, the antibody is conjugated to a drug, such as a toxin, chemotherapeutic agent, immune modulator, or radioisotope. Several methods for the preparation of ADCs (antibody drug conjugates) are known in the art, for example, US Pat. No. 8,624,003 (pot method), US Pat. Act). Antibodies or antigen-binding fragments thereof are antigen-binding radionuclides, cytotoxins, chemotherapeutic agents, drugs, prodrugs, toxins, enzymes, immunomodulatory agents, anti-angiogenic agents, pro-apoptotic agents, cytokines, hormones, oligonucleotides, etc. It can be conjugated to at least one agent including nucleotides, antisense molecules, siRNA, second antibodies, and second antibody fragments.

[0462] In some embodiments, the antibody modulates an immune response. In some embodiments, the antibody enhances the immune response. In some embodiments, the antibody enhances or initiates an immune response.

[0463] How to treat cancer In another aspect, the invention provides a method of treating an immune-related condition (eg, cancer) in an individual, comprising administering to the individual an effective amount of a composition comprising an anti-MARCO antibody. In another aspect, the invention provides a method of enhancing an immune response in an individual, comprising administering to the individual an effective amount of a composition comprising an anti-MARCO antibody.

[0464] In some embodiments, the methods provided herein are useful for treating immune-related conditions in an individual. In one embodiment, the individual is a human.

[0465] In some embodiments, the methods provided herein (such as methods of enhancing an immune response) are useful in the treatment of cancer, such that an individual receiving an anti-MARCO antibody has cancer. are doing. In some embodiments, the cancer is a solid cancer. In some embodiments, the cancer is a humoral cancer. In some embodiments, the cancer is immunoevasive. In some embodiments, the cancer is immunocompetent. In some embodiments, the cancer expresses IL-10. In some embodiments, the cancer is a hypoxic cancer. In certain embodiments, the cancer is lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, small cell lung cancer, kidney cancer, liver cancer, renal cell carcinoma, cervical cancer, ovarian cancer, colorectal cancer, colon cancer, Neuroblastoma, breast cancer, type 3 negative breast cancer, basal cell carcinoma, gastric cancer, gastric cancer, bladder cancer, prostate cancer, skin cancer, lymphoma, diffuse large B-cell lymphoma (DLBCL) , small lymphocytic lymphoma, non-Hodgkin's lymphoma, mesothelioma, pancreatic cancer, thyroid cancer, endometrial cancer, head and neck cancer, or head and neck squamous cell carcinoma (HNSC). In some embodiments, the cancer is colon cancer, breast cancer, basal cell-like breast cancer, ovarian cancer, or gastric cancer.

[0466] In some embodiments, treatment reduces the volume or size of the cancer. In some embodiments, the treatment is effective in reducing the volume of the cancer compared to the volume of the cancer prior to administration of the antibody. In some embodiments, the treatment results in a reduction in cancer growth rate. In some embodiments, the treatment is effective in reducing the cancer growth rate compared to the cancer growth rate prior to administration of the antibody. In some embodiments, the treatment is effective in eliminating cancer.

[0467] In some embodiments, MARCO is expressed at higher levels in cancer cells compared to non-cancerous cells. In some embodiments, IL-10 is expressed at higher levels in cancer cells compared to non-cancerous cells. MARCO and / or IL-10 levels can be measured using FACS, Western blot, ELISA, immunoprecipitation, immunohistochemistry, monoplex immunohistochemistry, multiplex immunohistochemistry, flow cytometry, immunofluorescence, radioimmunoassay, dot blotting, Immunodetection, surface plasmon resonance, optical spectroscopy, mass spectrometry, HPLC, qPCR, RT-qPCR, multiplex qPCR or RT-qPCR, RNA-seq, microarray analysis, SAGE, MassARRAY, Luminex, MSD, and FISH, It can be assessed by any technique known in the art including, but not limited to, protein assays or nuclear assays, as well as combinations thereof.

[0468] combination therapy In the treatment of cancer, anti-MARCO antibodies can be combined with one or more antibodies that inhibit immune checkpoint proteins. Of particular interest are immune checkpoint proteins displayed on the surface of tumor cells. Most actively studied in the context of clinical cancer immunotherapy, cytotoxic T lymphocyte-associated antigen 4 (CTLA4, also known as CD152), and programmed cell death protein 1 (PD1, also known as CD279). Both immune checkpoint receptors are inhibitory receptors. The clinical activity of antibodies blocking any of these receptors may enhance antitumor immunity at multiple levels, as well as the rational design of combinatorial strategies guided by mechanistic considerations and preclinical models. It means that you can.

[0469] Two ligands for PD-1 are PD-1 ligand 1 (also known as PD-L1, B7-H1 and CD274) and PD-L2 (also known as B7-DC and CD273). PD-L1 is expressed on cancer cells and through binding to the receptor PD-1 on T cells, it inhibits T cell activation / function. Inhibitors that block the interaction of PD-1 with its cognate ligands PD-L1 and PD-L2 on cancer cells result in increases in both T-cell activation and function, leading to increased cancer cell Prevents evasion of the immune system.

[0470] In some embodiments, the immunotherapy is an agent that interferes with the binding of PD-1 and PD-L1 or PD-L2. In some embodiments, the immunotherapy is an anti-PD1 antibody. In some embodiments, the immunotherapy is an anti-PD-L1 antibody. In some embodiments, the immunotherapy is an anti-PD-L2 antibody.

[0471] Various PD-1, PD-L1, and PD-L2 antibodies are known in the art. In some embodiments, the additional therapeutic agent is atezolizumab (PD-L1), avelumab (PD-L1), durvalumab (PD-L1), nivolumab (PD-1), pembrolizumab (PD-1), cemiplimab ( PD-1), ipilimumab (CTLA-4), tremelimumab (CTLA-4), or any combination thereof.

[0472] Additional therapeutic agents can be administered by any suitable means. In some embodiments, an antibody provided herein and an additional therapeutic agent are included in the same pharmaceutical composition. In some embodiments, an antibody provided herein and an additional therapeutic agent are included in different pharmaceutical compositions.

[0473] In embodiments where the antibody provided herein and the additional therapeutic agent are comprised in different pharmaceutical compositions, administration of the antibody can occur before, simultaneously with, and / or after administration of the additional therapeutic agent. can.

[0474] Methods of immunomodulation Immunosuppressive M2-like MARCO-expressing cells, such as MARCO+ tumor-associated macrophages (TAMs) and MARCO+ mMDSCs, are upregulated in the hypoxic tumor microenvironment (TME) rich in IL-10. These cells suppress immune cytotoxic activity. Immunosuppression also leads to increased angiogenesis and metastasis.

[0475] Anti-MARCO antibodies can activate intratumoral immunity by mediating at least the repolarization of MARCO+ myeloid M2-like TAMs to M1-like TAMs and the repolarization of mMDSCs to proinflammatory monocytes. This repolarization leads to the production of cytokines, chemokines, and activating receptors, leading to activation of T cells, B cells, and NK cells. Repolarization of bone marrow M2-like TAMs and mMDSCs can activate T cells, B cells, and NK cells. Once activated, these NK cells, CD8+ T cells, M1-like TAMs, and inflammatory monocytes can induce tumor destruction. Furthermore, anti-tumor immunity can be modulated by reducing M2-like TAMs and immunosuppressive mMDSCs. Anti-tumor immunity can also be mediated by increased antigen presentation and cellular activation in the spleen and lymph nodes. Binding of anti-MARCO antibodies to medullary cord macrophages (MCM) induces changes in lymph node adhesion and motility, and binding of anti-MARCO antibodies to splenic marginal zone macrophages (MZM) induces changes in adhesion and motility in lymph nodes. alters sex and motility and can potentially lead to activation of B cells.

[0476] In some embodiments, repolarization of MARCO+ cells affects molecular association, enzymatic activity, transcription, translation, and proinflammatory signaling (Src, SYK, NF-kB, PI3K / AKT, TLR, STAT6, IL2RA, CAMK). , PKC, Raf1, TPL2, MAPK, rapid regulation of phosphate signaling cascades involved in cell cycle, survival, cell adhesion and migration, cytoskeletal reorganization); changes in phagocytosis, adhesion, motility, chemotaxis; Activation of NF-kB reporter activity as a single agent and in combination with TLR agonists; IL-1α, IL-1β, IL-2, IL-4, IL-6, IL7R, IL-12, IL12-p70, IL -15, IL-18, IL-27, IP-10, IFN-γ, TNFα, MIP1-α, MIP1-β, MIP-2, CSF2, CSF3, G-CSF, M-CSF, CCL3, CCL4, CCL5 induction of secretion of pro-inflammatory cytokines and chemokines, including but not limited to, CCL20, CCL24, CXCL1, CXCL3, CXCL8, CXCL9, CXCL10, CXCL12, gro-α, MCP-1, MCP-3, LIF, eotaxin; and observed by inflammasome activation and enhanced phagocytosis.

[0477] The methods of administering MARCO antibodies described herein can result in modulation of immune responses. Modulation can be an increase or decrease in immune response. In some embodiments, modulation is an increase in immune response.

[0478] In one aspect, administration of a MARCO antibody described herein can result in the induction of pro-inflammatory molecules such as cytokines, chemokines, or expression of myeloid activating receptors by myeloid cells. Generally, induced pro-inflammatory molecules are present at levels higher than those achieved with isotype controls. In some embodiments, the bone marrow cells are MARCO expressing (MARCO+) cells. In some embodiments, the MARCO+ bone marrow cells are monocytes or macrophages. In some embodiments, the MARCO+ macrophage is a tumor-associated macrophage (TAM) or a monocyte-derived macrophage (MDM). Such pro-inflammatory molecules can stimulate anti-tumor immunity, including but not limited to T cell activation, T cell proliferation, T cell differentiation, M1-like macrophage activation, B cell regulation, and NK cell activation. bring about. Therefore, administration of anti-MARCO antibodies can induce multiple anti-tumor immune mechanisms leading to tumor destruction.

[0479] In another aspect, provided herein is a method of enhancing an immune response in an individual, comprising administering to the individual an effective amount of a composition comprising an anti-MARCO antibody or antigen-binding fragment thereof. In some embodiments, a method of enhancing an immune response in a subject comprises administering to the subject an antibody that binds to the SRCR domain of human MARCO (SEQ ID NO: 363). In some embodiments, a method of enhancing an immune response in a subject comprises administering to the subject an antibody that competes with a reference antibody for binding to human MARCO (SEQ ID NO: 363). In some embodiments, a method of enhancing an immune response in a subject includes administering to the subject an antibody that competes for binding to human MARCO (SEQ ID NO: 363), wherein the antibody competes for binding to human MARCO (SEQ ID NO: 363). ) binds to one of residues Q452, Y472, and K473. In some embodiments, a method of enhancing an immune response in a subject includes administering to the subject an antibody that competes for binding to human MARCO (SEQ ID NO: 363), wherein the antibody competes for binding to human MARCO (SEQ ID NO: 363). ) binds to one of residues E450, Q452, Q487 and T499. In some embodiments, a method of enhancing an immune response in a subject includes administering to the subject an antibody that competes for binding to human MARCO (SEQ ID NO: 363), wherein the antibody competes for binding to human MARCO (SEQ ID NO: 363). ) binds to one of residues H505, D507, S509 or E511.

[0480] In some embodiments, the antibody is present in a pharmaceutical composition that further includes a pharmaceutically acceptable excipient.

[0481] In any and all embodiments of enhancing an immune response described herein, any enhancement or decrease or change in feature(s) or aspect(s) of function is in contact with the anti-MARCO antibody. compared to cells without.

[0482] Enhancing an immune response can be both enhancing an immune response or inducing an immune response. For example, enhancing an immune response includes both initiating or initiating an immune response, or increasing or amplifying an ongoing or existing immune response. In some embodiments, the treatment induces an immune response. In some embodiments, the induced immune response is an adaptive immune response. In some embodiments, the induced immune response is an innate immune response. In some embodiments, the treatment enhances the immune response. In some embodiments, the enhanced immune response is an adaptive immune response. In some embodiments, the enhanced immune response is an innate immune response. In some embodiments, the treatment enhances the immune response. In some embodiments, the enhanced immune response is an adaptive immune response. In some embodiments, the enhanced immune response is an innate immune response. In some embodiments, the immune response is initiated or initiated by administration of an anti-MARCO antibody. In some embodiments, the immune response is enhanced by administration of an anti-MARCO antibody.

[0483] In another aspect, the application provides a method of contacting a cell with an anti-MARCO antibody to modulate immune function of the cell. Modulation can be to enhance the immune response or to reprogram MARCO expressing cells. In some embodiments, the modulation is an increase in immune function. In some embodiments, the modulation of function results in activation of MARCO-expressing bone marrow cells. In some embodiments, the modulation of function results in reprogramming of MARCO-expressing bone marrow cells.

[0484] In some embodiments, the cells are bone marrow cells. In some embodiments, the cells are MARCO expressing cells (MARCO+ cells). In some embodiments, the MARCO+ cells are one or more of monocytes, macrophages, tumor-associated macrophages (TAMs), and monocyte-derived macrophages (MDMs). In some embodiments, the MARCO+ cells are monocytes. In some embodiments, the MARCO+ cells are macrophages. In some embodiments, the MARCO+ cells are tumor-associated macrophages (TAMs). In some embodiments, the MARCO+ cells are monocyte-derived macrophages (MDM). In some embodiments, contacting a MARCO-expressing cell with a MARCO antibody induces activation of the cell.

[0485] In some embodiments, modulating the function of MARCO+ cells includes, for example, increasing the ability of MARCO-expressing cells to cross-present tumor antigens to naive CD8+ T cells of MHCI molecules, or increasing the ability of MARCO-expressing cells to cross-present cytokines or chemokines to naive CD8+ T cells. Increased secretion results in an increased ability of the cells to stimulate both natural and activated CD8+ T cells. In some embodiments, modulation of MARCO+ cell function is achieved by increasing the ability of MARCO-expressing cells to cross-present tumor antigens to naive CD4+ T cells, e.g., by increasing the ability of MARCO-expressing cells to cross-present tumor antigens to naive CD4+ T cells on MHCII molecules. resulting in an increase in the cell's ability to stimulate both. In some embodiments, the modulation of function enhances or increases the ability of the cell to produce cytokines, chemokines, or costimulatory or activating receptors. In some embodiments, modulation increases T cell stimulatory functions of MARCO+ cells, including, for example, the ability of the cells to induce T cell receptor (TCR) signaling, T cell proliferation, or T cell cytokine production. .

[0486] In some embodiments, the enhanced immune response is cytokine and chemokine secretion. In some embodiments, the MARCO antibody has agonist activity. In some embodiments, a MARCO antibody induces enhanced expression of at least one cytokine or chemokine within a cell compared to an isotype control antibody. In some embodiments, the MARCO antibody induces enhanced expression of at least one proinflammatory cytokine or chemokine in a cell compared to an isotype control antibody. In some embodiments, the at least one cytokine or chemokine is IL-1α, IL-1β, IL-2, IL-4, IL-6, IL7R, IL-12, IL12-p70, IL-15, IL -18, IL-27, IP-10, IFN-γ, TNFα, MIP1-α, MIP1-β, MIP-2, CSF2, CSF3, G-CSF, M-CSF, CCL3, CCL4, CCL5, CCL20, CCL24 , CXCL1, CXCL3, CXCL8, CXCL9, CXCL10, CXCL12, gro-α, MCP-1, MCP-3, LIF, or eotaxin. In some embodiments, the cytokine or chemokine is IL-2. In some embodiments, the cytokine or chemokine is IL-12. In some embodiments, the cytokine or chemokine secretion is about 1-100 times greater than untreated cells or cells treated with an isotype control antibody. , 70, 80, 90, 100, 1~10, 10~20, 20~30, 30~40, 40~50, 50~60, 60~70, 70~80, 80~90, or 90~100 times increases with In some embodiments, the chemokine is IL-2 and the secretion is about 1-100-fold, 1-fold, 5-fold, 10-fold, 20-fold compared to untreated cells or cells treated with an isotype control antibody. x, 30x, 40x, 50x, 60x, 70x, 80x, 90x, 100x, 1~10x, 10~20x, 20~30x, 30~40x, 40~50x , 50-60 times, 60-70 times, 70-80 times, 80-90 times, or 90-100 times. In some embodiments, the cytokine is IL-12 and the secretion is about 1-100-fold, 1-fold, 5-fold, 10-fold, 20-fold compared to untreated cells or cells treated with an isotype control antibody. x, 30x, 40x, 50x, 60x, 70x, 80x, 90x, 100x, 1~10x, 10~20x, 20~30x, 30~40x, 40~50x , 50-60 times, 60-70 times, 70-80 times, 80-90 times, or 90-100 times.

[0487] In some embodiments, the MARCO antibody induces decreased expression of at least one gene within a cell compared to an isotype control antibody. In some embodiments, the at least one gene is ALK, MPB, TMEM37, NHSL2, or SLC46A2. In some embodiments, the gene is about 1-100 times greater than untreated cells or cells treated with an isotype control antibody. , 90, 100, 1~10, 10~20, 20~30, 30~40, 40~50, 50~60, 60~70, 70~80, 80~90, or 90~100 times reduced.

[0488] In some embodiments, the MARCO antibody induces inflammasome activation compared to an isotype control antibody. Inflammasome activation can be determined by measuring IL-1β and / or IL-18 secretion.

[0489] In some embodiments, the MARCO antibody induces repolarization of myeloid M2-like TAMs into M1-like TAMs and / or repolarization of mMDSCs into proinflammatory monocytes compared to an isotype control antibody. .

[0490] In some embodiments, the MARCO antibody improves CD8+ T cells, CD4+ T cells, NK cells, dendritic cells, MHCII cells compared to isotype control antibodies. high monocytes, MHCII mid Increase monocytes, marginal zone macrophages, follicular B cells, and / or red pulp macrophages.

[0491] In some embodiments, upon cell contact, the antibody reduces TAMs, neutrophils, marginal zone B cells, CD19+ B cells, and / or MHCII-monocytes compared to an isotype control antibody.

[0492] In some embodiments, MARCO antibodies modulate changes in motility and / or phagocytosis by altering cytoskeleton, actin and muscle, and cell adhesion-related pathways in tumors. In some embodiments, the MARCO antibody induces macrophage reprogramming within the TME, including reprogramming M2 to M1 macrophages, increasing phagocytosis and / or inflammasomes, NK cell activation, and / or T cell activation. resulting in pro-inflammatory activation of

[0493] In some embodiments, MARCO antibodies modulate changes in cell signaling, cell adhesion, cytoskeleton, and motility in lymph nodes. In some embodiments, the MARCO antibody binds to medullary cord macrophages in lymph nodes and modulates cell adhesion and motility.

[0494] In some embodiments, MARCO antibodies modulate cell adhesion, cytoskeleton, migration, motility, cell signaling, and B cell activation in the spleen. In some embodiments, the MARCO antibody binds to splenic marginal zone macrophages and modulates cell adhesion, motility, and B cell activation.

[0495] In some embodiments, modulation increases cell adhesion, cytoskeleton, and cell migration compared to an isotype control antibody. In some embodiments, modulation induces B cell maturation in the spleen compared to an isotype control antibody. In some embodiments, the modulation induces cell signaling pathways including the cell cycle, T cell receptor, phagocytosis, autophagy, and the wnt pathway compared to an isotype control antibody.

[0496] In some embodiments, the enhanced immune response is the recruitment and activation of anti-tumor immune cells.

[0497] In some embodiments, the antibody induces a memory immune response compared to an isotype control antibody. Generally, a memory immune response is a protective immune response against subsequent exposure to a pathogen or antigen previously encountered by the immune system. Exemplary memory immune responses include immune responses following infection or vaccination with an antigen. Generally, memory immune responses are mediated by lymphocytes such as T cells and B cells. In some embodiments, the memory immune response is a protective immune response against cancer, including proliferation, proliferation, or metastasis of cancer cells. In some embodiments, the memory immune response inhibits, prevents, or reduces cancer cell growth, proliferation, or metastasis.

[0498] In some embodiments, the MARCO antibody induces or increases, compared to the isotype antibody, at least one of the following pathways or genes associated with: B cell maturation in the spleen, actin-mediated cell contraction. pathway, kinase activation and activation pathway, Toll-like receptor signaling pathway, TLR 4 and 9 pathway, GTPase binding and activity, and / or RAS-Rho signaling pathway. In some embodiments, the MARCO antibody induces or increases, compared to isotype antibodies, at least one of the following pathways or genes associated with: humoral immune response, NK-mediated immunity, NK activation, IL-2 and IL-12 production, cell killing, effector regulatory processes, T cell proliferation, activation, differentiation, chemotaxis and migration, cell-cell adhesion, phagocytosis, and / or myeloid differentiation.

[0499] In some embodiments, the MARCO antibody induces or increases, compared to the isotype antibody, at least one of the following pathways or genes associated with: natural killer cell-mediated cytotoxicity, T cell receptor signaling. transduction pathway, JAK / STAT signaling pathway, cytokine-cytokine receptor interaction, intestinal immune network for IgA production, leukocyte transendothelial migration, chemokine signaling pathway, hematopoietic cell lineage, type II diabetes, and Fc-epsilon RI Signal transduction pathway. In some embodiments, the MARCO antibody reduces or suppresses at least one of the following pathways or genes associated with: homologous recombination, Alzheimer's disease, RNA polymerase, arginine and proline compared to isotype antibodies. Metabolism, citric acid cycle (TCA cycle), porphyrin and chlorophyll metabolism, degradation of valine, leucine, and isoleucine, biosynthesis of unsaturated fatty acids, biosynthesis of N-glycans, and biosynthesis of aminoacyl-tRNA.

[0500] In some embodiments, the MARCO antibody induces or increases, compared to the isotype antibody, at least one of the following pathways or genes associated with: cytokine-cytokine receptor interaction, natural killer cell-mediated Cellular injury, primary immunodeficiency, chemokine signaling pathway, hematopoietic cell lineage, JAK / STAT signaling pathway, T cell receptor signaling pathway, intestinal immune network for IgA production, neuroactive ligand-receptor interaction, and Fc-ε RI signaling pathway. In some embodiments, the MARCO antibody reduces or suppresses at least one of the following pathways or genes associated with: glycolysis, gluconeogenesis, propanoic acid metabolism, proteasome, citric acid cycle, as compared to isotype antibodies. TCA cycle, myocardial contraction, Alzheimer's disease, Huntington's disease, oxidative phosphorylation, ribosomes, and Parkinson's disease.

[0501] In some embodiments, the MARCO antibody induces or increases, compared to the isotype antibody, at least one of the following pathways or genes associated with: phosphatidylinositol signaling system, focal adhesion, inositol phosphate metabolism. , axon guidance, adherens junctions, pathways in cancer, regulation of the actin cytoskeleton, progesterone-mediated oocyte maturation, ERBB signaling pathway, and Wnt signaling pathway. In some embodiments, the MARCO antibody induces or increases, compared to the isotype antibody, at least one of the following pathways or genes associated with: aminoacyl-tRNA biosynthesis, lysosomes, histidine metabolism, drug metabolism cytochromes. p450, proteasome, Alzheimer's disease, Huntington's disease, Parkinson's disease, oxidative phosphorylation, and ribosomes.

[0502] In some embodiments, the MARCO antibody induces or increases, compared to the isotype antibody, at least one of the following pathways or genes associated with: focal adhesions, phosphatidylinositol signaling system, neurotrophin signaling. transduction pathway, insulin signaling pathway, inositol phosphate metabolism, MAPK signaling pathway, cancer pathway, actin cytoskeleton regulation, ERBB signaling pathway, and adherens junctions. In some embodiments, the MARCO antibody reduces or suppresses at least one of the following pathways or genes associated with: xenobiotic metabolism by cytochrome p450, hematopoietic cell lineages, lysosomes, Alzheimer's disease, as compared to isotype antibodies. disease, proteasomes, cytokine-cytokine receptor interactions, Huntington's disease, Parkinson's disease compared to isotype antibodies, oxidative phosphorylation, and ribosomes.

[0503] In some embodiments, the MARCO antibody induces or increases at least one of the following pathways or genes associated with: ECM receptor interaction, focal adhesions, tight junctions, adherens junctions, proteasomes, complement, and Coagulation cascade, cell adhesion molecules and CAM, pathways in cancer, arrhythmogenic right ventricular cardiomyopathy ARVC, Wnt signaling pathway, regulation of actin skeleton, axon guidance, Huntington's disease, pathogenic Escherichia coli infection, Alzheimer's disease, leukocyte history Endothelial migration, cytokine-cytokine receptor interaction, basal cell carcinoma, melanogenesis, hedgehog signaling pathway. In some embodiments, the MARCO antibody reduces or suppresses at least one of the following pathways or genes associated with: cell cycle, aminoacyl-tRNA biosynthesis, mismatch repair, glycosylphosphatidylinositol GPI, as compared to isotype antibodies. Anchor biosynthesis, glycerophospholipid metabolism, and homologous recombination.

[0504] In some embodiments, the MARCO antibody induces or increases, compared to the isotype antibody, at least one of the following pathways or genes associated with: cell cycle, proteasome, T cell receptor signaling pathway; DNA replication, ubiquitin-mediated protein degradation, actin cytoskeleton regulation, adherens junctions, pathogenic E. coli infection, basal transcription factors, pentose phosphate pathway, Fc gamma R-mediated phagocytosis, neurotrophin signaling pathway, autophagy regulation, glycolysis Gluconeogenesis, oocyte meiosis, chronic myeloid leukemia, citric acid cycle TCA cycle, Wnt signaling pathway, P53 signaling pathway, and natural killer cell-mediated cytotoxicity. In some embodiments, the MARCO antibody reduces or suppresses at least one of the following pathways or genes associated with: ABC transporters, glycosylphosphatidylinositol GPI anchor biosynthesis, RNA polymerase, as compared to isotype antibodies. Ribosomes, arachidonic acid metabolism, glycerophospholipid metabolism.

[0505] In some embodiments, the MARCO antibody improves IL-2-STAT5 signaling, NF-kB signaling, TLR signaling, adhesion and motility signaling, cytoskeletal reorganization signaling, as compared to an isotype control antibody. , NF-kB-mediated TNFα signaling, IL-6-JAK-STAT3 signaling, SYK signaling, MAPK signaling, TPL2 signaling, calcium signaling, IFNγ response, or IFNα response, complement, inflammatory response pathway , or induce allograft rejection pathways.

[0506] In some embodiments, the MARCO antibody improves oxidative phosphorylation, mTOR signaling, endoplasmic reticulum stress response, cholesterol homeostasis, fatty acid metabolism, myc targets, glycolytic pathways, cell cycle pathways, as compared to isotype control antibodies. , cell survival, cell adhesion, E2F target pathway, hypoxia, PI3K-AKT signaling pathway, Src signaling pathway, PKC signaling pathway, epithelial-mesenchymal transition signaling pathway, oxidative phosphorylation, or MAPK signaling pathway. reduce

[0507] In some embodiments, the MARCO antibody induces increased expression of at least one pro-inflammatory or activating gene in cells in the tumor compared to an isotype control antibody. In some embodiments, the MARCO antibody induces or increases the expression of at least one of the following genes: Klrk1, Nrc1, Prf1, Cd40, Cd8α, Nod2, Tlr4, Tnf, Nlrp3, Cd274, Clec9α, Cd200r3, Il -27, Cxcl9, Cxcl10, or Cxcl12.

[0508] In some embodiments, the MARCO antibody increases CD8+ T cells, CD4+ T cells, NK cells, dendritic cells, MHCII+ macrophages, MHCIIhigh monocytes, and / or MHCIImid monocytes in the spleen and / or tumor.

[0509] In some embodiments, the MARCO antibody increases macrophages, marginal zone macrophages, follicular B cells, and / or red pulp macrophages in the spleen and / or tumor.

[0510] In some embodiments, the MARCO antibody targets TAMs, tumor-associated neutrophils, plasma B cells, marginal zone B cells, CD19+ B cells, MHCII-monocytes, and / or MHCII- in the spleen and / or tumor. Decreases macrophages.

[0511] In some embodiments, expression levels of chemokines, cytokines, genes, or pathways are detected by nucleic acid or protein assays. Exemplary nucleic acid or protein assays include FACS, Western blot, ELISA, immunoprecipitation, immunohistochemistry, immunofluorescence, monoplex immunohistochemistry, multiplex immunohistochemistry, immunofluorescence, radioimmunoassay, dot blotting, immunodetection. Methods, HPLC, surface plasmon resonance, optical spectroscopy, mass spectroscopy, qPCR, RT-qPCR, multiplexed qPCR or RT-qPCR, RNA-seq, microarray analysis, SAGE, MassARRAY techniques, Luminex, MSD, and FISH, and their including but not limited to combinations.

[0512] In some embodiments, MARCO antibodies induce changes in cell adhesion, cytoskeleton, chemotaxis, and cell migration upon binding to MARCO+ cells.

[0513] In some embodiments, the antibody cross-links MARCO to MARCO on the cell surface of MARCO+ cells. In some embodiments, the contacting is in vitro. In some embodiments, the contacting is in vivo. In some specific embodiments, the contacting is in vivo in a human. In some embodiments, the contacting is performed by administering an anti-MARCO antibody. In some embodiments, the individual (such as a human) receiving the antibody has cancer.

[0514] Methods of disabling, killing, or depleting MARCO-expressing cells In one aspect, the application provides a method of contacting a cell with an anti-MARCO antibody, such as a human or humanized antibody, which results in the disabling of the MARCO-expressing cell. Disabling MARCO-expressing cells also includes killing and / or depleting MARCO-expressing cells.

[0515] In another aspect, the application provides a method of contacting a MARCO-expressing cell with an anti-MARCO antibody, which results in disabling the MARCO-expressing cell.

[0516] In some embodiments, the MARCO expressing (MARCO+) is a bone marrow cell. In some embodiments, the MARCO expressing is one or more of monocytes or macrophages. In some embodiments, the MARCO-expressing cells are one or more of TAM cells and monocyte-derived macrophages (MDMs). In some embodiments, the MARCO-expressing cells are monocytic myeloid-derived suppressor cells (mMDSCs).

[0517] In some embodiments, the present application provides a method of disabling MARCO-expressing cells comprising contacting the MARCO-expressing cells with a MARCO antibody, thereby killing the MARCO-expressing cells. Disabling refers to rendering a cell partially or completely non-functional. In some embodiments, disabling the cell results in inducing growth arrest in the cell. In some embodiments, disabling the cell results in apoptosis in the cell. In some embodiments, disabling the cell results in lysis of the cell, eg, by complement-dependent cytotoxicity (CDC) or antibody-dependent cytotoxicity (ADCC). In some embodiments, disabling MARCO-expressing cells results in cell necrosis. In some embodiments, disabling MARCO-expressing cells results in inducing growth arrest in the cells. In some embodiments, disabling MARCO-expressing cells results in inactivation of the cells. In some embodiments, disabling MARCO-expressing cells results in neutralization of the activity of MARCO proteins within the cells. In some embodiments, disabling MARCO-expressing cells results in reduced proliferation of the cells. In some embodiments, disabling MARCO-expressing cells results in differentiation of the cells. In some embodiments, disabling MARCO expression results in a decreased ability of the cell to act as an inhibitory antigen-presenting cell or an increased ability of the cell to act as an activated antigen-presenting cell. In some embodiments, disabling MARCO-expressing cells results in mislocalization of cells within tumor tissue or the tumor microenvironment (TME). In some embodiments, disabling MARCO-expressing cells results in an alteration of the spatial organization of cells within the tumor tissue or tumor microenvironment. In some embodiments, disabling MARCO-expressing cells results in altered temporal expression of cells within the tumor tissue or TME. In some embodiments, the method further includes removing MARCO expressing cells.

[0518] In any and all embodiments of disabling MARCO-expressing cells described herein, any increase or decrease or change in the property(s) or aspect(s) of function is caused by contact with the anti-MARCO antibody. as compared to cells without.

[0519] In another aspect, the application provides a method of contacting a MARCO-expressing cell with an anti-MARCO antibody, thereby resulting in modulation of the function of the MARCO-expressing cell. Modulation can be any one or more of the following: In some embodiments, the MARCO expressing cells are one or more of monocytes, macrophages, TAMs and MDMs. In some embodiments, the modulation of cellular function involves increasing the ability of MARCO-expressing cells to cross-present tumor antigens to naive CD8+ T cells, e.g., by increasing the ability of MARCO-expressing cells to cross-present tumor antigens to naive CD8+ T cells with MHCI molecules. resulting in an increase in the cell's ability to stimulate both. In some embodiments, modulation of the function of MARCO-expressing cells includes, for example, increasing the ability of MARCO-expressing cells to cross-present tumor antigens to naïve CD4+ T cells on MHCII molecules. Both stimulate the cell's ability to increase. In some embodiments, the modulation increases the T cell stimulatory function of the myeloid cell, including, for example, the ability of the cell to induce T cell receptor (TCR) signaling, T cell proliferation, or T cell cytokine production. . In some embodiments, the modulation of function enhances or increases the ability of the cell to produce cytokines, chemokines, or costimulatory or activating receptors.

[0520] In any and all embodiments of reducing the function of a MARCO-expressing cell described herein, any increase or decrease or change in property(s) or aspect(s) of function is contacted with an anti-MARCO antibody. This is as compared to cells that do not.

[0521] In some embodiments, the present application provides a method of killing MARCO antibodies (also referred to as inducing cell death) comprising contacting a MARCO expressing cell with a MARCO antibody, thereby killing the MARCO antibody. . In some embodiments, killing is increased compared to MARCO expressing cells that have not been contacted with anti-MARCO antibodies. In some embodiments, the contact induces apoptosis in the MARCO expressing cell. In some embodiments, the MARCO-expressing cells are in a population of immune cells that includes MARCO-expressing cells and non-MARCO-expressing cells. In some embodiments, the method further comprises removing MARCO expressing cells. In some embodiments, 10% to 100% of the cells are killed. In some embodiments, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of the cells are killed.

[0522] In some embodiments, the number of MARCO expressing cells is reduced. In some embodiments, MARCO-expressing cells are killed, eg, by necrosis or apoptosis. In some embodiments, MARCO-expressing cells are induced to undergo growth arrest. In some embodiments, the MARCO expressing cells are no longer proliferating. In some embodiments, the spatial localization of MARCO-expressing cells is altered, increasing the ratio in specific regions of the TME. In some embodiments, the temporal expression of MARCO-expressing cells is altered such that the proportion increases during certain times during tumor development.

[0523] Additional methods Determination of MARCO expression Also provided herein are methods of treating cancer or modulating an immune response in an individual, including: This includes determining, or having already determined, the expression of MARCO in the subject, and administering, or having previously administered to the subject, an isolated antibody or antigen-binding fragment that binds MARCO. .

[0524] In some embodiments, the method comprises determining or having determined the expression level of MARCO in a biological sample from the individual. In some embodiments, biological samples include, but are not limited to, body fluids, tissue samples, organ samples, urine, feces, blood, saliva, CSF, and any combinations thereof. In some embodiments, the biological sample is derived from tumor tissue. In some embodiments, the expression level includes the mRNA expression level of mRNA encoding TREM1 protein. In some embodiments, the expression level of MARCO comprises the protein expression level of MARCO. In some embodiments, the expression level of MARCO is determined by FACS, Western blot, ELISA, immunoprecipitation, immunohistochemistry, monoplex immunohistochemistry, multiplex immunohistochemistry, immunofluorescence, radioimmunoassay, dot blotting, immunodetection. methods, HPLC, surface plasmon resonance, optical spectroscopy, mass spectrometry, qPCR, RT-qPCR, multiplexed qPCR or RT-qPCR, RNA-seq, microarray analysis, SAGE, MassARRAY techniques, Luminex, MSD, and FISH, and their detected in the sample using a method selected from the group consisting of:

[0525] In some embodiments, provided herein are methods for determining the expression level of a MARCO protein in a sample from a subject, the method comprising: contacting the sample with an anti-MARCO antibody; and performing an immunohistochemical assay. Including. In some embodiments, the antibody comprises RDM5, RDM9, PI-3010.15, PI-3010.25, or PI-3030.41.

[0526] In the embodiments described herein for detection and / or quantification, the anti-MARCO antibody binds to the MARCO protein, although it does not necessarily have to affect a biological response such as ADCC. May affect biological responses. In some embodiments, the antibody binds soluble MARCO.

[0527] In another aspect, the invention includes detecting the expression level of MARCO in a biological sample from the individual and determining whether the individual is likely to respond to immunotherapy based on the expression level of MARCO. Provides a method for identifying individuals capable of responding to immunotherapy (e.g., using anti-MARCO antibodies) for the treatment of immune-related conditions (e.g., cancer), with increased response compared to that of healthy individuals. The level of MARCO in a given individual indicates that the individual is likely to respond to immunotherapy. In some embodiments, MARCO expression in the individual has already been determined. In some embodiments, these methods may also be used to diagnose an immune-related condition (e.g., cancer) in an individual, based on the expression level of MARCO compared to that of a healthy individual. An increased level of MARCO in an individual indicates that the individual has cancer. In some embodiments, the expression level of MARCO comprises the mRNA expression level of MARCO. In other embodiments, the expression level of MARCO comprises the protein expression level of MARCO. In some embodiments, the expression level of MARCO is detected in the sample using a nucleic acid or protein assay. Exemplary nucleic acid or protein assays include FACS, Western blot, ELISA, immunoprecipitation, immunohistochemistry, monoplex immunohistochemistry, multiplex immunohistochemistry, immunofluorescence, radioimmunoassay, dot blotting, immunodetection methods, HPLC , surface plasmon resonance, optical spectroscopy, mass spectroscopy, qPCR, RT-qPCR, multiplexed qPCR or RT-qPCR, RNA-seq, microarray analysis, SAGE, MassARRAY techniques, Luminex, MSD, and FISH, and combinations thereof. However, it is not limited to these. In these embodiments, the anti-MARCO antibody binds to a MARCO protein, but does not necessarily have to affect a biological response such as ADCC. In some embodiments, the biological sample is derived from tumor tissue. In some embodiments, biological samples include, but are not limited to, body fluids, tissue samples, organ samples, urine, feces, blood, saliva, CSF, and any combinations thereof.

[0528] In some embodiments, the assay is an immunohistochemical assay and the antibody comprises RDM5, RDM9, PI-3010.15, PI-3010.25, or PI-3030.41.

[0529] Administration method In some embodiments, anti-MARCO antibodies are administered intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intracerebroventricularly, or intranasally. be done. An effective amount of an anti-MARCO antibody can be administered for the treatment of cancer. The appropriate dose of anti-MARCO antibody depends on the type of cancer being treated, the type of anti-MARCO antibody, the severity and course of the cancer, the individual's clinical condition, the individual's clinical history and response to treatment, and the person responsible for the treatment. It can be determined based on the discretion of the doctor.

[0530] Preparation method The antibodies described herein can be produced using recombinant methods and compositions, such as those described in US Pat. No. 4,816,567.

[0531] In one embodiment, isolated nucleic acids encoding antibodies described herein are provided. Such a nucleic acid may encode an amino acid sequence comprising the VL and / or the VH of an antibody (e.g., the light chain and / or heavy chain of an antibody) or the VHH of a single domain antibody. good. In a further embodiment, one or more vectors (eg, expression vectors) containing such nucleic acids are provided. In one embodiment, the nucleic acid is provided in a multicistronic vector. In further embodiments, host cells containing such nucleic acids are provided. In one such embodiment, the host cell is a vector comprising a nucleic acid encoding (1) an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antigen-binding polypeptide construct, or (2) an antigen-binding polypeptide. a first vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of the construct and a second vector comprising a nucleic acid encoding an amino acid sequence comprising the VH of the antigen-binding polypeptide construct (e.g., ). In one embodiment, the host cell is a eukaryotic cell, eg, a Chinese hamster ovary (CHO) cell, or a human embryonic kidney (HEK) cell, or a lymphoid cell (eg, YO, NS0, Sp20 cell). In one embodiment, a method of making an antibody is provided, which method comprises culturing a host cell containing a nucleic acid encoding an antibody, as provided above, under conditions suitable for expression of the antibody, and, optionally, , including recovering the antibody from the host cell (or host cell culture medium).

[0532] For recombinant production of antibodies, for example, nucleic acids encoding the antibodies described above are isolated and inserted into one or more vectors for further cloning and / or expression in host cells. Such nucleic acids can be easily isolated using routine procedures (e.g., by using oligonucleotide probes that can specifically bind to genes encoding the heavy and light chains of antibodies). and sequenced.

[0533] The term "substantially purified" refers to a specification that may be substantially or essentially free of components that normally accompany or interact with the protein as found in its naturally occurring environment. i.e., the host cell in the case of a native cell or, in certain embodiments, a recombinantly produced heteromultimer substantially free of extracellular material, is free of contaminating proteins. less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% (by dry weight). When a heteromultimer or variant thereof is recombinantly produced by a host cell, the protein in certain embodiments is about 30%, about 25%, about 20%, about 15%, about 10%, about Present at less than 5%, about 4%, about 3%, about 2%, or about 1%. When a heteromultimer or variant thereof is recombinantly produced by a host cell, the protein, in certain embodiments, is about 5 g / L, about 4 g / L, about 3 g / L, about 2 g / L of the dry weight of the cell, Present in the medium at about 1 g / L, about 750 mg / L, about 500 mg / L, about 250 mg / L, about 100 mg / L, about 50 mg / L, about 10 mg / L, or about 1 mg / L or less. In certain embodiments, "substantially purified" heteromultimers produced by the methods described herein are purified by suitable methods such as SDS / PAGE analysis, RP-HPLC, SEC, and capillary electrophoresis. Purification of at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, as determined level, specifically a purification level of at least about 75%, 80%, 85%, more specifically a purification level of at least about 90%, a purification level of at least about 95%, a purification level of at least about 99%. , or more.

[0534] Suitable host cells for cloning or expression of vectors encoding antibodies include the prokaryotic or eukaryotic cells described herein.

[0535] A "recombinant host cell" or "host cell" is used for insertion, e.g., direct uptake, transduction, f-crossing, or other methods known in the art for producing recombinant host cells. Refers to cells that contain exogenous polynucleotides, regardless of how they are obtained. Exogenous polynucleotides may be maintained as non-integrating vectors, eg, plasmids, or may be integrated into the host genome. The host cell can include CHO, a derivative of CHO, NSO, Sp2O, CV-1, VERO-76, HeLa, HepG2, Per.C6, or BHK.

[0536] As used herein, the term "eukaryote" refers to the phylogenetic domain Eukarya, including, but not limited to, animals (including, but not limited to, mammals, insects, reptiles, birds, etc.). ), ciliates, plants (including, but not limited to, monocots, dicots, algae, etc.), fungi, yeasts, flagellates, microsporidians, protists, etc.

[0537] The term "prokaryote" as used herein refers to prokaryotes. As used herein, the term "prokaryote" refers to prokaryotic organisms. For example, non-eukaryotes include Eubacteria (including, but not limited to, Escherichia coli, Thermus thermophilus, Bacillus stearothermophilus, Pseudomonas fluorescens). ), Pseudomonas aeruginosa, Pseudomonas putida, etc.), or Archaea (including but not limited to Methanococcus jannaschii, Methanobacterium thermoautotropicum). (Methanobacterium thermoautotrophicum), Halobacterium, such as Haloferax volcanii and Halobacterium species NRC-1, Archaeoglobus fulgidus, Pyrococcus furiosus ), Pyrococcus horikoshii, Aeropyrum pernix, etc.) may belong to the phylogenetic domain.

[0538] For example, antibodies may be produced in bacteria, particularly where glycosylation and Fc effector function are not required. On the expression of antibody fragments and polypeptides in bacteria, see, for example, U.S. Pat. .248 (B.K.C.Lo, ed., Humana Press, Totowa, N.J., 2003), pp. 245-254). After expression, antibodies may be isolated from the bacterial cell paste in the soluble fraction and can be further purified.

[0539] In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungal and yeast strains, and this glycosylation pathway glycosylation, resulting in the production of antibodies that partially or completely contain human glycosylation patterns. See Gerngross, Nat.Biotech.22:1409-1414 (2004), and Li et al., Nat.Biotech.24:210-215 (2006).

[0540] Suitable host cells for the expression of glycosylated antibodies are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. A number of baculovirus strains have been identified that can be used with insect cells, particularly, in the case of transfection, Spodoptera frugiperda cells.

[0541] Plant cell cultures can also be utilized as hosts. See, e.g., U.S. Pat. No. 5,959,177 (describing PLANTIBODIES™ technology for producing antibodies in transgenic plants), U.S. Pat. No. 6,040,498, U.S. Pat. About.

[0542] Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines include the monkey kidney CV1 strain transformed with SV40 (COS-7); the human embryonic kidney strain (e.g., Graham et al., J. Gen Virol. 36:59 ( infant hamster kidney cells (BHK); mouse Sertoli cells (e.g., TM4 cells as described in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells ( CV1); African green monkey kidney cells (VERO-76); human cervical cancer cells (HELA); dog kidney cells (MDCK); buffalo rat hepatocytes (BRL 3A); human lung cells (W138); human hepatocytes (Hep G2) ); mouse mammary tumor (MMT 060562); for example, TRI cells as described in Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC5 cells; and FS4 cells.Other useful Mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA77:4216 (1980)); and Y0, NS0, and SP2 For a review of specific mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (B.K.C.Lo, ed., Humana Press, Totowa, N.J.), pp. 255-268 (2003).

[0543] In one embodiment, the antibodies described herein are obtained by transfecting at least one stable mammalian cell with a nucleic acid encoding the antibody and expressing the nucleic acid in the at least one mammalian cell in a predetermined ratio. produced in stable mammalian cells by a method comprising: In some embodiments, the predetermined ratio of nucleic acids is determined in a transient transfection experiment to determine the relative ratio of input nucleic acids that results in the highest percentage of antibody in the expression product.

[0544] In some embodiments, there are methods of producing antibodies in stable mammalian cells as described herein, wherein at least one stable mammalian cell expression product comprises a monomeric heavy chain or Contains a greater proportion of the desired glycosylated antibody compared to light chain polypeptides or other antibodies.

[0545] In some embodiments, there are methods of producing glycosylated antibodies in stable mammalian cells as described herein, the methods comprising identifying and purifying the desired glycosylated antibodies. In some embodiments, the identification is by one or both of liquid chromatography and mass spectrometry.

[0546] If desired, antibodies can be purified or isolated after expression. Proteins may be isolated or purified in a variety of ways known to those skilled in the art. Standard purification methods include ion exchange, hydrophobic interactions, affinity, size or gel filtration, and reverse phase chromatography, performed at atmospheric or high pressure using systems such as FPLC and HPLC. Including methods. Purification methods also include electrophoretic techniques, immunological techniques, precipitation techniques, dialysis techniques, and chromatofocusing techniques. Ultrafiltration and diafiltration techniques combined with protein concentration are also useful. As is well known in the art, a variety of naturally occurring proteins bind Fc and antibodies, and these proteins may find use in the present invention for the purification of antibodies. For example, bacterial proteins A and G bind to the Fc region. Similarly, bacterial protein L binds to the Fab region of some antibodies. Purification can often be enabled by specific fusion partners. For example, antibodies can be purified using glutathione resin if a GST fusion is used, Ni+2 affinity chromatography if a His tag is used or immobilized, anti-Flag antibodies if a Flag tag is used. may be done. For general guidance on suitable purification techniques, see, eg, Protein Purification: Principles and Practice, 3rd Ed., Scopes, Springer-Verlag, NY, 1994, which is incorporated by reference in its entirety. The degree of purification required will vary depending on the use of the antibody. In some cases, no purification is necessary.

[0547] In certain embodiments, the antibodies are chromatographed on, but not limited to, Q-Sepharose, DEAE Sepharose, Poros HQ, Poros DEAF, Toyopearl Q, Toyopearl QAE, Toyopearl DEAE, Resource / Source Q and DEAE, Fractogel Q, and DEAE columns. It is purified using anion exchange chromatography including chromatography.

[0548] In certain embodiments, the proteins described herein include, but are not limited to, SP-Sepharose, CM Sepharose, Poros HS, Poros CM, Toyopearl SP, Toyopearl CM, Resource / Source S and CM, Fractogel S and CM columns. , and its equivalents and equivalents using cation exchange chromatography.

[0549] Additionally, the antibodies described herein can be chemically synthesized using techniques known in the art (e.g., Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman & Co. , N.Y. and Hunkapiller et al., Nature, 310:105-111 (1984)). For example, polypeptides corresponding to fragments of polypeptides can be synthesized through the use of a peptide synthesizer. Additionally, if desired, non-classical amino acids or chemical amino acid analogs can be introduced as substitutions or additions to the polypeptide sequence. Non-classical amino acids are generally D-isomers of common amino acids such as 2,4 diaminobutyric acid, α-aminoisobutyric acid, 4-aminobutyric acid, Abu, 2-aminobutyric acid, g-Abu, e-Ahx, 6-aminohexane Acid, Aib, 2-aminoisobutyric acid, 3-aminopropionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, These include, but are not limited to, designer amino acids such as alanine, fluoroamino acids, methylamino acids, C-methylamino acids, N-methylamino acids, and amino acid analogs. Additionally, the amino acid can be D (dextrorotatory) or L (levorotatory).

[0550] pharmaceutical composition Also encompassed by the invention are methods of treating immune-related diseases (eg, cancer). The method of the invention comprises administering a therapeutically effective amount of an anti-MARCO antibody or antigen binding fragment. MARCO antibodies or antigen-binding fragments can be formulated into pharmaceutical compositions. These compositions contain, in addition to one or more of the anti-MARCO antibodies or antigen-binding fragments disclosed herein, pharmaceutically acceptable excipients, carriers, buffers, stabilizers, or the like. Other materials known to those skilled in the art may be included. Such substances should be non-toxic and should not interfere with the effectiveness of the active ingredients. The precise nature of the carrier or other material may depend on the route of administration, eg, oral, intravenous, dermal or subcutaneous, nasal, intramuscular, intraperitoneal.

[0551] Pharmaceutical compositions for oral administration may be in tablet, capsule, powder, or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil, or synthetic oil. Physiological saline, dextrose or other sugar solutions, or glycols such as ethylene glycol, propylene glycol, or polyethylene glycol can be included.

[0552] For intravenous, dermal or subcutaneous injection, or injection at the affected site, the active ingredient is pyrogen-free and parenterally acceptable with suitable pH, isotonicity, and stability. It will be in the form of an aqueous solution. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilizers, buffers, antioxidants, and / or other additives can be included as required.

[0553] Administration, whether it is a polypeptide, antibody (e.g., anti-TREM1 antibody), nucleic acid, small molecule, or other pharmaceutically useful compound according to the invention to be given to an individual, is defined as "therapeutic". Preferably, it is a "prophylactically effective amount" or a "prophylactically effective amount" (in some cases, it can be therapeutic, but prophylaxis can be considered treatment), which is sufficient to show benefit to the individual. It is. The actual amount administered, and rate and course of administration, will depend on the nature and severity of the protein aggregation disease being treated. Formulating treatments, e.g. determining dosage, etc., is within the responsibility of general practitioners and other medical practitioners and will usually depend on the disorder to be treated, the individual patient's condition, the site of delivery, method of administration, and the practitioner. taking into account other factors known to Examples of the techniques and protocols described above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.

[0554] The compositions can be administered alone or in combination with other treatments, simultaneously or sequentially, depending on the condition to be treated.

[0555] Kits and manufactured articles This application provides kits containing any one or more of the antibody compositions described herein. In some embodiments, the kit further comprises: a secondary antibody, an immunohistochemistry reagent, a pharmaceutically acceptable excipient, and instructions for use, and any combination thereof. Contains constituent ingredients. In one particular embodiment, the kit comprises a pharmaceutical composition comprising any one or more of the antibody compositions described herein, along with one or more pharmaceutically acceptable excipients. include.

[0556] This application also provides articles of manufacture comprising any one of the antibody compositions or kits described herein. Examples of articles of manufacture include vials (including sealed vials).

[0557] Additional embodiments In one aspect, provided herein is an isolated antibody or antigen-binding fragment thereof that binds to human macrophage receptor with collagen structure (MARCO) (SEQ ID NO: 384) and competes for binding with a reference antibody; The antibody has a heavy chain variable (VH) sequence that includes three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and three light chain CDR sequences, CDR-L1, CDR-L2, and CDR -contains a variable light chain (VL) sequence containing L3; CDR-H1 contains the sequence GFSLTSYHVS (SEQ ID NO: 2), CDR-H2 contains the sequence AIWTGGSIA (SEQ ID NO: 3), CDR-H3 includes the sequence DLSDYYSSYTSFDY (sequence number 4), CDR-L1 comprises the sequence ASEGISNDLA (SEQ ID NO: 431) or XASEGISNDLA (SEQ ID NO: 383), where X is arginine (R) or leucine (L), CDR-L2 contains the sequence AASRLQD (SEQ ID NO: 8), CDR-L3 contains the sequence QQSYKYPLT (SEQ ID NO: 9).

[0558] In some embodiments, CDR-L1 comprises the sequence ASEGISNDLA (SEQ ID NO: 431).

[0559] In some embodiments, CDR-L1 comprises the sequence RASEGISNDLA (SEQ ID NO: 27).

[0560] In some embodiments, the VH sequence comprises the VH sequence set forth in SEQ ID NO: 61 and the VL sequence comprises the VL sequence set forth in SEQ ID NO: 66.

[0561] In some embodiments, the VH sequence comprises the VH sequence set forth in SEQ ID NO: 111 and the VL sequence comprises the VL sequence set forth in SEQ ID NO: 116.

[0562] In some embodiments, the VH sequence is as set forth in SEQ ID NO. Contains VH sequences.

[0563] In some embodiments, the VL sequence is as set forth in SEQ ID NO: 6, 16, 26, 36, 46, 57, 66, 76, 86, 96, 106, 116, 126, 136, 439, 449, or 479. Contains VL array.

[0564] In some embodiments, the VH sequence is as set forth in SEQ ID NO. The VH sequence includes the VL sequence as set forth in SEQ ID NOs: 6, 16, 26, 36, 46, 57, 66, 76, 86, 96, 106, 116, 126, 136, 439, 449, and 479. including.

[0565] In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO:65 and a light chain sequence set forth in SEQ ID NO:70.

[0566] In some embodiments, the antibody comprises a heavy chain sequence set forth in SEQ ID NO: 115 and a light chain sequence set forth in SEQ ID NO: 120.

[0567] In some embodiments, the antibodies have the sequences set forth in SEQ ID NOs: 5, 15, 125, 35, 45, 55, 65, 75, 85, 95, 105, 115, 125, 145, 438, 448, and 478. and from the sequences set forth in SEQ ID NOs: 10, 20, 30, 40, 50, 6, 70, 80, 90, 100, 110, 120, 130, 140, 443, 453, and 483. comprising a selected light chain sequence.

[0568] In some embodiments, the VH sequence consists of the VH sequence set forth in SEQ ID NO: 61 and the VL sequence consists of the VL sequence set forth in SEQ ID NO: 66.

[0569] In some embodiments, the VH sequence consists of the VH sequence set forth in SEQ ID NO: 111 and the VL sequence consists of the VL sequence set forth in SEQ ID NO: 166.

[0570] In some embodiments, the VH sequence is as set forth in SEQ ID NO: 1, 11, 21, 31, 41, 51, 61, 71, 81, 91, 101, 111, 121, 131, 434, 444, or 474. The VL sequence is SEQ ID NO: 6, 16, 26, 36, 46, 57, 66, 76, 86, 96, 106, 116, 126, 136, 439, 449, or 479. It consists of a VL sequence selected from the sequences described in .

[0571] In some embodiments, the antibody comprises a heavy chain and a light chain, the heavy chain sequence consisting of the heavy chain sequence set forth in SEQ ID NO: 65, and the light chain sequence consisting of the light chain sequence set forth in SEQ ID NO: 70. .

[0572] In some embodiments, the antibody comprises a heavy chain and a light chain, the heavy chain sequence consisting of the heavy chain sequence set forth in SEQ ID NO: 115, and the light chain sequence consisting of the light chain sequence set forth in SEQ ID NO: 120. .

[0573] In some embodiments, the antibody comprises a human Fc region.

[0574] In some embodiments, the human Fc region is wild type human IgG1 Fc.

[0575] In some embodiments, the antibody comprises a wild type human IgG1 Fc, the VH sequence comprises the VH sequence set forth in SEQ ID NO: 61, and the VL sequence comprises the VL sequence set forth in SEQ ID NO: 66.

[0576] In some embodiments, the antibody comprises a wild type human IgG1 Fc, the VH sequence comprises the VH sequence set forth in SEQ ID NO: 111, and the VL sequence comprises the VL sequence set forth in SEQ ID NO: 116.

[0577] In some embodiments, the antibody is directed to human MARCO with a KD of about 0.5, 1, 2, 3, 4, 5, 6, or 7 x 10 M or less, as measured by surface plasmon resonance (SPR) assay. Join.

[0578] In some embodiments, the antibody is humanized.

[0579] In one aspect, provided herein is a method of producing an antibody that includes expressing an antibody disclosed herein from a host cell and isolating the expressed antibody.

[0580] In one aspect, the invention provides a pharmaceutical composition comprising an antibody disclosed herein and a pharmaceutically acceptable excipient.

[0581] In one aspect, provided herein is a kit comprising an antibody disclosed herein and instructions for use.

[0582] In one aspect, provided herein is an isolated antibody or antigen-binding fragment thereof that binds human MARCO (SEQ ID NO: 384) and competes for binding with a reference antibody, wherein the reference antibody comprises three heavy chain CDR sequences. , a heavy chain variable (VH) sequence containing CDR-H1, CDR-H2, and CDR-H3, and a light chain variable (VH) sequence containing three light chain CDR sequences, CDR-L1, CDR-L2, and CDR-L3. ) array, CDR-H1 contains the sequence GYTFTDYAVN (SEQ ID NO: 232), CDR-H2 contains the sequence WINTQTGKPT (SEQ ID NO: 233), CDR-H3 contains the sequence DSYYYSSSLDY (SEQ ID NO: 234), CDR-L1 comprises the sequence ASAGISNDLA (SEQ ID NO: 432) or XASAGISNDLA (SEQ ID NO: 381), where X is arginine (R) or leucine (L), CDR-L2 contains the sequence AASRLQD (SEQ ID NO: 238), CDR-L3 contains the sequence QQSYKYPWT (SEQ ID NO: 239).

[0583] In one aspect, provided herein is a method of treating cancer in a subject comprising administering to the subject an antibody that competes with a reference antibody for binding to human MARCO (SEQ ID NO: 384), wherein the reference antibody is , a heavy chain comprising variable heavy chain (VH) sequences comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and three light chain CDR sequences, CDR-L1, CDR-L2, and a light chain comprising a variable light chain (VL) sequence comprising CDR-L3; CDR-H1 contains the sequence GFSLTSYHVS (SEQ ID NO: 2), CDR-H2 contains the sequence AIWTGGSIA (SEQ ID NO: 3), CDR-H3 includes the sequence DLSDYYSSYTSFDY (sequence number 4), CDR-L1 comprises the sequence ASEGISNDLA (SEQ ID NO: 431) or XASEGISNDLA (SEQ ID NO: 383), where X is arginine (R) or leucine (L), CDR-L2 contains the sequence AASRLQD (SEQ ID NO: 8), CDR-L3 contains the sequence QQSYKYPLT (SEQ ID NO: 9).

[0584] In some embodiments, the subject has previously received, is receiving concurrently with, or will receive subsequent immunotherapy, and the immunotherapy is a checkpoint inhibitor; a T-cell checkpoint inhibitor. Anti-PD1 antibody; Anti-PDL1 antibody; Anti-CTLA4 antibody; Adoptive T-cell therapy; CAR-T cell therapy; Dendritic cell vaccine; Monocyte vaccine; Antigen-binding protein that binds to both T cells and antigen-presenting cells; at least one of a heavy antigen binding protein; a Toll-like receptor ligand; a cytokine; a cytotoxic therapy; a chemotherapy; a radiation therapy; a small molecule inhibitor; a small molecule agonist; an immunomodulator; and an epigenetic modulator.

[0585] In some embodiments, the immunotherapy is an anti-PD1 antibody, an anti-PDL1 antibody, or an anti-CTLA4 antibody.

[0586] In one aspect, provided herein is a method of enhancing an immune response in a subject comprising administering to the subject an antibody that competes with a reference antibody for binding to human MARCO (SEQ ID NO: 384), wherein the reference antibody , a heavy chain comprising variable heavy chain (VH) sequences comprising three heavy chain CDR sequences, CDR-H1, CDR-H2, and CDR-H3, and three light chain CDR sequences, CDR-L1, CDR-L2, and a light chain comprising a variable light chain (VL) sequence comprising CDR-L3; CDR-H1 contains the sequence GFSLTSYHVS (SEQ ID NO: 2), CDR-H2 contains the sequence AIWTGGSIA (SEQ ID NO: 3), CDR-H3 includes the sequence DLSDYYSSYTSFDY (sequence number 4), CDR-L1 comprises the sequence ASEGISNDLA (SEQ ID NO: 431) or XASEGISNDLA (SEQ ID NO: 383), where X is arginine (R) or leucine (L), CDR-L2 contains the sequence AASRLQD (SEQ ID NO: 8), CDR-L3 contains the sequence QQSYKYPLT (SEQ ID NO: 9).

Example

[0587] The following are examples of specific embodiments for carrying out the invention. These examples are provided for illustrative purposes only and are not intended to limit the scope of the invention in any way. Efforts have been made to ensure accuracy with numbers used (eg, amounts, temperatures, etc.) but some experimental errors and deviations should, of course, be allowed for.

[0588] The practice of the present invention will employ, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA techniques, and pharmacology, within the skill of the art. Such techniques are fully explained in the literature. For example, T. E. Creighton, Proteins: Structures and Molecular Properties (W. H. Freeman and Company, 1993); A. L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition ,1989);Methods In Enzymology(S.Colowick and N.Kaplan eds.,Academic Press,Inc.);Remington's Pharmaceutical Sciences,18th Edition(Easton,Pennsylvania:Mack Publishing Company,1990);Carey and Sundberg Advanced Organic Chemistry 3 rd See Ed. (Plenum Press) Vols A and B (1992).

[0589] Example 1: MARCO is expressed in multiple tumor types MARCO bulk RNA expression in multiple cancer types MARCO mRNA expression in tumors and normal tissues for all indications in The Cancer Genome Atlas (TCGA) was generated by the BROAD Institute Gene Expression Viewer at firebrowse.org.

[0590] The ordered MARCO mRNA expression in tumor tissue (left bar) versus normal tissue (right bar) is shown in Figure 1. The following tumor types are listed on the x-axis: ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and cervical glandular carcinoma. Cancer; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; COADREAD, colon and rectal adenocarcinoma; DLBC, diffuse large B-cell lymphoma; ESCA, esophageal cancer; GBM, glioblastoma multiforme; GBMLGG; Glioblastoma multiforme and low-grade glioma; HNSC, head and neck squamous cell carcinoma; KICH, chromophobe renal carcinoma; KIRC, kidney clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; KIPAN, pankidney Cohort (KICH+KIRC+KIRP); LAML, acute myeloid leukemia; LGG, low-grade glioma of the brain; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, medium Dermatoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectal adenocarcinoma; SARC, sarcoma; SKCM, skin melanoma STAD, gastric adenocarcinoma; STES, gastric and esophageal cancer; TGCT, testicular germ cell tumor; THYM, thymoma; THCA, thyroid cancer; UCS, uterine carcinosarcoma; UCEC, endometrial cancer of the uterine body; UVM, grape Membrane melanoma. The y-axis represents log2-transformed values ​​of transcript abundance from RNA-seq data, quantified using RNAseq by expectation maximization (RSEM).

[0591] MARCO expression in primary tumors by scRNA-seq Single cell RNA sequencing (scRNA-Seq) 1 mL of freeze-dissociated tumor cells from various tumors were purchased from Discovery Life Sciences. The frozen pellet was thawed in a 37°C water bath, slowly diluted with 25 mL of warm RPMI containing 10% FBS and 10 mM HEPES, and centrifuged at 550 rcf for 5 minutes. Cell pellets were stained with anti-CD45-PE (clone HI30, Biolegend). DAPI - , CD45 + Cells were sorted on a BD FACSAria Fusion. After sorting, cells were washed 3 times with 3 mL of 0.04% BSA / PBS, and 5 × 10 5 Resuspend at cells / mL. Cells were loaded onto Chromium Chip B for targeted cell encapsulation of 10,000 cells and placed into the Chromium Controller (10X Genomics, Single Cell 3' v3 Reagent Kit). After GEM-RT cleanup, cDNA amplification and library construction were performed according to the Single Cell 3' v3 user manual of 10X Genomics. The library was sequenced on NovaSeq by MedGenome Inc.

[0592] Single cell data processing Sequencing data was processed using the 10X Genomics Cell Ranger v3.0.2 pipeline. MedGenome Inc. provided fastq files for each sample by converting the raw Illumina bcl files to fastq files using the Cell Ranger subroutine mkfastq. Cell Ranger counting was then performed utilizing STAR (Dobin et al., 2013) to align reads against the GRCh38 human reference genome. After filtering the reads with redundant unique molecular identifiers (UMIs), count the generated gene cell barcode files (filtered_feature_bc_matrix folder consisting of barcodes.tsv, features.tsv, and matrix.mtx). Both mkfastq and count were run with default parameters.

[0593] Cell identification, clustering, and visualization For each sample, the filtered_feature_bc_matrix file is passed to the R (v.3.6.0) software package Seurat (Satija et al., 2015) (https: / / satijalab.org / seurat) (v2.3.4) for all downstream An analysis was conducted. The features.tsv file was renamed to genes.tsv to be compatible with the Read10X function. Data were filtered for cells expressing a minimum of 200 genes, and all genes were expressed in at least 3 cells and had a UMI of 8500 or less. Cells with >20% of reads associated with mitochondrial genes and >45% of reads associated with ribosomal genes were removed. The count data are then log-transformed and scaled using the remaining UMI counts and the proportion of mitochondrial and ribosomal genes for each cell as nuisance factors (implemented with Seurat's ScaleData function) for downstream clustering and differential expression analysis. Corrected some unwanted effects. For each sample, principal component (PC) analysis was performed on the set of highly variable genes defined by Seurat's FindVariableGenes function. Genes associated with the top PCs obtained (selected by visual inspection of the scree plot) were used for graph-based cluster identification followed by dimensionality reduction using t-distributed stochastic neighbor embedding (tSNE). Cluster-based marker identification and differential expression was performed using Seurat's FindAllMarkers for all inter-cluster comparisons. Graphs were plotted using Seurat's built-in visualization functions (TSNEPlot, FeaturePlot).

[0594] MARCO was mainly expressed in human tumor monocytes and macrophages as determined by scRNA-seq analysis (data not shown). Tumor cells from lung, kidney (RCC), ovarian, colorectal, and head and neck cancers all showed MARCO expression on monocytes and macrophages.

[0595] MARCO RNA expression is induced by IL-10 Differentiated human macrophages were polarized by adding the following cytokines to the culture medium for 24 hours at 37°C: 50ng / ml lipopolysaccharide (LPS) (InvivoGen), 25ng / ml recombinant human IFN-γ (PeproTech), LPS+IFN. -γ, IL-4, IL-10, TGF-β, TGF-β+, or IL-10. The medium was then removed, macrophages were lysed with 300 μl of RLT buffer + BME, and RNA was extracted using the Qiagen kit. mRNA quantity and quality were assessed by Nanodrop and Agilent Bioanalyzer before sending samples to Medgenome for library preparation and RNAseq. MARCO mRNA expression under each polarization condition was then extracted from the RNAseq analysis and plotted in log2 CPM units.

[0596] As shown in Figure 2, MARCO RNA expression was induced by IL-10 in human monocyte-derived macrophages (MDM).

[0597] IL10 and MARCO expression correlates across indications All single metric, level 2, RNAseq data from TCGA were downloaded from the Broad Institute using firehose_get. RSEM values ​​for MARCO, IL-10, PTPRC (CD45), and TREM2 expression from tumor samples were converted to log2 counts per million. For each indication, the median values ​​of MARCO and IL10 expression were plotted in R. Dot size was scaled by the degree of IL10-MARCO Spearman rank correlation. The matrix of median expression values ​​for each indication for the above genes was converted to a matrix of Spearman correlations and plotted as a heatmap using the pheatmap package in R.

[0598] Figure 3A shows the correlation between MARCO and IL-10 expression in different tumor types, and Figure 3B shows the correlation heatmap between TREM2 expression, CD45 expression, IL-10 expression, and MARCO expression. As shown in Figures 3A and 3B, IL10 and MARCO expression is well correlated across cancer indications.

[0599] Correlation between MARCO expression and patient survival in different indications In colorectal cancer (CRC) Pre-normalized MARCO expression profiles and associated clinical data across 55 colorectal tumors were downloaded from NCBI's GEO website (accession GSE17537). The expression profile was divided into two cohorts based on the median level of MARCO. Kaplan-Meier survival curves were plotted for each cohort and associated log-rank tests were performed using R's survival and survminer packages. As shown in Figure 4A, MARCO expression was inversely correlated with patient survival probability in CRC, with higher MARCO expression associated with lower patient survival probability, and lower MARCO expression associated with higher patient survival probability.

[0600] In renal cell carcinoma (RCC) Two cohorts of kidney cancer (renal cell carcinoma) from TCGA based on median split of MARCO mRNA expression generated by Gene Expression Profiling Interactive Analysis (GEPIA2) viewer at http: / / gepia2.cancer-pku.cn / #index survival related.

[0601] As shown in Figure 4B, MARCO expression is inversely correlated with patient survival probability in RCC, with higher MARCO expression associated with lower patient survival probability and lower MARCO expression associated with higher patient survival probability. became.

[0602] in neuroblastoma Pre-normalized MARCO expression profiles and associated clinical data across 498 neuroblastoma tumors were downloaded from NCBI's GEO website (accession GSE62564). The expression profile was divided into two cohorts based on the median level of MARCO. Kaplan-Meier survival curves were plotted for each cohort and associated log-rank tests were performed using R's survival and survminer packages.

[0603] As shown in Figure 4C, MARCO expression is inversely correlated with patient survival probability in neuroblastoma, with higher MARCO expression associated with lower patient survival probability and lower MARCO expression associated with lower survival probability of patients in neuroblastoma. Patients have a higher chance of survival.

[0604] Pre-normalized MARCO expression profiles across 394 neuroblastoma tumors and associated clinical data were downloaded from NCBI's GEO website (accession GSE120572). MARCO expression profiles were plotted for all samples with identified INSS stages. Pairwise comparison statistics were generated using the Wilcoxon rank sum test in R. As shown in Figure 4D, MARCO expression increased as a function of neuroblastoma disease severity, depending on INSS stage.

[0605] In basal cell-like breast cancer MARCO expression from TCGA across PAM50 subtyping of human breast cancer generated by Gene Expression Profiling Interactive Analysis (GEPIA2) viewer at gepia2.cancer-pku.cn / #index. METABRIC expression profiling and associated clinical data were downloaded from cBioPortal at cbioportal.org. Normalized MARCO expression profiles were plotted in R across cohorts based on PAM50 subtyping. Pairwise comparison statistics were generated using the Wilcoxon rank sum test in R.

[0606] As shown in Figure 5, we show that MARCO is upregulated in basaloid breast cancer compared to other breast cancer subtypes. The left panel shows MARCO expression from TCGA and the right panel shows MARCO expression from METABRIC.

[0607] MARCO is highly expressed in the population of intratumoral intermediate monocytes. Immune desert and exclusion gene signatures were upregulated in the MARCO+ cluster. Aggregated TAMs and monocytes derived from single-cell sequencing of human immune cells from bladder, breast, colorectal, endometrial, gastric, head and neck, kidney, lung, and ovarian tumors were isolated from transitional monocytes (clusters). 2) generated a single cluster in which MARCO expression was significantly elevated. Gene Set Enrichment Analysis (GSEA) of the Hallmark pathway (MARCO-enriched cluster 2 versus all other macrophages and monocytes) showed that MARCO expression is associated with immunosuppressive, matrix-related gene sets (e.g., angiogenesis, EMT). , was shown to be downregulated due to inflammatory, interferon-based pathways. Significant (FDR<0.05) pathways identified to be upregulated in MARCO+ cells were glycolysis, oxidative phosphorylation, epithelial-mesenchymal transition, hypoxia, xenobiotic metabolism, angiogenesis, cholesterol homeostasis, These were adipogenesis, fatty acid metabolism, reactive oxygen species pathway, and mTORC1 signaling. Significant (FDR<0.05) pathways identified to be downregulated in MARCO+ cells were allograft rejection, TGF-b signaling, KRAS signaling down, NF-kB-mediated TNFα signaling, and IFNγ. response, and an IFNα response.

[0608] Example 2: Generation and characterization of anti-human MARCO antibodies First generation of hybridomas Antibody campaigns were conducted at Antibody Solutions (Sunnyvale, CA) using two Rapid campaigns in three Balb / c mice and one standard campaign in four Balb / c mice, and human MARCO His-tagged cells. The ectodomain (His-ECD 147-520, residues 147-419 of the collagen-like domain (CLD) and residues 424-520 of the scavenger receptor cysteine-rich (SRCR) domain, Pi-114) was used as the immunogen. The rapid vaccination program consisted of 10 injections twice weekly, using the footpad as the route. The standard vaccination program consisted of 5 injections over 12 weeks, utilizing sub-Q as the route. The Rapid 1 campaign included TLR+anti-CTLA4 as an adjuvant, and the Rapid 2 campaign included TLR+anti-GITR. Mouse sera were tested for antigen titer by ELISA at different time points. Spleens and lymph nodes of mice from higher titer Rapid 1 campaigns were fused and a hybridoma library was created to provide an immortal population of antibody producing cells representing a stimulated B cell population responsive to antigen. Single cell cloning by FACS sorting was performed to generate single clonal hybridomas for monoclonal antibody culture. Next, 2,880 clones were screened by dual flow cytometry for binding to mouse and human 293T-overexpressing MARCO cell lines, and a GFP-expressing cell line (GFP-293T) was used as a negative control with no binding. Thirty-three clones were identified from the primary screen with cross-reactivity to both human and mouse MARCO with zero to low background binding and were further screened by ELISA with the MARCO human antigen Pi-114. Cell binding of hybridoma supernatants from 33 clones was checked by flow cytometry.

[0609] Generation of stably overexpressing cell lines Mouse and human MARCO DNA sequences were cloned into the pLenti-GIII-CMV-GFP-2A-Puro lentiviral vector at Abmgood (Vancouver, Canada) and subjected to standard bacterial transformation using the E. coli DH5-alpha strain. protocol was used to produce high yields of lentiviral packaging plasmids. Viral particles were generated from empty GFP control vector, human MARCO, and mouse MARCO clone lentiviral vectors, packaged into 293T cells, and concentrated for high titers. 293T cells were used as target cells for infection using the virus provided by Abmgood according to its protocols and guidelines. Infectious pools were selected using puromycin and single clones expressing homogeneous high levels of mouse MARCO (293T_MuMARCO), human MARCO (293T_HuMARCO), and GFP (293T_GFP) were expanded.

[0610] Subsequently, pD2109-CMV-puromycin lentiviral backbones were generated to clone additional MARCO plasmids without or with IRES-GFP: human MARCO with full-length GFP (plasmid 3012) and without GFP (plasmid 3010); Mouse MARCO with full-length GFP (plasmid 3013) and without GFP (plasmid 3011), cynomolgus monkey MARCO (cyno MARCO) with full-length GFP (plasmid 3021) and without GFP (plasmid 3014), human MARCO CLD only (1-419, plasmid 3022) , and chimeric mouse MARCO CLD-human MARCO SRCR with IRES-GFP (plasmid 3020). Sigma's 293FT cells were transfected with the above constructs using Fugene to generate lentiviral particles and subsequently transduce 293T cells. Positive clones were selected using puromycin and expanded to generate the following stable cell pools for use in vitro: 3010 (Hu_MARCO), 3012 (Hu_MARCO_GFP), 3011 (Mu_MARCO), 3013 (Mu_MARCO_GFP), 3014 (Cy_MARCO), 3021 (Cy_MARCO_GFP), 3020 (MuCLD_HuSRCR_GFP), and 3022 (Hu_MARCO_CLD).

[0611] Characterization of binding of anti-MARCO hybridomas and anti-MARCO antibodies to cell surface-expressed MARCO HEK293T cells expressing human MARCO (293T_HuMARCO), mouse MARCO (293T_MuMARCO), cyno MARCO (CyMARCO), and a GFP-expressing control cell line (293T_GFP) were maintained in DMEM (Gibco) containing 10% FBS at 37°C. Cells were counted and then collected by centrifugation at 400×g for 5 minutes. Remove the supernatant and remove the cell pellet from Ca 2+ and Mg 2+ +1 x 10 in Dulbecco's phosphate buffered saline (D-PBS) 6Resuspend cells / ml. 100,000 cells / well were seeded in U-bottom 96-well plates for staining, all centrifugation steps were performed at 1500 rpm for 5 min at 4°C, and samples were protected from light throughout the protocol. Cells were pelleted and resuspended in 100 μl of Zombie NIR viability dye (BioLegend) prepared by diluting Zombie NIR dimethyl sulfoxide (DMSO) stock 1:1000 in D-PBS. Stain the cells by incubating for 10 min at room temperature (RT) in the dark, followed by the addition of 100 μl of staining medium (D-PBS containing 2% FBS and 2 mM ethylenediaminetetraacetic acid (EDTA)) to initiate the staining reaction. Quenched. Cells were pelleted and resuspended in 100 μl of freshly prepared staining medium of various antibodies and hybridoma supernatants required for screening such as PI-M014 and mIgG2b isotypes and corresponding isotype controls. All mAbs were tested at a final maximum concentration of 100 nM (15 μg / ml) followed by 8-point 3-fold serial dilutions including a 0 mg / ml control. Staining was performed on ice for 1 hour, followed by two washes with staining medium. Cells were then pelleted, resuspended in 100 ul of allophycocyanin (APC)-conjugated goat anti-mouse IgG (Fc-specific) secondary antibody prepared by diluting the antibody stock 1:500 in staining medium, and kept on ice for 30 min. Incubated for minutes. The plates were then washed twice with staining medium and subsequently resuspended in 150ul of the same buffer for acquisition on a flow cytometer (Attune NxT, Life Technologies). Flow cytometry data were analyzed using FlowJo software (version 10.6.1) and data processed with Microsoft Excel and GraphPad Prism software (version 8) for further analysis. Half the maximum effective concentration (EC 50 ) was calculated based on the geometric mean fluorescence intensity (gMFI). If the plates could not be analyzed on a cytometer, pellet the cells after washing and 2% paraformaldehyde (PFA) prepared by diluting a 16% (w / v) stock (Thermo Fisher) in DPBS for 15 min at room temperature. ) and fixed with 100 μl. Cells were then pelleted and, after removing the fixative, resuspended in 150 μl of staining medium and stored at 4°C until acquisition on a flow cytometer.

[0612] Figure 6A shows the binding of 33 antibodies to GFP-239T control cells (left bar), or cells expressing human MARCO (middle bar), or cells expressing mouse MARCO (right bar). show. Figure 6B shows flow cytometry histograms of one MARCO antibody, PI-M014, binding to cells expressing huMARCO, muMARCO, and Cyno MARCO compared to control cells (GFP control). Figure 6C shows titration of PI-M014 and isotype control antibodies binding to cells expressing huMARCO. PI-M014 bound to huMARCO with an EC50 of 1.37nM.

[0613] Characterization of binding of anti-MARCO hybridomas and anti-MARCO antibodies to recombinant MARCO by ELISA Hybridomas from antibody solutions or anti-MARCO antibodies were screened by enzyme-linked immunosorbent assay (ELISA) against recombinant human MARCO protein (Pi-114 His tag). Briefly, 96-well plates (Biolegend) were coated with 1 ug / well of recombinant MARCO protein overnight in D-PBS. Plates were washed three times with PBS / 0.1%TWEEN-20 / 2mM EDTA (ELISA wash buffer) and blocked with 1% BSA for 2 hours at room temperature. Antibodies were incubated at a final top concentration of 5 μg / ml for 1 h at room temperature, followed by 8-point 3-fold serial dilutions in PBS containing a 0 mg / ml control. Plates were washed as above and incubated with goat anti-mouse IgG F(ab')2 fragment-HRP conjugated secondary antibody (Jackson Immuno) at a 1:5000 dilution for 1 hour at room temperature. Plates were washed 4 times with the above ELISA wash buffer, developed with TMB substrate (Thermo) for 10 min, and TMB Stop Solution (1M H 3 P.O. 4 A450 was determined using a plate reader (SpectraMaxi 3x).

[0614] Characterization of MARCO antibody dynamics by SPR Surface plasmon resonance (SPR) was performed on a BIAcore™ T200 (GE Healthcare) instrument, and all data were collected at 25°C using multicycle speed. Anti-mouse Fc mAb (GE Healthcare) was immobilized on a CM4 biosensor chip (GE Healthcare) using 4500RU amine coupling chemistry as the target for mAb immobilization. Serial dilutions were made in mobile buffer containing 10mM HEPES pH 7.4, 150mM NaCl, 3mM EDTA, and 0.05% (v / v) surfactant P20. Anti-mouse Fc mAb was used to capture selected monoclonal antibodies against human MARCO antigen (ligand). The anti-MARCO antibodies tested were PI-M014, PI-M015, PI-M017, and PI-M018. The interaction analyte used was an N-terminal polyhistidine-tagged human MARCO ECD (147-520) called PI-RG-3000. The following range of antibody concentrations were injected into the flow cell: 0.625nM, 1.25nM, 2.5nM, 5nM and 10nM. The flow rate was 30 μL / min, and the binding and dissociation times were 90 and 600 seconds, respectively. After each cycle (consisting of antigen capture, antibody binding, and dissociation steps), the cell surface was regenerated by injecting 10 mM glycine HCl buffer pH 1.7 for 100 seconds at a flow rate of 50 μL / min. . Kinetic evaluations were performed using BIAevaluation 3.1 software to determine single-cycle and multi-cycle rates.

[0615] PI-M014 monomer has a K of 3.91 nM in one SPR cycle D and a K of 1.32 nM in multiple cycle assays. D showed that. PI-M015 monomer has a K of 0.39 nM in multiple cycle assays D It had PI-M017 monomer has a K of 0.96 nM in multiple cycle assay D It had PI-M018 monomer has a K of 1.65 nM in multiple cycle assay D It had

[0616] MARCO cell surface expression on human monocyte-derived macrophages Frozen human peripheral blood CD14 isolated from peripheral blood mononuclear cells using negative immunomagnetic selection (StemCell Technologies) + Thaw monocytes and add 10% (v / v) heat-inactivated FBS (HyClone), 1mM sodium pyruvate, non-essential amino acids, 2mM L-glutamine, 55μM 2-mercaptoethanol and antifungal antibiotics (all from Gibco). The cells were cultured in RPMI 1640 medium supplemented with Monocytes are 12-15 x 10 in a 15cm dish. 6 Cells were differentiated into macrophages by culturing in complete RPMI 1640 medium in the presence of 50 ng / ml human macrophage colony stimulating factor (M-CSF) (PeproTech) at a density of cells. On the third day of differentiation, fresh M-CSF was added to replenish the medium. After 7 days of differentiation, nonenzymatically remove macrophages into FACS buffer (D-PBS containing 2 mM EDTA and 0.5% (w / v) bovine serum albumin (BSA) (Sigma)) using a sterile cell scraper (Nunc). and then centrifuged at 400 x g for 5 minutes at approximately 20°C.

[0617] Cells were counted and seeded in 96-well plates at 250,000 cells per well. 100ul of Zombie NIR viability dye (BioLegend) prepared by diluting the stock 1:1000 in D-PBS was added to each well and incubated for 10 minutes at room temperature in the dark. The reaction was quenched by adding 150ul of FACS buffer followed by centrifugation at 400xg for 5 minutes at 4°C. Cells were then incubated in the dark for 20 min in 100 ul of blocking solution containing 2.5% mouse and 2.5% rat serum and human TruStain FcX (BioLegend) diluted 1:50 in Fc receptor blocker (Innovex Biosciences). did. Next, cells were washed and freshly prepared in FACS buffer (PI-M014, PI-M015, PI-M017, PI-M018, mouse IgG2a and mouse IgG2b, all conjugated with APC using the Thermo Fisher conjugation kit). and resuspended in 100 μl of the various antibodies required for screening and the corresponding isotype controls. mAbs were tested at a single point concentration (3.33 μg / ml for PI-M014 or 5 μg / ml for other mAbs), and the primary incubation was performed on ice for 20–30 min, followed by two washes with FACS buffer. Cells were resuspended in 150ul of the same buffer for acquisition on a flow cytometer (Attune NxT, Life Technologies). Flow cytometry data were analyzed using FlowJo software and data processed with Microsoft Excel and GraphPad Prism software for further analysis.

[0618] As shown in Figure 6D, PI-M014 bound to human monocyte-derived macrophages.

[0619] Mouse antibody-dependent cell phagocytosis (ADCP) assay Bone marrow-derived macrophages were generated as previously demonstrated using 25 ng / ml mouse CSF-1 (Peprotech) for differentiation. On day 6 of culture, 25 ng / ml mouse IFN-γ (Peprotech) was added to the BMDM culture for 18 hours. The next day, cells were stimulated with 200 ng / ml LPS (invivogen) for 2 hours before use in the ADCP assay. IFN-γ / LPS-induced BMDMs served as effector cells, and GFP+HEK293T cells transduced with human MARCO (293T Hu_MARCO) or control (293T_GFP) were targeted. After collection, effector BMDMs were stained with Cell-Trace Violet dye (invitrogen) for 20 minutes at 37°C. 50,000 target cells were seeded in a 96-well U-bottom plate and co-cultured with anti-MARCO mAb or the corresponding isotype (PI-M014 to PI-M018). Antibodies were serially diluted and prepared in culture medium for 30 min at 37°C. Effector cells were then added to the antibody-target plate at a 3:1 ratio (150,000 effector to 50,000 target) and incubated for 2 hours at 37°C. After incubation, cells were viability stained using Zombie NIR (BioLegend) and fixed using 2% paraformaldehyde (Invitrogen) for 20 min at room temperature before being run on an Attune NXT flow cytometer (ThermoFisher). ADCP activity was assessed based on double positivity of Cell Trace Violet and GFP levels and gated downstream of live cells.

[0620] Incubation of PI-M015 and PI-M017 with target cells both induced ADCP activity by effector cells. The results are summarized in Table 1.

[0621] HuMARCO antibody epitope binning Epitopes of anti-MARCO antibodies were analyzed using the ForteBio Blitz label-free system.

[0622] In a tandem format, the N-terminally his-tagged MARCO protein was loaded onto the ForteBio anti-his probe, followed by baseline loading before binding to the first antibody. Following binding of the first antibody, a second antibody was added and association of the second set of antibodies was measured. Additional binding observed for the second antibody, measured as an increased signal, indicates that the second antibody bound to a different epitope than the first antibody.

[0623] PI-M015 and PI-M017 competed with each other for binding to MARCO antigen, indicating that they bind to the same MARCO epitope (Figure 7). All other antibodies bound different epitopes and did not compete with other antibodies for binding to MARCO. However, the antibody bound only to the CLD domain of human MARCO, but not to the SRCR domain of human MARCO.

[0624] MARCO expression in primary human DTC tumors and peripheral blood leukocytes (PBL) MARCO expression was assessed in the microenvironment of human tumors from three indications: ovarian cancer and gastric cancer by flow cytometry using a newly developed human MARCO antibody. Tumor tissue was previously dissociated as “dissociated tumor cells” (DTC) and snap frozen (Folio Conversant). DTCs were thawed and counted to assess total viable cell numbers according to manufacturer's guidelines. PBLs were isolated from buffy coats (two donors from Stanford Blood Center). Single cell suspensions from DTC and PBL were diluted in PBS (Gibco), washed once, and stained with Zombie NIR (Biolegend) to determine cell viability. Fc receptors were also blocked with a combination of human serum (Jackson Immunoresearch), human FcX (Biolegend), and a peptide-based FcR blocking solution (Innovex Biosciences). After incubation with FcR blocking reagents, DTC surface receptors were treated with markers of major intratumoral immune subsets and isotype controls (5 μg / ml mIgG2a or mIgG2b or Rat IgG2a) and directly conjugated anti-human MARCO antibodies (5 μg / ml). ml PI-M017 or PI-M018 or PI-HX-3031). Cells were also fixed and permeabilized (True-Nuclear Transcription Buffer Set, Biolegend) to measure intracellular CD68 expression. PBL contained markers of major blood immune subsets, as well as isotype controls (10 μg / ml hIgG1 conjugated with PE Zenon label) and anti-human MARCO antibodies (10 μg / ml PI-3010, PI-3030 conjugated with PE Zenon label). , and PI-3031). Data from DTC and PBL were acquired using an Attune NxT analyzer (ThermoFisher) and analyzed using FlowJo (BD Biosciences).

[0625] Figures 8A and 8B show that MARCO is expressed in human MDM (Figure 8A) and tumor-associated macrophages (TAMs) from primary human tumor samples (gastric and ovarian cancer, Figure 8B). In Figures 8A and 8B, the peak on the right shows binding and staining of MARCO antibody PI-M018 or PI-M017, and the peak on the left shows binding of isotype mIgG2a.

[0626] A summary of the binding and functional properties of the antibodies selected from the first antibody campaign is shown in Table 1.

[0627]

table 1

[0628] Example 3: Generation and characterization of anti-mouse MARCO antibodies Materials and methods Immunization to generate anti-mouse MARCO antibodies Rat anti-mouse MARCO hybridomas were generated in Pionyr-generated recombinant N-terminal his-tagged mouse cells using the Sigma Adjuvant System (SAS) alone or alternately with mouse MARCO expressing HEK293 cells, also in SAS. Generated by immunizing Sprague Dawley rats with MARCO protein. The sequence of the recombinant N-terminal his-tagged mouse MARCO protein used is shown below. Recombinant mouse MARCO protein was analyzed by SDS-PAGE and size exclusion chromatography was used to confirm the correct molecular weight of the protein.

[0629] Rats were immunized twice weekly in the hind limb joints with Antibody Solutions (Santa Clara, Calif.) and serum titers were tested by ELISA on day 21. Rats with sufficient serum antibody titers against mouse MARCO were selected for electrofusion to generate hybridomas. Two final boosts were given on days -3 and -2 before harvesting in phosphate-buffered saline (PBS).

[0630] Mouse MARCO mAb RDM-9514 was purchased as a custom purified hybridoma clone from R&D biosystems (CUST017 MABP, clone 57914) and raised in rats against recombinant mouse MARCO Gln70-Ser518 derived from NSO.

[0631] Generation of hybridomas Lymph node cells were collected from immunized rats and a single cell suspension was prepared. Lymphocytes were fused with a myeloma cell line, SP2 / 0-Ag 14 (ATCC), using electrofusion using a BTX EC2000+ electrofusion device (Harvard Bioscience). Fused cells were seeded in 96-well flat bottom plates (Corning) and harvested overnight in Clona-Cell Medium E containing HT (Stem Cell Technologies). The next day, aminopterin (Sigma) was added to the culture to a 1× final concentration. Fusions were given on days 6 and 8 and screened on day 11.

[0632] Hybridoma screening Hybridomas were screened by enzyme-linked immunosorbent assay (ELISA) with either recombinant mouse MARCO protein or recombinant human MARCO protein depending on immunization. Briefly, 96-well Maxisorp plates (Nunc) were coated with 0.1 ug / well of recombinant MARCO protein overnight in DPBS containing Ca2+ and Mg2+ (Gibco Cat. No. 14040117). Plates were washed three times with PBS / 0.05% TWEEN-20 and blocked with PBS / Ca2+ containing 2% fetal bovine serum. Hybridoma supernatants were added 1:1 to wells containing PBS / Ca2+ / 2% FBS buffer and incubated for 1 hour at room temperature. Plates were washed as above and incubated with goat anti-rat IgG-HRP-conjugated secondary antibody (Jackson Immuno) or mouse anti-rat IgG (1, 2a, 2b) HRP-conjugated antibody (Southern Biotech) for 1 h at room temperature. did. Plates were washed, developed with TMB substrate (Thermo), stopped with TMB Stop Solution (Suromodics), and A450 determined using a plate reader (Tecan). Hybridomas producing anti-MARCO antibodies were transferred to 24-well plates and supernatants from positive clones were retested for MARCO reactivity and further tested in additional binding assays. Hybridomas were screened with recombinant human MARCO, recombinant mouse MARCO, and control recombinant his-tagged proteins to eliminate nonspecific or his-tag-specific clones, and mouse MSR1 (R&D Systems) or human MSR1 (R&D Systems) was also tested to confirm cross-reactivity to related scavenger receptor proteins. The hybridomas were also tested for binding to two chimeric proteins, N-terminal recombinant human MARCO SRCR / mouse CLD protein and N-terminal recombinant mouse MARCO SRCR / human CLD protein, and the antibody was specific for binding to MARCO protein. The domain has been decided. The sequences of the recombinant proteins used in these studies are as follows.

[0633] N-terminal his-tagged mouse MARCO protein: HHHHHHHHGERGSPGPKGAPGAPGIPGLPGPAAEKGEKGAAGRDGTPGVQGPQGPPGSKGEAGLQGLTGAPGKQGATGAPGPRGEKGSKGDIGLTGPKGEHGTKGDKGDLGLPGNKGDMGMKGDTGPMGSPGAQGGKGDAGKPGLPGLAGSPGVKGDQGKPGVQGVPGPQGAPGLSGAKGEPGRTGLPGPAGPPGIAGNPGIAGVKGSK GDTGIQGQKGTKGESGVPGLVGRKGDTGSPGLAGPKGEPGRVGQKGDPGMKGSSGQQGQKGEKGQKGESFQRVRIMGGTNRGRAEVYYNNEWGTICDDDWDNNDATVFCRMLGYSRGRALSSYGGGSGNIWLDNVNCRGTENSLWDCSKNSWGNHNCVHNEDAGVECS

[0634] Chimeric MARCO protein with N-terminal his tag (human SRCR / mouse CLD domain): HHHHHHHHKGERGSPGPKGAPGAPGIPGLPGPAAEKGEKGAAGRDGTPGVQGPQGPPGSKGEAGLQGLTGAPGKQGATGAPGPRGEKGSKGDIGLTGPKGEHGTKGDKGDLGLPGNKGDMGMKGDTGPMGSPGAQGGKGDAGKPGLPGLAGSPGVKGDQGKPGVQGVPGPQGAPGLSGAKGEPGRTGLPGPAGPPGIAGNPGIAGVKGS KGDTGIQGQKGTKGESGVPGLVGRKGDTGSPGLAGPKGEPGRVGQKGDPGMKGSSGQQGQKGEKGQKGENSVSVRIVGSSNRGRAEVYYSGTWGTICDDEWQNSDAIVFCRMLGYSKGRALYKVGAGTGQIWLDNVQCRGTESTLWSCTKNSWGHHDCSHEEDAGVECSV

[0635] N-terminal his-tagged chimeric MARCO protein (mouse SRCR / human CLD domain): HHHHHHKGEQGAPGLQGHKGAMGMPGAPGPPGPPAEKGAKGAMGRDGATGPSGPQGPPGVKGEAGLQGPQGAPGKQGATGTPGPQGEKGSKGDGGLIGPKGETGTKGEKGDLGLPGSKGDRGMKGDAGVMGPPGAQGSKGDFGRPGPPGLAGFPGAKGDQGQPGLQGVPGPPGAVGHPGAKGEPGSAGSPGRAGLPGSPGSPGATGLKGSKG DTGLQGQQGRKGESGVPGPAGVKGEQGSPGLAGPKGAPGQAGQKGDQGVKGSSGEQGVKGEKGERGESFQRVRIMGGTNRGRAEVYYNNEWGTICDDDWDNNDATVFCRMLGYSRGRALSSYGGGSGNIWLDNVNCRGTENSLWDCSKNSWGNHNCVHNEDAGVECS

[0636] cell binding Clones positive for binding to MARCO by ELISA were determined by staining human MARCO-293 cells, mouse MARCO-293 cells, or control 293 cells and testing them by flow cytometry using an Intellicyt iQue flow cytometer. Binding to surface MARCO was tested. Hybridomas that were positive for binding to MARCO by ELISA and cell surface MARCO by flow cytometry were selected for subcloning and purification.

[0637] Hybridoma subcloning and purification Subcloning of parental hybridomas was performed by single cell sorting on FACSAria. Single cells were sorted into Clona-Cell Medium E in flat-bottomed 96-well tissue culture plates. Single cells were cultured for 7-9 days and then assayed for anti-MARCO-specific clones by ELI...

Claims

1. 1. An isolated antibody or antigen-binding fragment thereof that binds to human MARCO (SEQ ID NO:384), comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), CDR-H1, CDR-H2, and CDR-H3 are derived from a heavy chain variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO: 61, 21, 31, 41, 51, 91, 121, 474, 1, 11, 71, 81, 101, 111, 131, 434, or 444, and CDR-L1, CDR-L2, and CDR-L3 are derived from a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO: 66, 26, 36, 46, 56, 96, 126, 479, 6, 16, 76, 86, 106, 116, 136, 439, or 449; The isolated antibody or antigen-binding fragment thereof.

2. a. CDR-H1, CDR-H2, and CDR-H3, and CDR-L1, CDR-L2, and CDR-L3 are defined according to AbM; b. CDR-H1, CDR-H2, and CDR-H3, and CDR-L1, CDR-L2, and CDR-L3 are defined according to Kabat; c. CDR-H1, CDR-H2, and CDR-H3, and CDR-L1, CDR-L2, and CDR-L3 are defined according to Chothia; d. CDR-H1, CDR-H2, and CDR-H3, and CDR-L1, CDR-L2, and CDR-L3 are defined according to IMGT; 2. The isolated antibody of claim 1.

3. a. CDR-H1 comprises the sequence GFSLTSYHVS (SEQ ID NO: 2); b. CDR-H2 comprises the sequence AIWTGGSIA (SEQ ID NO:3); c. CDR-H3 comprises the sequence DLSDYYSSYTSFDY (SEQ ID NO:4); d. CDR-L1 comprises the sequence ASEGISDLA (SEQ ID NO:431) or XASEGISDLA (SEQ ID NO:383), where X is arginine (R) or leucine (L); e. CDR-L2 comprises the sequence AASRLQS (SEQ ID NO:528) or AASRLQD (SEQ ID NO:8), and f. CDR-L3 comprises the sequence QQSYKYPLT (SEQ ID NO:9); 2. The isolated antibody of claim 1.

4. 2. The isolated antibody of claim 1, wherein the VH comprises the sequence set forth in SEQ ID NO:61 and the VL comprises the sequence set forth in SEQ ID NO:

66.

5. 2. The isolated antibody of claim 1, wherein the VH chain sequence comprises the VH sequence set forth in SEQ ID NO: 434 and the VL chain sequence comprises the VL sequence set forth in SEQ ID NO:

439.

6. 2. The isolated antibody of claim 1, wherein the VH comprises a sequence selected from the sequence set forth in SEQ ID NO: 61, 21, 31, 41, 51, 91, 121, 474, 1, 11, 71, 81, 101, 111, 131, 434, or 444.

7. The isolated antibody of claim 1 , wherein the VH comprises the sequence set forth in SEQ ID NO:

61.

8. 2. The isolated antibody of claim 1, wherein the VL comprises a sequence selected from the sequence set forth in SEQ ID NO: 66, 26, 36, 46, 56, 96, 126, 479, 6, 16, 76, 86, 106, 116, 136, 439, or 449.

9. The isolated antibody of claim 1 , wherein the VL comprises the sequence set forth in SEQ ID NO:

66.

10. 2. The isolated antibody of claim 1, wherein the VH comprises a sequence selected from the sequence set forth in SEQ ID NO: 61, 21, 31, 41, 51, 91, 121, 474, 1, 11, 71, 81, 101, 111, 131, 434, or 444, and the VL comprises a sequence selected from the sequence set forth in SEQ ID NO: 66, 26, 36, 46, 56, 96, 126, 479, 6, 16, 76, 86, 106, 116, 136, 439, or 449.

11. The isolated antibody described in claim 1, wherein the antibody comprises a heavy chain, and the sequence of the heavy chain comprises the heavy chain sequence set forth in SEQ ID NO:

65.

12. The isolated antibody described in claim 1, wherein the antibody comprises a heavy chain, and the sequence of the heavy chain comprises a heavy chain sequence set forth in SEQ ID NO: 65, 25, 35, 45, 55, 95, 125, 478, 5, 15, 75, 85, 105, 115, 135, 438, or 448.

13. The isolated antibody described in claim 1, wherein the antibody comprises a light chain, and the sequence of the light chain comprises the light chain sequence set forth in SEQ ID NO:

70.

14. The isolated antibody of claim 1, wherein the antibody comprises a light chain, and the sequence of the light chain comprises a light chain sequence set forth in SEQ ID NO: 70, 30, 40, 50, 60, 100, 130, 483, 10, 20, 80, 90, 110, 120, 140, 443, or 453.

15. The isolated antibody of claim 1, wherein the antibody comprises a heavy chain and a light chain, the sequence of the heavy chain comprises the heavy chain sequence set forth in SEQ ID NO:65, and the sequence of the light chain comprises the light chain sequence set forth in SEQ ID NO:

70.

16. The isolated antibody of claim 1, wherein the antibody comprises a heavy chain and a light chain, the heavy chain sequence comprising a heavy chain sequence set forth in SEQ ID NO: 65, 25, 35, 45, 55, 95, 125, 478, 5, 15, 75, 85, 105, 115, 135, 438, or 448, and the light chain sequence comprising a light chain sequence set forth in SEQ ID NO: 70, 30, 40, 50, 60, 100, 130, 483, 10, 20, 80, 90, 110, 120, 140, 443, or 453.

17. The isolated antibody of claim 1, comprising a human Fc region.

18. The isolated antibody of claim 1 , wherein the human Fc region is wild-type human IgG1 Fc.

19. The isolated antibody of claim 1, wherein the antibody comprises a wild-type human IgG1 Fc, the VH comprises the sequence set forth in SEQ ID NO:61, and the VL comprises the sequence set forth in SEQ ID NO:

66.

20. The isolated antibody of claim 1, wherein the antibody comprises a wild-type human IgG1 Fc, the VH comprises the sequence set forth in SEQ ID NO:434, and the VL comprises the sequence set forth in SEQ ID NO:

439.

21. The method of claim 20, wherein the .alpha.-amino acid is about 0.5, 1, 2, 3, 4, 5, 6, or 7×10 as measured by a surface plasmon resonance (SPR) assay. -9 K below M D The isolated antibody of claim 1 , which binds to human MARCO at

22. The isolated antibody of claim 1 which is humanized.

23. 13. A method for producing an antibody, comprising expressing the antibody of claim 1 from a host cell and isolating the expressed antibody.

24. A pharmaceutical composition comprising the antibody of claim 1 and a pharma- ceutically acceptable excipient.

25. A kit comprising the antibody of claim 1 and instructions for use.

26. A pharmaceutical composition for treating cancer in a subject, comprising an antibody that competes with a reference antibody for binding to human MARCO (SEQ ID NO: 384), wherein the reference antibody comprises three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), wherein CDR-H1, CDR-H2, and CDR-H3 are selected from the group consisting of SEQ ID NOs: 61, 21, 31, 41, the pharmaceutical composition comprising a heavy chain variable domain (VH) comprising the amino acid sequence set forth in SEQ ID NO: 51, 91, 121, 474, 1, 11, 71, 81, 101, 111, 131, 434, or 444, and CDR-L1, CDR-L2, and CDR-L3 derived from a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO: 66, 26, 36, 46, 56, 96, 126, 479, 6, 16, 76, 86, 106, 116, 136, 439, or 449.

27. ​​The pharmaceutical composition of claim 26, wherein the subject has previously received, is concurrently receiving, or will subsequently receive immunotherapy, and the immunotherapy is at least one of: checkpoint inhibitors; T cell checkpoint inhibitors; anti-PD1 antibodies; anti-PDL1 antibodies; anti-CTLA4 antibodies; adoptive T cell therapy; CAR-T cell therapy; dendritic cell vaccines; monocyte vaccines; antigen binding proteins that bind to both T cells and antigen presenting cells; BiTE dual antigen binding proteins; Toll-like receptor ligands; cytokines; cytotoxic therapy; chemotherapy; radiation therapy; small molecule inhibitors; small molecule agonists; immunomodulators; and epigenetic modulators.

28. The pharmaceutical composition of claim 27, wherein the immunotherapy is an anti-PD1 antibody, an anti-PDL1 antibody, or an anti-CTLA4 antibody.

29. A pharmaceutical composition for enhancing an immune response in a subject, comprising an antibody that competes with a reference antibody for binding to human MARCO (SEQ ID NO: 384), wherein the reference antibody comprises three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) and three light chain complementarity determining regions (CDRs) (CDR-L1, CDR-L2, and CDR-L3), and wherein CDR-H1, CDR-H2, and CDR-H3 are selected from the group consisting of SEQ ID NOs: 61, 21, 31, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, , 51, 91, 121, 474, 1, 11, 71, 81, 101, 111, 131, 434, or 444, and CDR-L1, CDR-L2, and CDR-L3 are derived from a light chain variable domain (VL) comprising the amino acid sequence set forth in SEQ ID NO: 66, 26, 36, 46, 56, 96, 126, 479, 6, 16, 76, 86, 106, 116, 136, 439, or 449.